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1. General Introduction 
Chemical biology research dissects different biological phenomena with small molecules. In 
the corresponding forward chemical genetics approach,[1,2] changes in phenotype upon 
compound treatment are recorded, and biologically active molecules are used as chemical 
probes to identify and validate the target proteins associated with the observed phenotype. 
In reverse chemical genetics on the other hand, high-throughput screening of large 
compound collections against a known biological target is employed (Figure 1), and the hits 
are then investigated in biological systems.[3] 
 
 
Figure 1: Forward and reverse chemical genetics. SAR: Structure-Activity Relationship. 
 
Novel biologically active small molecules are key to investigate different biological processes 
and to gain better understanding of their role in diseases and for the development of 
possible therapeutics.[4] In the absence of a specific protein target in a forward chemical 
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genetics exploration, the development of new biologically relevant small molecules in 
principle can target any synthetically accessible compound. However, practically, it is 
impossible to synthesize all the possible small molecules, even by keeping limits in molecular 
properties depicted by the Lipinski rule of five.[5,6] Alternatively, targeting biologically 
relevant chemical architectures derived from natural products or drug molecules might 
provide higher chances to identify potent active molecules that can be developed into 
chemical probes for chemical biology research as well as into candidates for medicinal 
chemistry investigations.[7]  
 
Natural products represent only a small fraction of the chemical space representing all the 
energetically stable compounds, but more than half of the existing drugs[8,9] are either 
directly derived from them or have natural products as starting points. Many natural 
products show multiple activities against a spectrum of targets, and therefore the 
exploration of the chemical space around these inherently active molecules is highly 
desirable to find candidates with better activity for a given target. Owing to their biosynthetic 
origins, natural products have evolved to interact with biomolecules and interestingly, unlike 
combinatorial compound collections, posess important properties, like solubility and 
membrane permeability.[10,11] While the core-structures of natural products play a key role 
in the interactions with biological targets, these scaffolds can be used as templates to build 
up natural product inspired libraries. In contrast to the total synthesis of natural products 
that provides only few molecules in a highly tedious synthetic design for further studies,  
natural products inspired compound collection synthesis targets synthetic access to 
numerous compound for the discovery of new active molecules.[12] Thus, synthetic designs 
leading to compound collections inspired from natural products retain the main structure of 
the natural product of interest and build up a library by possible modifications and 
decorations with various functional and appending moieties on the periphery of the core-
framework.[13,14]  These libraries are highly useful sources of chemical probes for chemical 
biology research and novel structures for drug discovery and may provide hit rates 10 to 100 
fold higher than libraries generated on the basis of chemical feasibility.[15,16] In many cases, 
natural product inspired molecules surpass the efficiency and selectivities of the parent  
natural products and exhibit lower toxicity .  
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The structural complexity and diversity of these natural products and thereby natural 
product based compound collections, calls for the development of efficient synthesis 
methods that provide concise and stereoselective syntheses amenable to construct 
numerous complex compounds in the most straightforward way. With this in mind, concepts 
like atom[17,18] and step economy[19] are important to design a pathway that builds up varying 
structural complexity.  
 
This work describes the development and the optimization of such a natural product-
inspired compound collection with two different synthesis strategies. In chapter 2, the 
investigations about the mechanism and the scope of the synthesis of indoloquinolizines by 
an unprecedented 12-step cascade reaction are described. Then, the development of an 
asymmetric inverse electron demand imino Diels-Alder (IEDIDA) reaction as an alternative 
synthesis of the indoloquinolizines is detailed in chapter 3. Finally in chapter 4, the scope of 
the IEDIDA reaction is studied, and the biological activity of the natural product-inspired 
compound collection is evaluated in an phenotypic screening. 
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2. Cascade Synthesis Routes to Centrocountins 
Chapter relating to: Cascade Synthesis Routes to the Centrocountins 
V. Eschenbrenner-Lux, H. Dückert, V. Khedkar, H. Bruss, H. Waldmann, K. Kumar  
Chem. Eur. J. 2013, 19, 2294 – 2304. 
2.1. Introduction 
The indole ring system represents one of the most abundant and important heterocycles in 
nature.[20] It is found in a diverse group of biologically relevant natural compounds, from very 
simple neurotransmitters like serotonin, to complex alkaloids used as anticancer agents like 
vinblastine 1. Furthermore, polycyclic indole alkaloids are potent modulators of the mitotic 
cycle. Indoloquinolizines like vinblastin 1, yohimbin 2 or 10-hydroxyaugustin 3 are interesting 
molecules for the study of mitosis and therefore potential anticancer drugs[21–26] (Figure 2).  
Figure 2: Structures of representative polycyclic indole alkaloids related to mitosis and 
cancer.  
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2.1.1. Domino or Cascade Reactions in Organic Synthesis 
Building molecules of varying complexity is a unique ability and characteristic of organic 
synthesis. Despite major developments made in this field of science, the synthesis of small 
molecules with desired functional decorations remains a major challenge. Long and 
multistep synthesis routes are often unavoidable to synthesize complex molecules 
containing for instance, many stereogenic centres.[27]  
 
Cascade or domino reactions, wherein several reactions proceed are viable alternatives to 
multistep sequences to synthesize structurally diverse and complex compound 
collections[28,29] and, therefore, strategies based on these reactions are highly desired. In 
recent years, various domino- and one-pot multi-component reaction strategies yielding 
various classes of molecules were developed,[30] but there is still a lot to be achieved in this 
field, for instance asymmetric construction of complex molecules decorated with 
stereogenic centers. The development of robust, scalable, economical, and stereoselective 
domino or cascade reactions that are also amenable to compound library synthesis is a 
formidable challenge. Chirality of the products is an important factor that determines the 
biological effects of a molecule.[31–33] Therefore enantioselective and diastereoselective 
cascade reactions are of particular interest in this area. Notably unlike multistep syntheses 
that often employ protection and deprotection steps, these reactions also address the 
challenge of atom economy in most of the cases.[34]  
 
Among the few strategically designed cascade reactions towards natural product inspired 
compounds, the Waldmann group developed a silver catalyzed domino sequence leading to 
different classes of isoquinolines (Scheme 1). This cascade reaction was also used as a key 
step in the concise synthesis of the natural product fascaplysin. This sponge derived alkaloid 
is a CDK-4 inhibitor[35,36]. In their approach, aniline 4 and acetylenic benzaldehyde 5 form   
imine 7, which then undergoes a silver-catalyzed cycloisomerization to form isoquinolinium 
intermediate 8.[37] An intramolecular nucleophilic attack of the pendant malonate 
nucleophile followed by decarboxylation of the tetracyclic intermediate 9 ends the cascade 
with the formation of the targeted indoloisoquinolines 6 (Scheme 1).  
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Scheme 1: Silver catalyzed cascade synthesis of indoloisoquinolines 6. 
 
This strategy led to the synthesis of a small compound library of indoloisoquinolines with 
substitutions at both aromatic rings (R1 – R4) and yields up to 95%. Furthermore, a concise 
synthesis of the natural products fascaplysin and homofascaplysin was achieved employing 
this domino reaction sequence as a key transformation.  
 
Another example of the synthesis of a small-molecule library from a cascade sequence 
providing a complex indole alkaloid-inspired compound collection was reported by Van der 
Eycken et al.[38] In this case, an Ugi four-component reaction[39] with indole-carboxaldehyde 
10, nitrile 11, amine 12, and carboxylic acid 13 yielded the highly functionnalized indole 14 
that was used as a substrate for a subsequent gold-catalyzed cyclization reaction (Scheme 
2). In the presence of a gold(I) catalyst a tetracyclic spiroindoline 16 was formed 
diastereoselectively instead of the expected indoloazepinone 15 that could be formed via an 
endo-dig cyclization. 
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Scheme 2: Synthetic strategy to produce a spiroindole 15 library 
 
2.1.2. Centrocountins: Previous Work  
The Waldmann group describes a one-pot cascade reaction sequence of unprecedented 
length that combines commercially available reagents as starting materials to yield 
tetracyclic indoloquinolizines embodying  the basic scaffold of polycyclic alkaloids like 
Yohimbine 1.[40] These compounds delayed mitosis in HeLa cells, induced chromosomal 
congressional defects, formation of multipolar spindles (Figure 3b), and targeted the 
centrosome associated proteins nucleophosmin (NPM) and Crm1. As they impair the 
mechanism that ensures the correct duplication of one centrosome per cell into two 
daughter centrosomes in the course of mitosis, they were termed centrocountins 17 (Figure 
3a).  
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Figure 3: Centrocountin-1 17a and its mitotic modulation activity on HeLa cells. a) Structure 
of centrocountin-1 17a and -2 17b as hits from the screening of indoloquinolizines. b) 
Influence of (R)-17a on chromosome congression and spindle pole formation in HeLa cells. 
Multiple defects including chromosome congression defects (middle picture) and aberrant 
spindle structures (right picture) induced by (R)-17a. HeLa cells were treated with 25 µM 17a 
for 18h before staining with DAPI for DNA (blue), -tubulin (green) and -tubulin (green).  
 
The one-pot cascade synthesis of the centrocountins proceeded with the attack of the 
triphenylphosphine catalyst on an alkyne 19 to form nucleophilic phosphozwitterion 20, that 
subsequently adds to formylchromones 18 to form intermediates 21.[41–43] These would then 
cyclize by means of an addition–elimination mechanism to yield tricyclic benzopyrones 22 
with regeneration of the catalyst (Scheme 3). Tryptamine derivatives 23 then attack the 
electrophilic benzopyrone 22 by adding to the C ring of the tricyclic benzopyrones, followed 
by ring opening in which a phenol group acts as a leaving group to generate intermediates 
24. The phenols 24 can add again to the generated α,β-unsaturated carbonyl compounds, 
thereby initiating a pyran ring opening to generate intermediates 25 with an enamine and 
an α-ketoester in close vicinity. Addition of acid at that point of the cascade sequence 
initiates the condensation with the ketone, thus forming dihydropyridines 28 followed by 
another chromone ring opening with a phenol leaving group, and readdition of the phenol 
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to form pyridinium salts 29, these give rise to tricyclic dienes 30 and set the stage for a 
sigmatropic aza-Claisen rearrangement that yields α-iminoesters 31. The neighboring indole 
ring then serves as a substrate for an intramolecular Pictet–Spengler cyclization to generate 
secondary amines 32. The final steps of the sequence consists of a conjugate aza-Michael 
addition of the secondary amine to the doubly vinylogous esters to yield addition products 
33. Then a final acid-mediated pyran ring opening with phenol serving again as a leaving 
group culminates in the formation of centrocountins 17.[44] 
 
The optimized procedure for the cascade synthesis of the centrocountins 17 consists in the 
reaction of 1.0 equivalent of formylchromone 18 with 1.3 equivalents of DMAD 19, in the 
presence of 0.6 equivalents of triphenylphosphine in toluene at 80°C. Subsequently 1.0 
equivalent of tryptamine was added, followed by the addition of 1.0 equivalent of 
trifluoroacetic acid (TFA) or camphor sulphonic acid (CSA) (after disappearance of the 
tryptamine, monitored by thin layer chromatography) and the reaction mixture is stirred at 
the same temperature for 5 to 30 minutes. Flash column chromatographic purification of the 
concentrated reaction mixture led to centrocountins in yields varying from 20 to 88% 
(Centrocountin-1 17a, 88%). By this method, a small compound collection of thirty 
indoloquinolzines was synthesized, using differently substituted tryptamines and 
chromones, as described in Table 1. 
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Scheme 3: Proposed mechanism of the one-pot cascade sequence leading to the formation 
of centrocountins 17. 
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Table 1: Cascade synthesis of centrocountins 17. 
 
 
 
 
 
 
[a] isolated yields 
Product R1 R2 R3 R4 R5 R6 R7 R8 Yield(%)[a] 
17a H H H H Me H H H 58 
17b H Me H H Me H H H 56 
17c H iPr H H Me H H H 66 
17d H H H H Et H H H 88 
17e H Me H H Et H H H 65 
17f H Cl H H Me H H H 39 
17g H H H H Me H OMe H 76 
17h H H H H Me H Br H 73 
17i H H H H Me H Me H 74 
17j H H OBn Me Me H H H 59 
17k H H H H Et H OMe H 76 
17l H H H H Me H OH H 67 
17m H Br H H Me H OMe H 62 
17n H Br H H Me H H H 39 
17o H Cl H Cl Me H H H 20 
17p H Br H Br Me H H H 20 
17q H Cl Me H Me H H H 60 
17r H H H H Me CO2Me H H 69 
17s H H H H tBu H H H 42 
17t OMe H H H Me H H H 26 
17u H H H H Me H H Me  78b 
17v H Me H H Et H OMe H 45 
17w H iPr H H Et H OMe H 65 
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2.1.3. Goals for the Further Development of the Cascade Reaction 
Thus, a very easy and efficient cascade synthesis of natural product inspired 
indoloquinolizines was established. In order to establish the proposed mechanism of this 
long and complex cascade sequence, key intermediates in the sequences were to be isolated. 
Also, it was observed that the initial [4+2] annulation between 3-formylchromones 18 and 
acetylenedicarboxylates 19 was quite sensitive to substitutions on the chromone. For 
instance, halogen-substituted 3-formylchromones always provided very low yields of 
indoloquinolizines (Table 1) and these were corresponding to the yields of the phosphine-
catalyzed formation of the initial tricyclic benzopyrones 22. That means, the cascade reaction 
sequence from tricyclic benzopyrones onwards to indoloquinolizines 17 was almost 
quantitive in yield. The major limitation of the cascade reaction was the irreplaceability of 
the tryptamines. Only tryptamines yielded the cascade products and carbo- or heterocyclic 
analogues could not be obtained with the cascade synthesis. Therefore, alternative methods 
for the synthesis of a diverse centrocountin collection were developed. In the following 
sections, investigations to prove the proposed reaction mechanism of the reaction cascade, 
and alternative cascade reactions that provide efficient and broader access to centrocountin 
analogues is described. 
 
2.2. Confirmation of the Proposed Mechanism 
 This part of the work was conducted in collaboration with Heiko Dückert and Hanna 
 Bruss. 
The isolation and the characterization of key intermediates of the cascade reaction supports 
the proposed mechanism. The synthesis of tricyclic benzopyrones 22 was first developed as 
a separate reaction by the group. These intermediates are stable and can be stored in non 
acidic conditions and were fully characterized by NMR and HRMS.[41] Tricyclic aminal 27 was 
isolated and characterized by NMR spectroscopy as well. However its reactivity under acidic 
conditions rendered the recording of its NMR spectra difficult. Also, formation of 
indoloquinolizine from 27 was observed in the NMR sample in CDCl3. In contrast, 
intermediate 30 was isolable, stable and crystallizable, so that X-ray analysis was performed, 
which unambiguously confirmed the structure of this aminal. These intermediates however 
define only some of the cornerstones of this unprecedentedly long cascade process, and 
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careful stepwise investigations of the remaining steps of the mechanism is necessary for its 
confirmation (Scheme 4). 
 
Scheme 4: Isolated intermediates in the cascade sequence to centrocountins 17. The isolated 
and characterized intermediates constitute the cornerstones to dissect the reaction 
sequence of the whole cascade process into smaller sequences (I to IV).  
 
The phosphine catalyzed [4+2] cycloaddition of 3-formylchromones 18 with 
acetylenecarboxylates 19 to yield benzopyrones 22 sets the start of the sequence of the 
formation of indoloquinolizines 17. However, the addition of tryptamine to the electrophilic 
benzopyrones 22 may occur at different steps of the proposed cascade by attacking either 
the tri- or the tetra-substituted olefin. The addition of nucleophiles to tri-substituted olefins 
is shown by the arrow in Scheme 5, thereby leading to a chromone ring opening to yield 
aminal 25. Aminal 25 then opens up to form aza-triene 26, that undergoes 6π-
electrocyclization to form the 2-hydroxy-dihydropyridine 27 (Schemes 4 and 5, Reaction 
Sequence II). Indeed, compound 27 could be isolated in quantitative yield from a reaction of 
22 with tryptamine in dichloromethane by directly evaporating the solvent. However, the 
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flash chromatography purification of aminal 27a on silica gel converted it quantitatively into 
tricyclic aminal 30a (Scheme 5, Reaction Sequence III).  
 
 
Scheme 5: Stepwise analysis and isolation of intermediates in the cascade reaction 
sequence: isolation of dihydropyridine 27 as precursor to tricyclic aminal 30. 
 
However, tricyclic benzopyrone 22b led to the direct and quantitative formation of 30b, and 
the formation of intermediate 27b was not observed (Scheme 6). Intermediate 27b might be 
formed by the addition of tryptamine to any of the two electrophilic olefinic sites (indicated 
by arrows). Probably, in the absence of an ester moiety, intermediate 27b is not stable 
enough and quickly rearranges to form an azadiene that yields 30b.  
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Scheme 6: Tricyclic intermediates 30b generated from 22b by the addition of tryptamine. 
 
The transformation of 27a in the presence of silica gel into tricyclic aminal 30a is a further 
proof of the influence of mild acidic conditions on this transformation. If aminals 27 are 
indeed leading to intermediates 30, two different pathways are possible (Scheme 7). Tricyclic 
aminals 30 may be directly formed by addition of the phenol to the α,β-unsaturated 
vinylogous amide (dotted arrow in Scheme 7) or through the formation of pyridinium salts 
29 as intermediates. The isolation of indoloquinolizines 17 (Scheme 3) as side products 
suggests the formation of the pyridinium salts as they would be synthesized by an addition-
elimination sequence from dihydropyridines 28 derived from 27.  
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Scheme 7: Proposed reaction sequence from aminal 27 to tricyclic aminal 30 via pyridinium 
salt 29 and isolation of indoloquinolizine side product 30. 
 
Intermediates 28 embody a push–pull system that favors the formation of aromatic 
pyridinium salts 29. The tricyclic benzopyrones 28 are structurally related to compounds 22 
which are known to undergo rearrangement leading to ring-open ketoesters/aldehydes 34 
(Scheme 8a).[45] This rearrangement, proceeds through pyrylium cations 35, similar to the 
proposed transformation of 28 into 29. In addition, we observed that the N-tosyl analogue 
37 did not rearrange because the push–pull effect is lacking in this acid-stable 
dihydropyridine (Scheme 8b).  
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Scheme 8: Insights into the formation of key intermediates and side products in the cascade 
reaction sequence: a) ring opening of tricyclic benzopyrones 22; b) attempted ring opening 
of N-tosyl analogues of 37 under acidic conditions. 
 
The 1H NMR spectra of tricyclic intermediates 30a and 30b in CDCl3 at room temperature 
showed similar broadened peaks. Moreover, 30a showed slow conversion to 
indoloquinolizine 17a. It was therefore necessary to modify the conditions in which the NMR 
measurements were performed for refined results. The best results were obtained in 
deuterated DMSO at 60 °C. However, even under these conditions, all the expected signals 
did not appear properly in the spectrum (21 signals observed in the 13C NMR spectrum 
instead of 26 expected from HRMS calculations). Thus, a conclusive structural assignment of 
30a was not possible by means of NMR spectroscopy, but the comparison of the NMR 
spectra of 30a and 30b clearly proved their structural resemblance as depicted in Figure 4. 
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Figure 4. Overlay of the gHSQC spectra of the aromatic regions of 30a and 30b. The depicted 
sections of the spectra show all detected gHSQC signals except the CH2 signals and the ethyl 
ester or methyl ester signal, respectively. 
 
To rule out a hypothetic direct transformation of pyridinium salt 29 to indoloquinolizine 17 
by the addition of the indole ring to the iminium salts (Scheme 9), further experiments were 
performed. An equimolar solution of 30a in the presence of triethylamine in toluene resulted 
in no reaction, thus ruling out another possible addition of the indole moiety to the 
dihydropyridine ring in the intermediate 30a. However, 30a is stable under acidic and basic 
conditions. These observations clearly stand against the possible direct conversion of either 
pyridinium salts 29a or tricyclic aminals 30a to the indoloquinolizine 17a. 
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Scheme 9: Proposed reaction sequence from pyridinium salts 29 to inodoloquinolizines 17 
 
To further validate this notion, pyridinium salt 39 was synthesized by treating trisubstituted 
pyridine 40 with 3-(2-bromoethyl)indole 41 in the presence of triethylamine. Under basic 
reaction conditions, centrocountin 17a was not formed. Unexpectedly, the treatment of 39 
with trifluoroacetic acid (TFA) or camphorsulphonic acid (CSA) led to decomposition and the 
formation of indoloquinolizine 17a was not observed by means of LC-MS analysis of the 
crude reaction mixture (Scheme 10). By analogy, pyridinium salt 42 decomposed under 
acidic conditions. These results thus strongly argue against the direct formation of 
indoloquinolizines 17 from pyridinium salts 29. 
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Scheme 10: Synthesis of pyridinium salts 39 and 42 and their attempted conversion to 
centrocountins. 
 
In the proposed cascade sequence, -iminoesters 31 are formed from tricyclic aminals 
embodying two ester groups (Scheme 3). We assume that the aza-Claisen rearrangement is 
facilitated by an energetically low-lying LUMO of 30a. In 30b, the LUMO will be higher in 
energy, resulting in a less facile rearrangement. The -iminoesters are potent electrophiles 
and Pictet–Spengler substrates due to their electrophilicity[46] and yield the secondary 
amines 32 in a fast cyclization reaction (Scheme 3). This intermediate contains a reactive 
secondary amine in proximity to a conjugated chromone moiety, so that a conjugate addition 
leads to hexacyclic intermediates 33 that undergo a retro-Michael-reaction and concerted 
chromone ring opening, thereby yielding centrocountins 17 (Scheme 3). 
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Scheme 11: Attemped reduction of 30a. 
 
The proposed transformations of 30 to 17 proceeded in quick succession and all attempts to 
trap intermediates 31, 32, or 33 failed. Thus, the attempted reduction of intermediate 30a 
with sodium cyanoborohydride led to dihydropyridines 45 (Scheme 11). This formation can 
be explained by either a direct 1,4-addition of hydride or the reduction of -iminoester 31a 
to a secondary amine that adds to the chromone ring, which then opens up. 
 
2.3. Scope of the Reaction 
2.3.1. Use of Other Amines in the Cascade Reaction 
For the synthesis of new analogues of the mitosis modulating centrocountins, replacement 
of the indole ring by other heterocyclic or aromatic cycles in the cascade was assumpted to 
expand the scope of the cascade reaction. To simplify the execution of the cascade reactions, 
pre-formed tricyclic benzopyrone 22a was used and directly underwent amine addition, and 
side reactions due to trace amounts of triphenylphosphine were avoided. Tricyclic 
benzopyrone 22 reacted with electron-rich dopamine 46a to provide the expected product, 
which was O-methylated to yield stable tetrahydroisoquinoline 47a in 35 % overall yield. A 
cascade reaction with 2-(3,4-dimethoxyphenyl)ethylamine 46b led to the desired product 
47b in 61 % yield. The less electron-rich 2-phenylethylamine did not yield the expected 
product (Scheme 12). 
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Scheme 12: Cascade synthesis of diverse tetrahydroisoquinolines 47. 
 
Electron-rich histamine and histidine derivatives 48 yielded the desired annulation products 
49, albeit in low yields. The N-methylated histamine and histidine derivatives also reacted 
with the tricyclic benzopyrone to give the expected products in higher yields than obtained 
with their NH counterparts (Scheme 13).  
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Scheme 13: Cascade synthesis of imidazoquinolizines 49.  
 
2.3.2. Alternative Cascade Route to the Centrocountins 
Variations in the appended substitutions on a scaffold are required for the synthesis of a 
compound collection. Halogens are handles for combinatorial coupling reactions in library 
synthesis. It was observed that the synthesis of halogenated indoloquinolizines is low 
yielding in the long cascade reaction. The formation of the tricyclic benzopyrones 22 is the 
limiting factor in the cascade reaction sequence. To solve this problem, an alternative 
cascade route was envisioned in which dihydropyridine intermediate 28 could be formed by 
an aza-Diels–Alder reaction between choromonylimines 50 and DMAD 19. This route should 
yield halogenated indoloquinolizines in higher yields than in the 12-step cascade, by avoiding 
the low yielding [4+2] annulation of halogenated 3-formychromones with 
acetylenedicarboxylates (Scheme 14).  
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Scheme 14: Alternative cascade synthesis of centrocountins 17 by means of an aza-Diels–
Alder reaction.  
 
Different reaction conditions for the aza-Diels–Alder reaction were screened by increasing 
the reaction time and temperature and by testing different solvents and Lewis acids (Table 
2). The best results were observed by using 1.2 equivalents of ZnCl2 in DMSO at 80 °C for 24 
hours to yield 17a in 79 % yield (Table 2, Entry 4). Gratifyingly, differently substituted 3-
formylchromones, in particular with halogen substituents, reacted smoothly with 
acetylenedicarboxylates and provided indoloquinolizines 17 in higher yields than recorded 
before for the 12-step cascade reaction. (Table 3) 
 
Table 2: Optimization of the reactions conditions for the alternative synthesis of 17a. 
Entry Lewis Acid Solvent Temperature Reaction time Yield[a] [%] 
1 ZnCl2 toluene r.t. 12h - 
2 ZnCl2 toluene 40 °C 12h 28 
3 ZnCl2 toluene 80 °C 12h 41 
4 ZnCl2 DMSO 80 °C 1h 79 
5 ZnCl2 DMSO r.t. 1h - 
[a] Isolated yields 
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Table 3: Aza-Diels-Alder cascade synthesis of indoloquinolizines. 
 
Product R1 R2 R3 R4 R5 R6 R7 Yield[a,b] [%] Yield[a,c] [%] 
17a H H H H Me H H 58 79 
17f H Cl H H Me H H 39 91 
17g H H H H Me H OMe 76 64 
17m H Br H H Me H OMe 62 62 
17n H Br H H Me H H 39 77 
17o H Cl H Cl Me H H 20 53 
17p H Br H Br Me H H 20 83 
17t OMe H H H Me H H 26 29 
17v H Br H H Et H H 45 64 
17w H Cl H Cl Et H H 65 40 
17aa H Cl H H Et H H - 93 
17ab H Cl H Cl Et H OMe - 87 
17ac H Br H H Et H OMe - 69 
17ae H Br H H Et H H - 82 
17af H Cl H H Me H OMe - 74 
17ag H Cl H Cl Me H OMe - 91 
17ah H Br H Br Me H OMe - 51 
17ai H Cl H Cl Et H OMe - 31 
17aj H Br H Br Et H OMe - 42 
[a] isolated yields, [b] synthesis by the 12-step cascade, [c]synthesis by the cascade aza-
Diels-Alder reaction 
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2.4. Conclusion and Outlook 
Analogues of centrocountin 17a were synthesized to further develop a natural product 
inspired compound collection by means of an efficient and particularly long cascade 
sequence, involving at least twelve distinct reaction steps and nine distinct reaction types 
from commercially available starting material. The cascade synthesis also provides new 
tetrahydroquinolizines fused to other aromatic rings. The proposed mechanism of this 
reaction sequence was further proved by performing different control experiments, and led 
to an alternative shortcut cascade reaction from readily accessible substrates employing an 
aza-Diels-Alder reaction with DMAD as a key step. Nevertheless, the scope of the synthesis 
could not be substantially expanded, and the necessity of developing a new synthetic 
strategy for the elaboration of more various centrocountins analogues remains essential for 
an efficient use in chemical biological investigations. 
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3. Inverse Electron Demand Imino-Diels-Alder 
Reaction 
Chapter relating to: 
An Enantioselective Inverse Electron Demand Imino Diels-Alder Reaction 
V. Eschenbrenner-Lux, P. Küchler, S. Ziegler, K. Kumar, H. Waldmann 
Angew. Chem. Int. Ed. 2014, 53, 2134 - 2137. 
 
3.1. Introduction 
In order to further explore the unusual bioactivity of the centrocountins, and given the 
limited scope of the long cascade synthesis of this heterocyclic class, an alternative 
enantioselective synthesis was envisaged. The aza-Claisen rearrangement and the Pictet-
Spengler cyclization steps limited the potential of the long cascade reaction sequence 
leading to the centrocountins. While the aza-Claisen reaction required the presence of an -
iminoester, the Pictet-Spengler proceeds efficiently only for indole derivatives. Therefore, a 
strategy was developed to overcome these limitations (Scheme 15).  
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Scheme 15: Limitating steps of the cascade synthesis of Centrocountin 17. 
 
3.1.1. Synthesis of Indoloquinolizines by an imino Diels Alder reaction 
The [4+2] cycloaddition between dienophiles and dienes, the Diels-Alder reaction, is a very 
useful method for the formation of substituted 6-membered rings.[47,48] The concerted 
mechanism and the stereospecific character of this reaction was formally accepted, even 
before the importance of the orbital symmetry was recognized.[49,50] For a non-symmetrical 
diene, two stereochemical orientations toward the diene are possible. These two 
orientations, endo or exo, are illustrated in Scheme 16. In the endo transition state, the 
substituent is oriented in the direction of the diene, when in the exo state it is oriented in 
the opposite direction. The preference of the transition state depends on different factors 
like steric or electrostatic interactions, and yields different stereoisomers. For instance, the 
endo selectivity is prefered in the presence of a carbonyl functional groups in the 
dienophile.[51,52] Also, the preferred mode of cycloaddition depends on the type of catalysis 
used to accelerate the reaction.[53] 
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Scheme 16: Endo-exo selectivity of the Diels-Alder reaction between cyclopentadiene and 
maleic anhydride. 
 
It is possible to control the regioselectivity, as well as the stereoselectivity by modulating the 
reaction conditions or using an asymmetric catalyst, making this reaction suitable for the 
total synthesis of natural products or for the construction of natural-product derived 
compound collections.[54] 
 
3.1.2. The Inverse Electron Demand Imino Diels-Alder Reaction 
A Diels-Alder cycloaddition reaction where a diene or a dienophile has at least one hetero-
atom incorporated is termed hetero Diels-Alder reaction.[55] For an oxygen atom as 
heteroatom, the reaction is called oxa-Diels-Alder reaction[56] and when it is a nitrogen atom, 
the term aza-Diels-Alder reaction is used. A nitroso Diels-Alder[57] reaction is a variant where 
both N and O are implied in the cycloaddition (Figure 5). Despite its efficiency and potential, 
the aza-Diels-Alder reaction has been far less exploited and explored in organic syntheses 
compared to the all-carbon Diels-Alder cycloaddition. The first hetero Diels-Alder reaction 
was for instance only reported 22 years after the first Diels-Alder reaction, in 1949.[58] 
 
The aza-Diels-Alder reaction is one of the most powerful reactions for the construction of 
polyfunctional heterocyclic molecules with high chemo-, regio-, and stereoselectivity.[59] The 
imino Diels-Alder reaction[60] a subclass of the aza-Diels-Alder reaction, in which an imine 
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serves as dienophile, is one of the most direct methods for the formation of six-membered 
nitrogen-containing rings such as tetrahydroquinolines. These reactions are also of high 
interest for the total synthesis of natural products, as they give access to a variety of 
structures in an atom-economic manner, in most of the cases, with a very high tolerance of 
functional groups present in the substrates. Considerable efforts have been committed to 
the development of asymmetric aza-Diels-Alder reactions with 1- or 2-azadienes, or imino 
dienophiles.[61,62] However only few examples describe the application of asymmetric imino-
Diels-Alder reactions to the synthesis of biologically or pharmacologically relevant 
products.[63] 
 
 
 
 
 
 
 
 
 
Figure 5: Hierarchy of the hetero-Diels-Alder reactions. 
 
While major improvements have been achieved in the development of asymmetric carbo-
Diels-Alder reactions, efforts to develop stereoselective hetero Diels-Alder reactions are less 
important. Interestingly, for several natural products it has been hypothesized that their 
biosynthesis includes a hetero Diels-Alder step.[64] Despite the discovery of enzymes 
catalysing Diels-Alder reactions for the synthesis of secondary metabolites[65], the Diels-
Alderases, no enzyme was discovered to date for the catalysis of hetero Diels-Alder 
reactions.[66] Nevertheless, the formation of six-membered heterocycles in one step by [4+2] 
cycloaddition between heterodienes or heterodienophiles is a logical method in synthetic 
strategies designed to yield biologically active small molecules.  
 
3. Inverse Electron Demand Imino-Diels-Alder Reaction  33 
 
 
The relative HOMO-LUMO orbital energies of the diene and the dienophile can be modulated 
with appropriate reaction conditions and catalysts, like Lewis-acids, nucleophilic 
organocatalysts or just thermal promotion.[62] The type of activation required depends on 
the electronic configuration of the molecular orbitals of the diene and dienophile. Thus, in 
the case of a normal demand imino Diels-Alder reaction between an electron-poor imine and 
an electron-rich diene[67], a Lewis acid is used to lower the energy of the LUMO of the 
dienophile, making it more reactive for the [4+2] cycloaddition (Figure 6). Similarly, in the 
case on an inverse electron demand imino Diels-Alder reaction, for instance between an 
electron-poor diene and an electron-rich dienophile, the Lewis acid lowers the energy of the 
diene.[68] Typical Lewis acids used in [4+2] cycloadditions are among others ZnCl2, BF3, AlCl3, 
SnCl4.[69] There are however to the best of my knowledge, no reports to date of an 
asymmetric inverse electron demand imino Diels-Alder reaction. 
 
 
Figure 6: Comparison of the normal electron demand and inverse electron demand imino 
Diels Alder reaction and its translation concerning the orbital interactions between HOMOs 
and LUMOs. (EWG = electron withdrawing group, EDG = electron donating group) 
 
3.1.3. Application of aza-Diels-Alder Reactions in the Synthesis of Natural 
Products and Analogues 
The application of asymmetric hetero Diels-Alder reactions in the synthesis of small bioactive 
molecules has successfully yielded diastereo- and enantioselective methods which employ 
3. Inverse Electron Demand Imino-Diels-Alder Reaction  34 
 
 
either chiral catalysts or chiral auxiliaries embedded in the substrates to induce the desired 
chirality to the products.  
 
Melonine (52, Scheme 17a), a tetracyclic indole alkaloid, is used in the treatment of various 
diseases, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and 
psychiatric disorders.[70,71] An aza-Diels-Aldre reaction was used for the synthesis of a 
compounds collection inspired from the tetracyclic scaffold of this bioactive molecule.[72] In 
this case, a one-pot three component reaction leads to the tetrahydroquinoline scaffold in 
one direct step with up to 92% yield and 93% ee.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 17: Synthesis of a indole alkaloid-inspired compound collection. a) Example of 
bioactive products containing the common scaffold. b) One-pot three component reaction 
hetero Diels-Alder reaction. c) Synthesis of a Melonine-inspired compound library 61.  
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Aldehydes 54 and anilines 55 form imines 58, which undergo an aza-Diels-Alder reaction with 
indoles 56 assisted by catalysis with phosphoric acid 57 to form tetrahydroquinolines 59 
(Scheme 17b). Three stereogenic centres are installed by the chiral catalyst with high 
enantiomeric excess as well as high diastereoselectivity (95:5) in tetracylic indoles 59. The 
presence of an oxetane ring on aldehyde 60 as a directing group is necessary for the synthesis 
of a melonine-inspired tetracyclic indoles 61. Indeed, addition of secondary amine induces 
oxetane ring-opening and thereby the formation of the targeted compound 61 in good yields 
and diastereoselectivity (Scheme 17c). 
 
Other alkaloids, like indolizidines, quinolizidines, and piperidines can also be synthesized 
with an asymmetric imino Diels-Alder reaction. Lasubines are quinolizidine alkaloids isolated 
from plants of the Lythraceae family.[73] A chiral ferrocene complex is used, in this case, as 
the catalyst for the asymmetric HDA reaction.[74] Thus, the piperidinone core was generated 
by imino Diels-Alder reaction between diene 62 and aryltosylimide 63 catalyzed by Cu-
Fesulphos bromo dimer complex 64 and AgClO4 in DCM leading to cycloadduct 65 in 71% 
yield and 94% ee. Further functionalization steps of 65 yielded lasubines I and II 67-68 
through the common building blocks 65 and 66 (Scheme 18). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 18: Synthesis of lasubines 67-68 using an enantioselective normal electron demand 
imino Diels-Alder reaction as the key step.  
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3.2. Design of the Synthetic Pathway to Centrocountin Analogues with the 
Hetero Diels-Alder Strategy 
A [4+2] cycloaddition to form directly intermediate 33 (Scheme 3) was considered as the key 
step for the synthesis of centrocountin analogues and in general of natural product-inspired 
ring-fused quinolizines. With this aim, the reaction of indole-derived cyclic imines 69 as 
dienophiles with chromone olefins 70 as dienes was envisioned to synthesize tetrahydro[2,3-
b]indoloquinolizines 72 via intermediate 71 (Scheme 19). 
 
Scheme 19: Alternative synthesis of centrocountin analogues 72 by [4+2] cycloaddition. 
 
The IEDIDA strategy would allow to introduce different substitutes at the positions R1 and 
R2, as these groups would be originating from each the diene and the dienophiles. This would 
allow to decorate the indoloquinolizine scaffold with different functional groups. (Scheme 
20). 
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Scheme 20: Difference in the bond formation between the cascade reaction and the 
proposed IEDIDA reaction. The red line indicates the bonds formed during the main 
cycloaddition step. The green ones are formed by the synthesis of the substrates prior to the 
cycloaddition cascades. 
 
3.3. Preparation of the IEDIDA Substrates 
3.3.1. Preparation of the Cyclic Imines 
The cyclic imines were synthesized following a reported procedure[75], in which tryptamines 
23 were reacted with ethyl formate 73 leading to tryptamine-derived imines 69 (Eq. 1), or 
with an acyl chloride 74 to form the corresponding amide. After evaporation of the solvent 
was dissolved in DCM and treated with phosphorous oxychloride under argon to yield after 
purification by acid and basic extraction of the product the cyclic -substituted imines 69 in 
good yields (Eq. 2 and Table 4). 
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Table 4: Preparation of cyclic imines 69. 
 
Compound R1 R2 R3 Yield[a] 
69a H H H 63 
69b OMe H H 68 
69c OBn H H 59 
69d Me H H 64 
69e Cl H H 51 
69f H H Me 81 
69g OMe H Me 86 
69h H H Ph 59 
69i  OMe H Ph 64 
69j OMe H Et 71 
[a] Isolated yields 
 
For imines derived from serotonin hydrochloride 23b, the amine was first pre-dissolved in 
DMF due to solubility issues in ethyl formate and was then acylated to yield intermediate 75. 
To avoid the reaction of the free hydroxyl group of serotonin with phosphorous oxychloride, 
amides 75 were protected with a triisopropylsilyl group to yield silyl ethers 76, subsequent 
dehydratation proceeded smoothly to yield the targeted imines, albeit in low yields (Table 
5). The same method was used for the formation of substituted imines through the acyl 
chloride pathway. 
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Table 5: Synthesis of cyclic imines from serotonin hydrochloride 23b. 
 
Compound R1 R2 R3 Yield[a] 
69m OTIPS H H 49 
69n OH H H 48 
69o OTIPS H Me 53 
69p OH H Me 52 
[a] Isolated overall yields 
 
3.3.2. Preparation of the Chromone Dienes 
The dienes for the IEDIDA reaction were prepared by Wittig reaction[76], in which the 
chromone dienes were synthesized from 3-formylchromones 18 with various 
phosphoranylidenes 77 in DCM at room temperature (Table 6). The Z and E isomers were 
readily separated by flash chromatography, and were obtained in a (Z/E) ratio of 1:2 for the 
different chromone dienes 70 synthesized. 
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Table 6: Preparation of the chromone dienes 70. 
 
Compound R4 R5 R6 R7 Yield[a] [%] 
70a H H H CO2Me 82 
70b F H H CO2Me 85 
70c Cl H H CO2Me 59 
70d Br H H CO2Me 54 
70e Me H H CO2Me 67 
70f Et H H CO2Me 64 
70g iPr H H CO2Me 63 
70h NO2 H H CO2Me 39 
70i H H H CN 81 
70j F H H CN 75 
70k Cl H H CN 76 
70l Br H H CN 69 
70m Me H H CN 84 
70n Et H H CN 85 
70o iPr H H CN 74 
70p NO2 H H CN 38 
70q H H H CO2Et 64 
70r F H H CO2Et 69 
70s Cl H H CO2Et 60 
70w H H H COOH 48 
70x F H H COOH 52 
70y Cl H H COOH 46 
70z H H H COPh 78 
[a] Isolated yields of (Z)- and (E)-Isomers combined 
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3.4. Optimization of the Reaction Conditions for  IEDIDA Reaction 
Treatment of imine 69g with diene 70a in DMSO at 80 °C for 48 hours without any catalyst 
induced the IEDIDA reaction to form the desired indoloquinolizine 72a in 61% yield. Both (Z)- 
and (E)-stereoisomers of the chromone diene 70a led to the expected product in similar 
yields. However, for the sake of clarity, all the further attempted reactions were performed 
using the (E)-isomer exclusively. Different reaction conditions were tested to optimize the 
yield, the reaction time and the side product spectrum. Variation of solvent and temperature 
and exploration of different Lewis acids revealed that the cycloaddition proceeds best in the 
presence of ZnCl2 in toluene or DMSO at 80 °C (Table 7). Similar results were obtained when 
the reaction was performed at lower temperature for longer time. 
 
Table 7: IEDIDA reaction between imine 69g and chromone diene 70a. 
 
Entry Lewis Acid Solvent Temperature Reaction time Yield[a] [%] 
1 None DMSO 80 °C 48h 61 
2 AlCl3 DCM r.t. 12h [b] 
3 ZnCl2 THF 60 °C 12h - 
4 ZnCl2 DMF 80 °C 12h - 
5 ZnCl2 DCM r.t. 12h 69 
6 ZnCl2 toluene 80 °C 12h 83 
7 ZnCl2 DMSO 80 °C 1h 94 
8 ZnCl2 DMSO r.t. 1h 85 
[a] Isolated yields, [b] decomposition of the starting materials 
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3.5. Scope of the IEDIDA Reaction in the Synthesis of Indoloquinolizines 
A total of 97 indoloquinolizines were synthesized using the optimised reaction conditions 
with substitutions on the indole-derived imine, as well as on the chromone diene. The yields 
of indoloquinolizines ranged from 67 to 93%. Harmaline 69k was most reactive with reaction 
times of a few minutes, whereas unsubstituted tryptimines, like 69a, required 1h for 
complete conversion (Scheme 21). -Substitutients R3 on the imine had a drastic effect on 
the reaction, the reaction was found impossible to happen with for R3 different to H or 
methyl. Also, the reaction of -methyl imines 69 only proceeded when a methoxy group was 
present on the indole ring. On the other hand, no influence of the substitution pattern on 
the chromone ring was observed regarding yield or reaction velocity. The indoloquinolizine 
72 synthesized by the inverse electron demand imino Diels-Alder reaction are collected in 
Table 8. 
 
Scheme 21: Reaction velocity for IEDIDA reactions with tryptimine 69a and harmaline 69k. 
 
Table 8: Scope of the IEDIDA reaction to the indoloquinolizines. 
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Table 8: Indoloquinolizine compound collection 
Compound R1 R2 R3 R4 R5 R6 R7 Yield [%][a] 
72a OMe H Me H H H CO2Me 94 
72b H H H H H H CO2Et 82 
72c H H H H H H CO2tBu 81 
72d H H H H H H CN 87 
72e H H H H H H COOH 74 
72f H H H H H H CO2Me 71 
72g OMe H H H H H CO2Me 95 
72h OMe H H H H H CO2Et 82 
72i OMe H H H H H CO2tBu 89 
72j OMe H H H H H CN 91 
72k OMe H H H H H COOH 72 
72l H OMe Me H H H CO2Et 83 
72m H OMe Me H H H CO2tBu 85 
72n H OMe Me H H H CN 89 
72o H OMe Me H H H COOH 72 
72p H H H F H H CO2Me 77 
72q H H H Cl H H CO2Me 79 
72r H H H Br H H CO2Me 74 
72s H H H Me H H CO2Me 83 
72t H H H Et H H CO2Me 81 
72u H H H iPr H H CO2Me 80 
72v H H H NO2 H H CO2Me 84 
72w OMe H H F H H CO2Me 90 
72x OMe H H Cl H H CO2Me 88 
72y OMe H H Br H H CO2Me 79 
72z OMe H H Me H H CO2Me 84 
72aa OMe H H Et H H CO2Me 91 
72ab OMe H H iPr H H CO2Me 81 
72ac H OMe Me F H H CO2Me 91 
72ad H OMe Me Cl H H CO2Me 97 
72ae H OMe Me Br H H CO2Me 80 
72af H OMe Me Me H H CO2Me  94 
[a] isolated yields  
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Table 8 (continued): Indoloquinolizine compound collection  
Compound R1 R2 R3 R4 R5 R6 R7 Yield [%][a] 
72ag H OMe Me Et H H CO2Me 85 
72ah H OMe Me iPr H H CO2Me 79 
72ai H OMe Me NO2 H H CO2Me 61 
72aj H H H F H H CN 92 
72ak H H H Cl H H CN 92 
72al H H H Br H H CN 83 
72am H H H Me H H CN 81 
72an H H H Et H H CN 90 
72ao H H H iPr H H CN 87 
72ap OMe H H F H H CN 91 
72aq OMe H H Cl H H CN 82 
72ar OMe H H Br H H CN 80 
72as OMe H H Me H H CN 87 
72at OMe H H Et H H CN 85 
72au OMe H H iPr H H CN 79 
72av H OMe Me F H H CN 91 
72aw H OMe Me Cl H H CN 97 
72ax H OMe Me Br H H CN 90 
72ay H OMe Me Me H H CN 98 
72az H OMe Me Et H H CN 92 
72ba H OMe Me iPr H H CN 89 
72bb OTIPS H H H H H CO2Me 47 
72bc OTIPS H H F H H CO2Me 51 
72bd OTIPS H H Me H H CO2Me 47 
72be OTIPS H H H H H CN 51 
72bf OTIPS H H F H H CN 56 
72bg OTIPS H H Me H H CN 52 
72bh OEt H H H H H CO2Me 74 
72bi OEt H H F H H CO2Me 77 
72bj OEt H H Me H H CO2Me 79 
72bk OEt H H H H H CN 79 
72bl OEt H H F H H CN 79 
72bm OEt H H Me H H CN  71 
[a] isolated yields 
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Table 8 (continued): Indoloquinolizine compound collection 
Compound R1 R2 R3 R4 R5 R6 R7 Yield [%][a] 
72bn Cl H H H H H CO2Me 80 
72bo Cl H H F H H CO2Me 71 
72bp Cl H H Me H H CO2Me 82 
72bq Cl H H H H H CN 84 
72br Cl H H F H H CN 77 
72bs Cl H H Me H H CN 82 
72bt Me H H H H H CO2Me 79 
72bu Me H H F H H CO2Me 84 
72bv Me H H Me H H CO2Me 84 
72bw Me H H H H H CN 90 
72bx Me H H F H H CN 87 
72by Me H H Me H H CN 92 
72bz H OMe Me H H H CO2Me 91 
72ca OMe H Me F H H CO2Me 90 
72cb OMe H Me Me H H CO2Me 88 
72cc OMe H Me H H H CN 85 
72cd OMe H Me F H H CN 81 
72ce OMe H Me Me H H CN 78 
72cf H OMe H H H H CO2Me 79 
72cg H OMe H F H H CO2Me 71 
72ch H OMe H Me H H CO2Me 72 
72ci H OMe  H H H H CN 87 
72cj H OMe H F H H CN 89 
72ck H OMe H Me H H CN 83 
72cl H H H H Me Cl CO2Me 81 
72cm H H H H Me Cl CN 84 
72cn H OMe Me H Me Cl CO2Me 90 
72co H OMe Me H Me Cl CN 93 
72cp H H H Cl H Cl CO2Me 89 
72cq H H H Cl H Cl CN 87 
72cr H OMe Me Cl H Cl CO2Me 94 
72cs H OMe Me Cl H Cl CN 95 
[a] isolated yields 
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3.6. Development of an Enantioselective Inverse Electron Demand Imino 
Diels-Alder Reaction 
3.6.1. The Use of Chiral Catalysts 
Enantioselective steering of a reaction may be accomplished by use of a chiral catalyst. 
Therefore, different metal-chiral ligand complexes were investigated as Lewis acids to form 
indoloquinolizines 72 enantioselectively.[77] 
 
One important feature in the development of a stereoselective reaction, is the 
straightforward measurement of the stereoselectivity, in this case the determination of the 
enantioselective excess with which the product is obtained. The expression of the 
enantioselectivity is most commonly described as an enantiomeric excess.[78] 
 
 
 
The determination of the enantiomeric excess was, in this work, performed by the 
separation and the evaluation of the quantity of each enantiomer by high-pressure liquid 
chromatography employing a chiral stationary phase and UV detection. The CHIRALPAK® IC 
HPLC bulk stationary phase used in this work consists of a 20 µm silica support onto which 
the polymeric chiral selector: cellulose tris (3,5-dichlorophenylcarbamate) has been 
immobilized.  
 
For the separation of the indoloquinolizines produced by imino Diels-Alder, the same solvent 
mixture was used as for the separation of the racemic mixture of centrocountins 17a 
obtained in the 12-step cascade reaction as a racemic mixture, isohexane: dichloromethane: 
ethanol 80:20:1. The separation of a racemic mixture of a product was first performed to 
test the separation performance as well as to determine the position of the peaks for each 
enantiomer. The enantioselective excess was then determined by the comparison of the 
area below each peaks for the separation of stereoselective reaction products. 
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3.6.2. Development of the Enantioselective IEDIDA 
Binol ligands have previously been successfully used in the enantioselective catalysis of aza-
Diels-Alder reactions catalyzed by Zn-Lewis acids.[67] Guillarme and Whiting employed a Zn-
Binol complex in DCM or toluene at -78°C to room temperature to catalyze the normal 
electron demand imino Diels-Alder reaction of electron-poor -iminoester 78 with electron-
rich Danishefsky’s Diene 79 (Scheme 22). 
 
Scheme 22: Enantioselective normal electron demand imino Diels-Alder reaction with 
Danishefsky’s diene 79. 
 
It was envisioned that tetra-coordination of zinc by the Binol ligand 80a, the imine nitrogen 
and the vinylogous ester incorporated into the chromone-derived diene would allow for 
efficient steric discrimination in the ensuing cycloaddition reactions in the case of an inverse 
electron demand reaction as well.[79] With this hypothesis in mind, a procedure was crafted 
where the zinc complex was pre-formed from 20 mol% of the diethylzinc and 40 mol% Binol 
in the reaction solvent followed by the sequential addition of imine 69g and diene 70a. The 
mixture was then left reacting for 12h, purified and the enantiomeric excess was then 
determined by chiral HPLC. The reaction was investigated in different solvents: DMSO, DCM, 
toluene, THF and methanol (Table 9).  
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Table 9: Enantioselective IEDIDA reaction of 69g and 70a. 
 
Entry Metal Ligand Solvent Temp. Time Yield [%][a] ee%[b] 
1 ZnEt2 (S)-Binol DCM R.T. 1h 95 20 
2 ZnEt2 (S)-Binol Toluol R.T. 1h 83 24 
3 ZnEt2 (S)-Binol MeOH R.T. 1h 83 14 
4 ZnEt2 (S)-Binol THF R.T. 1h 75 5 
5 ZnEt2 (S)-Binol DMSO R.T. 1h 88 27 
[a] Isolated yields, [b] Enantiomeric excess determined by chiral HPLC 
 
The thermal imino Diels-Alder reaction between 69g and 70a proceeds without catalyst at 
room temperature, therefore only a low enantiomeric excess was observed in the test 
reactions. A decrease in the reaction temperature was considered as a parameter that would 
increase the enantiomeric excess, by slowing down the non-catalyzed racemic IEDIDA 
reaction. The screening of temperature was performed in DCM and toluene as these were 
the solvents showing the best yields and enantiomeric excess at room temperature (Table 
10). Although the reaction in DMSO showed the highest enantioselectivity, it was not further 
used in the temperature screening as DMSO freezes at lower temperatures. 
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Table 10: Temperature screening for the enantioselective IEDIDA 
 
Entry Metal Ligand Solvent Temp. [°C] Time Yield %][a] ee%[b] 
1 ZnEt2 (S)-Binol 80a DCM (0.02M) 20 1h 95 20 
2 ZnEt2 (S)-Binol 80a DCM (0.02M) 0 4h 80 31 
3 ZnEt2 (S)-Binol 80a DCM (0.02M) -78 12h 71 47 
4 ZnEt2 (S)-Binol 80a Toluene (0.02M) 20 1h 83 24 
5 ZnEt2 (S)-Binol 80a Toluene (0.02M) 0 4h 72 39 
6 ZnEt2 (S)-Binol 80a Toluene (0.02M) -78 12h 66 88 
[a] Isolated yields, [b] Enantiomeric excess determined by chiral HPLC 
 
Treatment of imine 69g and diene 70a with a catalyst formed from 20 mol% of ZnEt2 and 40 
mol% of Binol in toluene at -78°C yields product 74a in 66% yield and 88% ee. To explore the 
influence of the Binol ligands, Binol derivatives 80 substituted at the 3-position (Figure 7) 
were screened using the best reaction conditions determined (Table 11). The highest 
enantiomeric excess, 93%, was obtained using 80e as a chiral ligand. This ligand embodies 
sterically demanding substituents at the 3- positions of the naphtalene rings. The use of 
dibromo-Binol 80b, on the other hand led to the decomposition of the starting materials. 
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Table 11: Screening of the Binol ligands 80 in the development of the enantioselective 
IEDIDA. 
 
Entry Ligand Temp. Time Yield [%][a] ee%[b] 
1 (S)-80a (40mol%) -78°C 12h 66 88 
2 (R)-80a (40mol%) -78°C 12h 63 90 
3 (R)-80b (40mol%) -78°C 12h - - 
4 (R)-80c (40mol%) -78°C 12h 70 83 
5 (R)-80d (40mol%) -78°C 12h 51 93 
6 (R)-80e (40mol%) -78°C 12h 13 89 
[a] Isolated yields, [b] Enantiomeric excess determined by chiral HPLC 
 
Figure 7: Binaphtol derivatives 80 tested in the screening of the enantioselective imino Diels-
Alder reaction 
 
 
3.6.4. Scope of the Enantioselective Reaction 
In the IEDIDA reaction introduction of substituents into the chromone ring of the diene 
consistently yields cycloadducts with high ee and does not markedly influence the reactivity. 
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Thus, both chromenyl acrylates (70a, R7 = CO2Me) as well as chromenyl acrylonitriles (70i, R7 
= CN) react smoothly with imines 69 to provide indoloquinolizines 72 in excellent yields 
(Table 12).[80]  
 
Table 12: Enantioselective synthesis of tetrahydroindoloquinolizines 72 by means of the 
IEDIDA reaction. 
 
Entry Prod. Ligand R1 R2 R3 R4 R5 R6 R7 
Yield[a,b] 
[%] 
Yield[a,c]/ee[d] 
[%] 
1 72a (R)-80e H OMe Me H H H CO2Me 94 81/95 
2 72a (R)-80a H OMe Me H H H CO2Me 94 94/93 
3 72d (R)-80a H H H H H H CN 97 84/23 
4 72g (R)-80a H H H H H H CO2Me 71 82/19 
5 72j (R)-80e H OMe Me H H H CN 89 79/91 
6 72p (R)-80a H OMe Me H H H CN 89 97/86 
7 72ah (R)-80a H OMe Me Cl H H CO2Me 97 80/91 
8 72aj (R)-80a H OMe Me Me H H CO2Me 94 94/90 
9 72ch (R)-80e OMe H Me H H H CO2Me 91 51/93 
10 72ch (R)-80a OMe H Me H H H CO2Me 91 67/90 
11 72ck (R)-80e OMe H Me H H H CN 85 82/92 
12 72ck (R)-80a OMe H Me H H H CN 85 75/86 
13 72cz (R)-80a H OMe Me Cl H Cl CO2Me 94 95/71 
 
[a] Isolated yields, [b] racemic synthesis, [c] enantioselective synthesis, [d] enantiomeric 
excess determined by chiral HPLC 
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However, electron-rich indole-derived imines incorporating at least one methoxy group are 
required for efficient product formation. Imines with a substituent R3 at the imine carbon 
yielded the desired indoloquinolizines in very high yields and predominantly with high 
enantioselectivity. In contrast, in the absence of a substituent at the imine carbon (69a, R3 = 
H) the enantioselectivity was only low. Despite the higher enantioselectivity observed with 
the use of anthracenyl binol 80e, most of the investigation on the scope of the 
enantioselective version of the reaction was carried out for economic considerations with 
the unsubstituted binol 80a. Indeed, the molar cost of 80e is 100 times higher than for 80a. 
 
3.7. Determination of the Absolute Configuration 
The three most common methods for the determination of the absolute configuration of a 
compound are X-ray crystallography, NMR analysis of chirally derivatized compounds, and 
CD-spectroscopy. 
 
3.7.1. X-Ray Crystallography 
X-Ray crystallography is the most reliable way to obtain the three-dimensional absolute 
structure of a molecule, and by extension its absolute configuration.[81,82] Once a single 
crystal is obtained and isolated, a beam of X-ray is projected on it and the intensity and 
angles of the diffraction patterns are analyzed to obtain the structure of the molecule.  
 
Disappointingly, due to the low solubility of the indoloqunolizines in the most common 
solvents used in crystallization or recrystallization processes,[83] no single crystal was 
obtained for any of the compounds depicted in Figure 8a. Some crystallisation was 
attempted from concentrated solutions in DMSO, but none of these experiments led to 
satisfying results: the products either stayed in solution or precipitated abruptly, thus not 
producing any crystal. 
 
Compounds containing nitro groups are known to crystallize better than the equivalent 
lacking the nitro group, therefore indoloquinolizine 72am was synthesized for further 
crystallization attempts (Figure 8). This works as well with compounds containing bromine, 
with the additional advantage, that the determination of the absolute configuration is easier 
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for halogenated compounds. (Compound 72ap). Nevertheless, none of these compounds 
crystallized either, so that X-ray crystallography was abandoned for the determination of the 
absolute configuration of the indoloquinolizines synthesized by imino-Diels-Alder reaction. 
 
Figure 8: Attempted crystallisation of indoloquinolizines 72. 
 
3.7.2. Chiral Derivatization 
The chiral derivatization of indoloquinolizine 72 was envisaged for the determination of the 
absolute configuration by NMR analysis. It consists in the addition of a chiral auxillary with 
known stereochemistry to the Diels-Alder product, thus forming diastereoisomers with one 
known stereogenic center. The NMR properties of diastereoisomers may be different, and it 
is therefore possible to deduce the configuration of the remaining unknown stereogenic 
center based on a Nuclear Overhauser Effect (nOe) spectroscopy experiments.[84,85] In these 
experiments, the orientation and the distances of the protons in the molecule may be 
determined to discriminate the diastereoisomers, thus determining the absolute 
configuration of the unknown stereogenic center.[86,87] 
 
Mosher’s acyl chloride, or -methoxy--trifluoromethylphenylacetyl choride 81 is a 
commercially available chiral derivatizing agent and is widely used for the determination of 
the enantiomeric composition of alcohols and amines. It is possible to determine the 
enantiomeric excess by separation and quantification of the formed diastereoisomers but 
also to determine the absolute configuration by NMR spectroscopy.[88–90] 
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Two strategies were followed for the synthesis of Mosher-derivatized indoloquinolizine 82: 
on one hand, Mosher-functionalized tryptamine derived imine 83 was employed as a 
substrate for a subsequent enantioselective IEDIDA reaction with chromone diene 70a. On 
the other hand, the synthesis of indoloquinolizine 72a by asymmetric IEDIDA was followed 
by protection of the phenol and addition of the Mosher acyl chloride on the indole (Scheme 
23). The formation of the Mosher-functionalized tryptamine derived imine 83 was 
performed following a described procedure[91], in the presence of triethylamine and DMAP 
in DCM at 0 °C. 
 
Disappointingly, none of these experiments led to the targeted compound. The IEDIDA 
reaction resulted in the hydrolysis of the Mosher amide and the recovery of the non-
functionnalized indoloquinolizine 72a  in high yields. The attempts at forming the Mosher 
amide from enantioselectively generated indoloquinolizines were not successful either, 
leading to no reaction. This is probably due to the steric hindrance between the Mosher acid 
and the quite rigid indoloquinolizine tetracycle. 
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Scheme 23: Strategies for the synthesis of Mosher-functionalized indoloquinolizine 82. 
 
3.7.3. CD Spectroscopy 
The determination of the chirality by circular dichroism is a non-empirical method based on 
the Cotton effect, variation of optical rotation as a function of wavelength, and on the 
difference of absorption between left and right circularly polarized light. 
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The absolute configuration of imino Diels-Alder product 72a was determined by comparison 
of its CD-spectrum with the spectrum recorded for the structurally closely related 
centrocountin-1 17a reported earlier (Figure 9).[40] The absolute configuration of 
centrocountins-1 was determined by circular dichroism as well. A circular dichroism 
spectrum was computed from ab-initio time dependent DFT calculations of its molecular 
chiroptical properties for one enantiomer of centrocountin-1 and compared with the 
experimental spectrum.[92,93] As depicted in Figures 9a and 9b, the profiles of the CD-spectra 
match very well with synchronized phase inversions, for both (R)- and (S)-enantiomers. The 
good agreement between the two spectra justifies the assignment of the absolute 
configuration by analogy as (R) for (-)-72a and (S) for (+)-72a. Thus (S)-configured ligand 80 
induces the prefered formation of (S)-configured cycloadducts 72.  
 
 
Figure 9a: Experimental CD-spectra of (R)-centrocountin-1 17a and (-)-72a in ethanol 
(wavelength in nm, CD in mdeg). 
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Figure 9b: Experimental CD-spectra of (S)-centrocountin-1 17a and (+)-72a in ethanol 
(wavelength in nm, CD in mdeg). 
 
The CD spectra for four more enantiopure IEDIDA products were measured to determine the 
consistency of the measurements. The absolute configuration of the other 
indoloquinolizines was assigned by analogy. Analysis of the HPLC traces revealed that the (R) 
enantiomers have shorter retention times in all the separations. 
 
Figure 10: Superposition of chiral HPLC trace for determination of the absolute configuration 
of the centrocountins and indoloquinolizine analogues. 
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3.7.4. Mechanistic Considerations 
The stereochemical course of the IEDIDA reaction can be rationalized by the formation of a 
preformed zinc-Binol complex which then coordinates the imine-nitrogen and the vinylogous 
ester oxygen of the diene (Scheme 24). In the ensuing complex 85, one naphthalene ring 
would be oriented orthogonal to the plane of the heterodienophile and thus shields the Si-
face of the imine. Thereby the attack of the diene is directed to the Re-face of the imines. -
Alkyl groups on the imines also avoid the steric bulk of the naphthalene ring which provides 
further steric bias and leads to high stereoselectivity.  
cScheme 24: Rationale for stereoselection in the asymmetric imino Diels-Alder reaction. 
 
3.8. Conclusion and Outlook 
An enantioselective inverse electron demand imino Diels-Alder reaction was developed for 
the synthesis of centrocountin-like indoloquinolizines 72. The IEDIDA reaction of cyclic 
tryptamine-derived imines 69 with chromone dienes 70 went smoothly, in good yields and 
with enantioselectivity up to 94%. However, new classes of quinolizine molecules could also 
be synthesized using this reaction by replacing indole rings by other cycles in the imines. The 
expanded centrocountin-analogue compound collection accessible thereby opens up to 
establish a structure-activity relationship in plurotypical assays monitoring. 
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4. Synthesis of Ring-fused Tetrahydroisoquinolizines 
by IEDIDA 
 
4.1. Introduction 
It was planned to synthesize a compound collection of centrocountin-analogues in order to 
identify potent biologically active molecules exhibiting similar phenotypic effects on cancer 
cell lines as displayed by centrocountin-1 17a, and with improved activity and selectivity for 
the targets. Therefore, all compounds synthesized by the cascade or the imino Diels-Alder 
reaction were screened in a cell based assay. The extension of the compound library was 
then guided by the results of these screening results. 
 
4.2. Phenotypical Screening and Structure-Activity Relationship 
 The cell biology work was performed by Philipp Küchler and Dr Slava Ziegler. 
 
The synthesized compound collection was subjected to a phenotypic cell based screening in 
order to determine if it shares the bioactivity recorded for the centrocountins 17.[94,95] 
Centrocountins impair centrosome integrity which leads to defects in chromosome 
congression and to an arrest of the cells in metaphase of mitosis. Human cervical carcinoma 
(HeLa) cells were treated with the compounds for 24 h, and the cells were then stained for 
DNA and the mitotic marker phospho-histone H3 to determine the proportion of cells 
arrested in mitosis. For the compounds inducing a mitotic arrest in cells higher than the 
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threshold of 10% of the cell population, a further experiment was performed in order to 
obtain pictures of the cells blocked in mitosis. Thus, HeLa cells were treated with 25µM of 
the hit compounds for 18h before staining for tubulin (green) and DNA (blue). In figure 11, 
for example, compound (R)-centrocountin-1 17a blocked mitosis in cells and induced 
chromosome congression defects (middle image) or aberrant spindle structures (right 
image) in comparison to the negative DMSO control. 
 
 
Figure 11: Representative images of mitotic cells treated with 25µM (R)-17a. 
 
The screening of the indoloquinolizine library revealed 2 compounds, indoloquinolizines 72b 
and 72h showing a biological activity with similar phenotype as displayed by centrocountin-
1 17a (Figure 12). However, the mitotic ratio of HeLa cells upon treatment with these 
compounds was lower than for centrocountin-1, and higher concentrations of the 
substances were required for a similar activity profile. These results led to further expansion 
of the compound collection by applying the inverse electron demand imino Diels-Alder 
reaction to new subclasses of molecules, and for instance replacing the indole ring with other 
heterocycles. 
 
 
Figure 12: New active indoloquinolizines 72b and 72h. 
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4.3. Stability Considerations of Indoloquinolizines and Synthesis of 
Indolopyridinium Salts 
4.3.1. Stability of Indoloquinolizine Samples 
The mass analysis of indoloquinolizine 72h stored as a 10 mM solution in DMSO at room 
temperature, 0°C or -25°C showed the formation of a new by-product over time with a 
molecular weight 2 units lower than the original compound (Figure 13). Some 
indoloquinolizines also showed a mass corresponding to the addition of an equivalent of 
water to the molecules. 
 
  
Figure 13: LC-MS Spectrum of a sample of 72h conserved for 2 weeks in DMSO at room 
temperature. The substance with a retention time of 5.93 min displays a mass [M+H]+ of 399, 
and the one at 9.46 min, a mass [M+H]+ of 401. 
 
Characterization of the byproduct by means of NMR spectroscopy hinted at aromatization 
of the indoloquinolizines to yield the corresponding indolopyridinium salts, e.g. 87e, in which 
the positively charged quaternary amine forms an internal salt with the deprotonated 
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phenol (Figure 14). The 13C NMR spectra also confirmed the formation of the pyridinium salts 
as oxidation products of the indoloquinolizines. Crystallization of the purified pyridinium was 
attempted for X-ray crystallographic analysis, but was not achieved due to the low solubility 
of the pyridinium salts in the most common crystallization solvents. 
 
 
Figure 14: 1H NMR spectra comparison between the fraction with mass 401 and 399. The 
major changes are the disappearance of the signal at 6.28ppm corresponding, and the 
displacement of the signals to 9.09 and 9.37 ppm corresponding to the pyridinium aromatic 
signals. 
 
Monitoring the aromatization of indoloquinolizines showed that in the case of 
indoloquinolizine 72b, in DMSO at room temperature 10% of pyridinium 87a was formed 
over 4 weeks. Nitrile bearing indoloquinolizines showed the fastest aromatization, in which 
the byproducts already appear during the formation of the indoloquinolizines by IEDIDA 
reaction, and fully aromatize within one week at room temperature in DMSO solution as well 
as a dry solid.  
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Table 13: Synthesis of Indolopyridinium inner salts 87. 
 
 
 
 
 
 
 
Product R1 R2 R4 R5 R6 R7 Yield[a] [%] 
87a H H H H H CO2Me 36 
87b H H H H H CN 87 
87c H H H H F CO2Me 41 
87d H H H H F CN 82 
87e OMe H H H H CO2Me 42 
87f OMe H H H H CN 81 
87g H H H H Br CN 92 
[a] isolated yields 
 
It was observed that indoloquinolizines with a hydrogen at the -position to the amine 
undergo this aromatization process and not the analogues with alkyl chains. Forcing the 
formation of the pyridinium was achieved, on the one hand by using DDQ in DCM to oxidize 
the indoloquinolizine, and on the other hand in the case of nitrile bearing compounds, by 
simply heating to 80°C in DMSO, under these conditions oxidation of the quinolizine was 
complete within 24h (Table 13). 
 
4.3.2. Attempts to Avoid Oxidation of Indoloquinolizines and to Induce Stability 
To resolve the problem of the instability of the indoloquinolizines 72, several solutions were 
considered in the synthesis of more stable analogues. However, the synthesis of these 
compounds either should not require too many additional steps from the original product, 
or include a direct IEDIDA reaction from easily modified imines or chromone dienes, to be 
suitable for a compound collection synthesis.  
 
4. Synthesis of Ring-fused Tetrahydroisoquinolizines by IEDIDA  65 
 
 
There are only a few positions where indoloquinolizines can be modified after their 
synthesis, i.e. the free NH of the indole, and the hydroxyl group of the phenol. It has been 
shown before for the centrocountins that modification of the phenolic OH renders the 
molecules inactive in HeLa cells. However, the protection of the indole was not attempted 
previously, and was therefore the major point of focus for the protection of 
indoloquinolizines against oxidation. 
 
With this goal, tryptamine-derived imines were methylated at the indole NH following a 
reported procedure[96] and using methyl iodide and sodium hydride to form both methyl 
protected tryptimine 88 and methyl-protected harmaline 89 (Scheme 25a). These imines 
underwent the asymmetric IEDIDA reaction under standard conditions to yield the 
corresponding indoloquinolizines 90, in very high yields and with high enantioselectivity 
(Scheme 25b). 
 
 
Scheme 25: Attempts at the stabilisation of the indoloquinolizines. a) Synthesis of N-
methylated indole imines 88 and 89. b) Synthesis of N-methylated indoloquinolizines 90. 
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Analysis by mass spectrometry and 1H NMR spectroscopy of a sample of indoloquinolizines 
90 after two weeks in DMSO at room temperature indicated no decomposition or formation 
of the oxidation products. Thus the methyl-derivated indoloquinolizines 90 are stable 
alternatives to the initial indoloquinolizines. Disappointingly, the treatment of HeLa cells 
with these compounds did not reveal any activity with regard to mitotic arrest or 
chromosome alignment anomalies. 
 
4.3.3. Synthesis of Centrocountin Analogues by IEDIDA 
In order to incorporate an ester moeity in -position to the imine in the indoloquinolizines 
(centrocountin has an ester at this carbon), tryptamine-derived iminoester 91 and chromone 
diene 70 were submitted to the imino Diels-Alder reaction (Scheme 26). The synthesis of 
these intermediates would have been interesting for the confirmation of the absolute 
configuration determination by synthesizing enantioselectively centrocountin-1 17a and 
closely related analogues by IEDIDA reaction. -Iminoester 91 was synthesized following a 
procedure described by Tietze et al.[97], by reaction of tryptamine with ethyl glyoxylate in 
ethanol to form a cyclic amine that was then oxidized with potassium permanganate. 
 
Scheme 26: Synthesis of centrocountin analogue 17. 
 
Disappointingly, the expected products were not formed. The NMR and mass analyses 
revealed the formation of carboline 92a and amine 93a, as products of the dismutation of 
-iminoester 91a (Figure 15 and Scheme 27). 
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Scheme 27: Dismutation of iminoester 91a. 
 
A set of screening reactions was performed in the absence of heating or zinc chloride and in 
different solvents, but the dismutation was always faster than the imino Diels-Alder reaction 
giving no traces of the targeted centrocountin 17.  
 
 
Figure 15: LCMS profile of the reaction outcome from -iminoester 91a after 5min in DMSO 
at room temperature with ZnCl2. 
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4.4. Synthesis of Pyridoisoquinolines and Pyridoisoquinoliums 
4.4.1. Preparation of the Dihydroisoquinolines 
In order to study the importance of the indole ring on the biological activity, it was replaced 
with another ring-system. Therefore, it was planned to employ different cyclic imines 
embodying other aryl or hetero/carbocyclic rings. Several 3,4-dihydroisoquinolines 94 are 
commercially available, and in addition, further imines were synthesized from 
phenylethylamines 46 following the procedure described for the indole-derived imines 69 
(Table 14). 
 
Table 14: Preparation of 3,4-dihydroisoquinolines 94 by Bischler-Napieralski reaction. 
 
Compound R1 R2 R3 Yield[a] 
94a H H Et 83 
94b H H iPr 86 
94c H H Cy 74 
94d OMe OMe Et 89 
94e OMe OMe iPr 84 
[a] isolated yields 
 
An alternative method for the synthesis of these imines is the N-chlorination of cyclic amines 
95 with N-chlorosuccinimide followed by treatment with KOH in ethanol (Scheme 28). This 
synthesis was adapted from the described procedure in Rouchaud and co-workers.[98] 
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Scheme 28: Preparation of 3,4-dihydroisoquinolines 94 by oxidation. 
 
4.4.2. Development and Scope of the Reaction 
The synthesis of the pyridoisoquinolines 96 was performed following the optimized general 
procedures for the racemic and asymmetric synthesis of indoloquinolizines 72. Application 
of this method led to the formation of the desired products in appreciable yields and with 
enantiomeric excesses in similar ranges as observed for the indole-derived compounds. 
Moreover, some limitations observed previously for the IEDIDA synthesis of the 
indoloquinolizines were not recorded for isoquinolizines. For instance, it was possible to 
enantioselectively synthesize isoquinolizines bearing bigger groups on R3 (Table 15), like 
ethyl-, iso-propyl- or cyclohexyl groups which was not possible for indole derivatives. A 
decrease of yield and enantioselectivity was observed in correlation with the increase in the 
size of the R3 groups. The introduction of a phenyl group or an ester group at this position 
still remains challenging. 17 pyridoisoquinolines 96 were synthesized enantioselectively 
(Table 15), and 48 additional racemic pyridoisoquinolines 96 were synthesized with the 
IEDIDA reaction.  
 
Table 15: Scope of the IEDIDA reaction to the pyridoisoquinolines 96. 
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Table 15: Pyridoisoquinolines 96 compound collection. 
Compound R1 R2 R3 R4 R5 R6 R7 
Yield[a,b] 
[%] 
Yield[a,c]/ee[d] [%] 
96a H H H H H H CO2Me 93 81/27 
96b H H H H H H CO2Et 92 - 
96c H H H H H H CO2tBu 87 - 
96d H H H H H H CN 96 84/24 
96e H H H H H H COOH 79 - 
96f OMe OMe Me H H H CO2Me 94 - 
96g OMe OMe Me H H H CO2Et 93 - 
96h OMe OMe Me H H H CO2tBu 82 - 
96i OMe OMe Me H H H CN 97 - 
96j OMe OMe Me H H H COOH 83 - 
96k OEt OEt Me H H H CO2Me 76 71/83 
96l OEt OEt Me H H H CO2Et 79 - 
96m OEt OEt Me H H H CO2tBu 78 - 
96n OEt OEt Me H H H CN 77 80/83 
96o OEt OEt Me H H H COOH 64 - 
96p OH OH H H H H CO2Me 51 - 
96q OH OH H H H H CN 52 - 
96r OH OH Me H H H CO2Me 60 - 
96s OH OH Me H H H CN 63 - 
96t OH OH H Cl H Cl CO2Me 49 - 
96u OH OH H Cl H Cl CN 47 - 
96v OH OH Me Cl H Cl CO2Me 48 - 
96w OH OH Me Cl H Cl CN 53 - 
96x H H Me H H H CO2Me 89 75/93 
96y H H Et H H H CO2Me 84 54/83 
96z H H iPr H H H CO2Me 80 51/69 
96aa H H Cy H H H CO2Me 79 47/91 
96ab OMe OMe Et H H H CO2Me 81 67/82 
96ac OMe OMe iPr H H H CO2Me 84 - 
96ad OMe OMe Cy H H H CO2Me 85 - 
96ae H H Me H H H CN 91 79/91 
96af H H Et H H H CN 83 - 
96ag H H iPr H H H CN  78 - 
[a] Isolated yields, [b] racemic synthesis, [c] enantioselective synthesis, [d] enantiomeric 
excess determined by chiral HPLC 
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Table 15: Pyridoisoquinolines 96 compound collection. (continued) 
Compound R1 R2 R3 R4 R5 R6 R7 Yield[a,b] [%] Yield[a,c]/ee[d] [%] 
96a H H Cy H H H CN 64 - 
96ai OMe OMe Et H H H CN 93 - 
96aj OMe OMe iPr H H H CN 90 - 
96ak OMe OMe Cy H H H CN 83 41/83 
96al H H H F H H CO2Me 90 - 
96am H H H Cl H H CO2Me 90 - 
96an H H H Br H H CO2Me 84 - 
96ao H H H Me H H CO2Me 92 - 
96ap H H H Et H H CO2Me 90 - 
96aq H H H iPr H H CO2Me 93 - 
96ar OMe OMe Me F H H CO2Me 97 - 
96as OMe OMe Me Cl H H CO2Me 92 86/87 
96at OMe OMe Me Br H H CO2Me 81 - 
96au OMe OMe Me Me H H CO2Me 92 61/87 
96av OMe OMe Me Et H H CO2Me 80 - 
96aw OMe OMe Me iPr H H CO2Me 87 - 
96ax H H H F H H CN 89 - 
96ay H H H Cl H H CN 81 - 
96az H H H Br H H CN 70 - 
96ba H H H Me H H CN 88 - 
96bb H H H Et H H CN 91 - 
96bc H H H iPr H H CN 92 - 
96bd OMe OMe Me F H H CN 97 - 
96be OMe OMe Me Cl H H CN 96 90/83 
96bf OMe OMe Me Br H H CN 89 - 
96bg OMe OMe Me Me H H CN 94 84/80 
96bh OMe OMe Me Et H H CN 90 - 
96bi OMe OMe Me iPr H H CN 90 - 
96bj H H H Cl H Cl CO2Me 90 - 
96bk H H H Cl H Cl CN 93 - 
96bl OMe OMe Me Cl H Cl CO2Me 91 90/88 
96bm OMe OMe Me Cl H Cl CN 97 86/86 
[a] Isolated yields, [b] racemic synthesis, [c] enantioselective synthesis, [d] enantiomeric 
excess determined by chiral HPLC 
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4.4.3. Pyridoisoquinolinium Salts 
Stability experiments were performed with pyridoisoquinolines 96 (R3 = H), to detect the 
formation of pyridoisoquinolinium zwitterionic salts 97. Indeed, the formation of these 
pyridinium salts was also observed in DMSO samples at room temperature, however the 
amount (only 17% after 2 weeks for 97a) was much smaller than for indoloquinolizines 72. 
The nitrile bearing pyridoisoquinolines were oxidizing much faster here as well, and the 
corresponding pyridoisoquinoliniums 97 were obtained with yields up to 97% in DMSO at 80 
°C (Table 16). 
 
Table 16: Synthesis of pyridoisoquinolinium inner salts 97. 
 
 
 
 
Product R1 R2 R4 R5 R6 R7 Yield[a] [%] 
97a H H H H H CO2Me 15 
97b H H H H H CN 97 
97c H H H H F CO2Me 18 
97d H H H H F CN 94 
97e OMe OMe H H H CO2Me 25 
97f OMe OMe H H H CN 85 
97g H H H H Br CN 96 
97h H H H H Et CN 91 
97i H H H H iPr CN 92 
97j H H H H NO2 CN 79 
97k H H H Cl Me CN 85 
97l H H Cl H Cl CN 90 
[a] isolated yields using Method A 
 
4.4.4. Phenotypical Screening of the Pyridoisoquinolines  
The screening of the compound collection of pyridoisoquinolines 96 and 
pyridoisoquinolinium salts 97 identified compounds that led to the accumulation of mitotic 
cells. When pyridinium salts 97 were found inactive, compound 96a was identified as the 
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most potent, more potent than centrocountin-1 17a (Figure 16). Separate investigation of 
the enantiomers of 96a revealed that only the (S)-configured cycloadduct arrested the cells 
in mitosis whereas the (R)-enantiomer was inactive at the applied concentrations (see Figure 
16a). To further assess the ability of 96a for inhibition of cell proliferation HeLa cells were 
treated for 48 h with (R)- and (S)-enantiopure 96a as well as with racemic 96a and cell 
viability was determined by means of the WST-1 reagent[99]. Whereas pyridoisoquinoline 96a 
reduced the viability of HeLa cells with a half-maximal inhibitory concentration (IC50) of 9.7 
± 1.1µM, (S)-96a more potently inhibited cell proliferation with an IC50 of 4.7 ± 0.5 µM (Figure 
16b). The (R)-enantiomer again proved to be inactive. It was concluded that 96a and (S)-96a 
were more potent than the centrocountin-1 17a (IC50 17.2  ± 2.4 µM). Increase of the 
proportion of mitotic cells upon treatment with pyridoisoquinoline 96a followed by cell 
death was independently confirmed by live cell imaging. Cell death was observed 24 hours 
after treatment of the cells with the compound. Immunostaining of DNA and tubulin 
revealed the same phenotype as for the centrocountins, with misaligned chromosomes 
during metaphase and tripolar spindles. (Figure 16c).  
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Figure 16: Pyridoisoquinoline 96a induces chromosome congression defects and mitotic 
arrest in HeLa cells. a) HeLa cells were treated with enantiopure and racemic 96a for 24 h 
prior to staining with anti-phospho-histone H3 antibody and DAPI to detect the mitotic 
marker and DNA respectively. Data are shown as mean values ± SD. b) Influence of 96a and 
the enantiomers (S/R)-96a on the viability of HeLa cells. Cells were treated with the 
compounds for 48 h prior to determination of cell viability using the WST-1 proliferation 
reagent. Data were normalized to DMSO and represent mean values ± SD. c) 96a and (S)-96a 
cause chromosome congression defects. (R)-96a is inactive. HeLa cells were treated with 
compounds at a concentration of 10 µM for 24 h prior to staining with anti--tubulin 
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antibody coupled to FITC (green) and DAPI (blue) to visualize tubulin and DNA respectively. 
Arrows indicate misaligned chromosomes during metaphase. Scale bar: 10 µm. 
 
4.5. Synthesis of Ring-fused Quinolizines 
Exploration of the scope of the reaction was attempted by replacing the indole or phenyl 
groups by other cycles like thiophene, cyclohexane or by the synthesis of bicyclic 
quinolizines. The synthesis of these new compound subclasses 98-101 (Table 17), proceeded 
under the same reaction conditions as applied for the synthesis of indoloquinolizines 72.  
 
Table 17: Synthesis of ring-fused quinolizines 98-101. 
 
 
 
 
 
 
 
 
Product R
4 R5 R6 R7 Yield[a] [%] Yield [%][a] / ee[c] [%] 
98a H H H CO2Me 87 - / - 
98b H H H CN 91 - / - 
99a F H H CO2Me 95 - / - 
99b F H H CN 97 - / - 
99c H H H CO2Me 77 - / - 
99d H H H CN 83 - / - 
100a Br H H CO2Me 66 62/44 
100b Et H H CN 68 62/29 
101a iPr H H CO2Me 51 - / - 
101b NO2 H H CN 54 - / - 
 [a] isolated yields using Method A, [b] isolated yields using method B, [c] enantiomeric 
excess determined by chiral HPLC. 
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However, compounds 98, 99 and 101 proved to be unstable and the measurement of the 
enantiomeric excess by chiral HPLC was not successful as the compounds decomposed 
before or during the measurements. For dihydroquinolizines 100, the enantiomeric excess 
was low, possibly due to a lack of chiral bias in the absence of any directing aromatic cycle 
that could interact with the naphtalene of the Binol ligands. 
 
4.6. Synthesis of Indoloindolizines and Dihydropyridoisoindoles 
4.6.1. Preparation of the Methanamine Derived Imines 
The indolemethanamine derived imines 107 and benzylamine derived imines 110 were 
synthesized as described above for the tryptamine and the phenylethylamine derived imines 
by Bischler-Napieralski reaction in good yields (Scheme 29). 
 
Scheme 29: Preparation of the cyclic imines 107 and 110. 
 
4.6.2. Development and Scope of the Reaction 
No further optimization of the IEDIDA reaction was required for the reaction of cyclic imines 
107 and 110 and chromone dienes 70. A small collection of these dihydroindoloindolizines 
111 was synthesized in order to evaluate their biological activity compared to centrocountin-
1 17a as well as to compound 96a (Table 18). The yields, reaction velocity and 
enantioselectivity were coherent with the observations made for the synthesis of 
indoloquinolizines 72 by means of the imino Diels-Alder reaction. However, none of these 
compounds was active in the cell based assay. 
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Table 18: Synthesis of dihydroindoloindolizine 111. 
 
 
 
 
 
 
 
 
 
 
 
Product R1 R2 R3 R4 R5 R6 R7 
Yield[a/b] 
[%] 
ee[c] [%] 
111a H OMe Me H H H CO2Me -/97 84 
111b H OMe Me F H H CO2Me -/97 74 
111c H OMe Me H H H CN -/91 92 
111d H OMe Me F H H CN -/92 88 
111e H H H H H H CO2Me 78/- - 
111f H H H F H H CO2Me 79/- - 
111g H H H H H H CN 68/- - 
111h H H H F H H CN 64/- - 
[a] isolated yields using method A, [b] isolated yields using method B, [c] enantiomeric 
excess determined by chiral HPLC. 
 
4.6.3. The Dihydropyridoisoindoles 
Similarly, dihydropyridoisoindoles 112 were synthesized following the general procedures 
and using cyclic imines, synthesized from benzylamines by Bischler-Napieralski reaction 
(Table 19). Dihydropyridoisoindoles 112 were obtained in comparable yields and 
enantiomeric excesses, and had similar properties compared to the pyridoisoquinolines 96. 
However, no formation of pyridinium or other byproduct was observed this time, making 
them interesting compounds for chemical biological investigations. Disappointingly, 
dihydropyridoisoindoles 112 also did not show any activity in the phenotypical screening. 
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Table 19: Synthesis of dihydropyridoisoindole 112 
 
 
 
 
Product R1 R2 R3 R4 R5 R6 R7 
Yield[a/b] 
[%] 
ee[c] [%] 
112a OMe OMe Me H H H CO2Me -/83 79 
112b OMe OMe Me F H H CO2Me -/86 82 
112c OMe OMe Me H H H CN -/79 84 
112d OMe OMe Me F H H CN -/74 77 
112e H H H H H H CO2Me 78/- - 
112f H H H F H H CO2Me 82/- - 
112g H H H H H H CN 67/- - 
112h H H H F H H CN 68/- - 
[a] isolated yields using method A, [b] isolated yields using method B, [c] enantiomeric 
excess determined by chiral HPLC. 
 
Lacking of biological activity of compounds 111 and 112 might be due to the change in the 
3D structure of the compound compared to the ring-fused quinolizines 72 or 96. This 
difference in geometry is depicted in the computed structures shown in Figure 17. 
 
 
Figure 17: Three-dimensional structures of a) dihydropyridoisoindole 112a and b) 
pyridoisoquinoline 96a. These 3D structures were obtained by molecular dynamics and 
modelization in the MM2 force field.[100] 
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4.7. Synthesis of Hexacyclic indoloquinolizines 
4.7.1. Design of the Synthesis 
The synthesis of hexacyclic indoloquinolizines was envisaged to further expand the scope of 
the imino-Diels-Alder reaction as well as to elucidate the mechanistic proposal made for the 
IEDIDA reaction between chromone dienes 70 and indole-derived cyclic imines 69. The use 
of disubstituted chromone dienes 113 was planned to prevent the retro-Michael/chromone 
ring opening step and thus to provide hexacyclic products (114, Scheme 30).  
 
Scheme 30: Trapping of the intermediate 35 to obtain hexacyclic indoloquinolizines 114. 
 
4.7.2. Preparation of the Disubstituted Chromone Dienes 
Disubstituted dienes were synthesized using a different method than the procedure 
employed for the monosubstituted dienes described by Hangarge et al.[101] 3-
formylchromones 18 were reacted with malonates 116 in water to undergo a Knoevenagel 
condensation (Scheme 31). The dienes were formed quantitatively and simple filtration of 
the compounds from the aqueous reaction mixture yielded the pure products that were used 
in the imino Diels-Alder reaction. 
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Scheme 31: Preparation of the disubstituted chromone dienes 113. 
 
4.7.3. Development and Scope of the Reaction 
The disubstituted chromone dienes 113 underwent the asymmetric IEDIDA reaction with 
both tryptamine-derived imines 69 and the dihydroisoquinolines 94 to form hexacyclic 
indoloquinolizines 114 and pentacyclic pyridoisoquinolines 117, in yields ranging from 64 to 
85% respectively as a 1:1 mixture of two diastereoisomers (Table 20 and 21). The 
diastereoisomers could not be separated, as under the condition of purification by flash 
chromatography, the mixture underwent a retro-IEDIDA reaction catalysed by acidic silica 
gel that led to the recovery of up to 60% of the starting materials. 
 
Table 20: Synthesis of the hexacyclic indoloquinolizines 114 
 
 
 
 
 
 
 
Product R1 R2 R3 R4 R5 R6 R7 
Yield[a] 
[%] 
114a H H H H H H CN 64 
114b H H H H H H CO2Me 65 
114c H OMe Me H H H CN 81 
114d H OMe Me H H H CO2Me 82 
 
[a] isolated yields of the diastereoisomer mixture 
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Table 21 Synthesis of the pentacyclic pyridoisoquinolines 117 
 
 
 
7 
 
 
 
Product R1 R2 R3 R4 R5 R6 R7 
Yield[a] 
[%] 
117a H H H H H H CN 61 
117b H H H H H H CO2Me 59 
117c H OMe Me H H H CN 68 
117c H OMe Me H H H CO2Me 72 
 
[a] isolated yields of the diastereoisomer mixture 
 
4.8. Use of Other Dienes 
In order to further explore the scope of the imino Diels-Alder reaction, the reaction was also 
attempted with other cyclic and non-cyclic dienes, in replacement for the chromone dienes. 
To this end, commercially available diene 118, and dienes 119 and 120 obtained from the 
corresponding aldehydes following Wittig reaction with phosphoranylidenes, were 
subjected to the IEDIDA reaction with tryptimine 69a, harmaline 69p, and 3,4-
dihydroisoquinoline 94a, following the general procedure for the synthesis of racemic 
indoloquinolizines (20mol % of zinc chloride in DMSO at 80°C, Scheme 32). No conversion 
was observed after one week. The use of harsher conditions was also attempted by refluxing 
the substrates with 1 equivalent of zinc chloride in xylene, and only decomposition of the 
dienes was observed after 2 days. 
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Scheme 32: IEDIDA reaction of cyclic dienes 123-125. 
 
4.9. Summary of the Compound Collection Synthesis 
The investigation of the scope of the enantioselective inverse electron demand imino-Diels-
Alder reaction led to the synthesis of numerous ring-fused isoquinolines and quinolizines 
subclasses that are related to the natural product-inspired centrocountins 17 (Figure 18).  
 
Figure 18: The common quinolizine core of the IEDIDA reaction and the principle hits 17a, 
96a and 72b developed in this work. 
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This further exploration led, among others, to the discovery of pyridoisoquinoline (S)-96a a 
mitotic modulator more potent than centrocountin-1 17a regarding its ability to influence 
the cell cycle in HeLa cells. However it seems that small modifications of the structure of the 
ring-fused quinolizines induces a substantial change in the activity of the compounds. The 
addition of a methyl group on the indole nitrogen leads to complete loss of the mitotis 
modulating activity. The depletion of one of the CH2 groups in the C ring of the ring-fused 
quinolizines also leads to inactivity. On the other hand, the substitution patterns on the 
indole and the chromone aromatic rings is less significant important for the activity of the 
ring-fused quinolizines. The activity was consistently the highest in the absence of further 
substituents (Figure 19). 
 
 
Figure 19: Structure activity relationship of the ring-fused quinolizines library toward mitotic 
modulation of HeLa cells. In red, the positions where substitution is not tolerated for the 
retention of the biological activity, green for tolerated substitution, orange for non 
conclusive.  
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5. Summary 
Natural product- inspired compound libraries are efficient tools for the discovery of 
compounds with interesting biological activities and may provide inspiration for medicinal 
chemistry research[102] The goal is the assembly in the most efficient and concise way of 
substances with a structural ressemblance to known natural products. The design of these 
analogues can also rely on the interaction of the substances with the corresponding 
biological target.[7,103,104] 
 
In the syntheses of ring-fused quinolizines described in this work, the inspiration for the 
construction of the compound collection came from an interesting class of indole alkaloids 
displaying cytotoxic or anti-cancer activities, and particularly from the centrocountins, 
mitotic modulators that target centrosomal proteins. A unique 12-step organocatalysed 
cascade sequence yielded a small collection of centrocountins in a straightforward one-pot 
procedure from commercially available starting materials: 3-formylchromones, DMAD and 
tryptamines. Mechanistic investigations of the 12-step cascade reaction were carried out by 
trapping and characterizing intermediates as well as control experiments. These 
informations yielded in the development of new alternative cascade synthesis routes to 
indoloquinolizines and analogues, and overcame the limitations of the long cascade 
syntehsis established before.  
 
Inspired from the last part of the cascade synthesis of the centrocountins, an inverse electron 
demand imino-Diels-Alder between cyclic imines and chromone dienes was developed to 
access new centrocountin analogues (Scheme 33), as well as, an enantioselective version of 
this reaction using a pre-formed zinc-Binol complex providing access to the 
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indoloquinolizines 72 and the pyridoisoquinolines 96. Indeed, diethylzinc and (R)-Binol (R)-
80a or (R)-dianthracenylbinol (R)-80e were dissolved under argon in dry toluene and stirred 
for 15 minutes. After the sequential addition of cyclic imine (synthesized by a Bischler-
Napieralski reaction) 69 or 94 and chromone diene 70 (synthesized by a Wittig reaction) the 
mixture was allowed to react for 12 to 24h at -78°C in a sealed tube under Ar to yield after 
purification by flash chromatography the targeted quinolizines in yields up to 97% and ees 
up to 94%. 
 
Scheme 33: Synthesis of indoloquinolizine 72a by asymmetric IEDIDA reaction of cyclic imine 
69g with chromone diene 70a. 
 
These very encouraging results led to further expansion of the scope of the reaction and 
further construction of the centrocountin-based compound collection. New subclasses of 
compounds were synthesized by means of the IEDIDA reaction: various ring-fused 
quinolizines including pyridoisoquinolines 96, dihydropyridoisoindole 111, hexacyclic 
indoloquinolizines 114 and pentacyclic pyridoisoquinolines 117, as well as internal 
indolopyridinium 87 and pyridoisoquinolinium 97 salts obtained by oxidation (Figure 20). 
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Figure 20: Representation of the diverse quinolizine subclasses synthesized by the inverse 
electron demand imino-Diels-Alder reaction. 
 
Pyridoisoquinoline 96a was identified as a potent mitotic modulator displaying the same 
phenotype (Figure 21) when exposed to  HeLa cells as was observed for centrocountin-1 17a, 
but at lower concentrations. Treatment of cells with (S)-96a led to a higher count of mitotic 
cells at equivalent concentrations (mitotic ratio at 10 µM: 25% instead of 12%), and an effect 
on the cells was observable at lower concentration than for centrocountin-1 17a (IC50 : 4.7 ± 
0.5 µM instead of 17.2 ± 2.4 µM). Furthermore, it was observed that only the (S)-96a 
enantiomer was active on HeLa cells, experiments carried out with (R)-96a rendered no 
activity at all. 
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Figure 21: Images of mitotic HeLa cells under the influence of hit compound 96a. 
 
Further application of the inverse electron demand imino-Diels-Alder reaction can be easily 
imagined, for instance, using  new cyclic dienes to replace the chromones, in order to find 
new compound classes which may be very different to centrocountins but still provide 
interesting molecules for chemical biology research. 
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5. Zusammenfassung 
Die Synthese Naturstoffinspirierter Substanzsammlungen sind effiziente Werkzeuge für die 
Entdeckung neuer Verbindungen mit interessanten biologischen Aktivitäten, und 
möglicherweise zur Entdeckung neuer Leitstrukturen für die Wirkstoffentwicklung.[103] Ziel 
dieser Methode ist es, auf einfachem und elegantem Wege Substanzen mit strukturellen 
Ähnlichkeiten zu dem zugrundeliegenden Naturstoff zu synthetisieren.[7, 104-105] 
 
Die in dieser Arbeit beschriebene Synthese anellierter Quinolizine wurde durch Indol-
Alkaloide mit antitumor- und zytotoxischen Effekten inspiriert, insbesondere durch die 
Centrocountine, eine Klasse von Mitosemodulatoren, die zentrosomale Proteine 
addressieren.  
 
Durch eine einzigartige organokatalysierte Kaskadenreaktion über 12 Stufen wurde eine 
kleine Sammlung von Centrocountinen in einem direkten Ein-Topf-Verfahren aus 
kommerziell erhältlichen 3-Formylchromonen, DMAD und diversen Tryptaminen erhalten. 
Die mechanistische Untersuchung dieser 12-Stufen-Kaskadenreaktion wurden 
Zwischenprodukte abgefangen. Diese Erkenntnisse ermöglichen einen neuen Zugang zu 
alternativen Kaskadenreaktionen zur Synthese von Indoloquinolizinen und deren Analoga, 
die die bisherigen Einschränkungen langer Kaskadenreaktionen überwinden. 
 
Inspiriert vom letzten Teil der Kaskadenreaktion zur Synthese von Centrocountinen wurde 
eine enantioselektive Imino-Diels-Alder Reaktion mit inversem Elektronbedarf (IEBIDA) 
zwischen zyklischen Iminen und Chromondienen entwickelt um Zugang zu neuen 
Centrocountinanaloga zu erhalten (Abbildung 1), wie Indoloquinolizine 72 and 
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Pyridoisoquinoline 96. Zu trockenem Toluol wurde Diethylzinc and (R)-Binol (R)-80a or (R)-
dianthracenylbinol (R)-80e gegeben bei raum Temperatur unter Argon. Nach 15 Minuten, 
wurde zyklische Imin 69 oder 94 (synthetisiert durch eine Bischler-Napieralski reaktion) 
zugegeben, und die Reaktionsmischung wurde dann auf -78 °C gekühlt. Nach Zugabe von 
Chromone dien 70 (synthetisiert durch eine Wittig reaktion) wurde die Lösung weitere 12 
bis 24 Stunde gerührt unter Argon und ergab nach Reinigung mittels Flash Chromatographie 
die gezielten quinolizine mit Ausbeute bis 97% und ees bis 94%. 
 
Abbildung 1: Synthese von Indoloquinolizin 72a durch asymmetrische IEBIDA-Reaktion von 
zyklischen Imin 69g mit Chromondien 70a. 
 
Diese ermutigenden Ergebnisse führten zur Erweiterung des Anwendungsbereiches der 
Reaktion und dem weiteren Ausbau der Centrocountin-inspirierten Substanzsammlung. Als 
neue Verbindungsunterklassen wurden mittels der IEBIDA Reaktion Pyridoisoquinoline 96, 
Dihydropyridoisoindole 111, hexazyklische Indoloquinolizine 114 und pentazyklische 
Pyridoisoquinoline 117, sowie die Zwitterionen aus deren Oxidation, die 
Indolopyridiniumsalze 87 und Pyridoisoquinolinesalze 97 synthetisiert (Abbildung 2). 
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Abbildung 2: Darstellung von den diversen Quinolizines Unterklassen synthetisiert durch 
Imino-Diels-Alder Reaktion mit inversem Elektronbedarf. 
 
Bei der biologischen Evaluierung wurde Pyridoisoquinolin 96a als potenter Modulatorder 
Mitose identifiziert, der denselben Phänotyp wie Centrocountin-1 in Hela-Zellen induziert 
jedoch bereits bei niedrigeren Konzentrationen wirksam ist. Die Behandlung von Zellen mit 
(S)-96a ergab einen höheren Anteil mitotischer Zellen bei gleicher Substanzkonzentration 
(bei 10µM 25% statt 12%) in Vergleich zu Centrocountin-1, und der Effekt auf die Zellen war 
bereits bei niedrigeren Konzentrationen nachweisten (17a, IC50 : 4.7 ± 0.5 µM statt 17.2 ± 
2.4 µM). Es wurde zudem beobachtet, dass nur das (S)-Enantiomer für die biologische 
Aktivität verantwortlich ist, das (R)-Enantiomer ist inaktiv. 
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Abbildung 3: Bilder von den mitotischen HeLa-Zellen bei Behandlung mit 96a. 
 
Weitere Anwendungen der im Rahmen dieser Arbeit entwickelten Imino-Diels-Alder-
Reaktion mit inversem Elektronbedarf sind aufgeregt und scheinen möglich. Zum Beispiel 
könnten die Chromondiene durch andere zyklische Diene ersetzt werden, um neue 
Substanzunterklassen zu entdecken, die sich strukturell von den originalen Centrocountinen 
unterscheiden, aber weiterhin biologische Aktivität aufweisen und somit neue interessante 
Substanzen für die Forschung im Bereich der chemischen Biologie darstellen. 
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II. Abbreviations 
Ac  Acyl 
Ar  Aryl 
AU   Arbitrary Units 
Binol  1,1'-Bi-2-naphthol 
Boc  tert-Butoxycarbonyl 
CC1  Centrocountin-1 
CD  Circular dichroism 
CDCl3  Deuterated chlroform 
Crm1  Chromosomal region maintenance exportin 1 
CSA  Camphorsulfonic acid 
Cy  Cyclohexyl 
DAPI  4’,6-Diamidino-2-phenylindole 
DCM   Dichloromethane 
DDQ  2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DMAD  Dimethyl acetylenedicarboxylate 
DMSO  Dimethylsulfoxide 
DMSO-d6 Deuterated dimethylsulfoxide 
EDG  Electron donating group 
ee  Enantiomeric excess 
Eq.  Equivalents 
ESI  Electrospray Ionisation 
Et  Ethyl 
Et3N  Triethylamine 
EWG  Electron withdrawing group 
gHSQC  Gradient heteronuclear single quantum coherence 
HOMO  Highest occupied molecular orbital 
HPLC  High pressure liquid chromatography 
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HRMS  High resolution mass spectrometry 
Hz  Hertz 
IC50  Half maximal inhibitory concentration 
IEDIDA  Inverse-electrion-demand imino-Diels-Alder 
iPr  Iso-propyl 
J  Coupling constant 
LCMS  Liquid chromatography mass spectrometry 
LUMO  Lowest unoccupied molecular orbital 
Me  Methyl 
MeCN  Acetonitrile 
MW  Microwave irradiation 
NMR  Nuclear magnetic resonance 
Ph  Phenyl 
Ref.  Reference 
Rf  Retention factor 
RT  Room temperature 
SAR  Structure Activity Relationship 
SN  Nucleophilic substitution 
TFA  Trifluoroacetic acid 
THF  Tetrahydrofurane 
TLC  Thin layer chromatography 
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III. Experimental Part 
III.1. General 
Unless otherwise noted, chemicals were obtained from Aldrich, Acros, TCI, or Alfa and were 
used without further purification. Reactions were carried out in standard glassware or a 
Radleys Carousel 12 parallel reactor using anhydrous solvents. 1H and 13C NMR 
spectroscopic data were recorded on a Varian Mercury VX 400 or Varian 500-inova 500 
spectrometer at RT unless stated otherwise. NMR spectra were calibrated to the solvent 
signals of CDCl3 or DMSO. Enantiomeric resolution was performed using a Dionex UltiMate 
2000 HPLC with a 10mm Daicel IC column. HRMS-(FAB)-MS were taken on Finnigan MAT 
MS 70. HRMS-ESI were taken on an Accela HPLC-System (HPLC column 50/1 Hypersil 
GOLD 1.9 µm) with an LTQ Orbitrap mass spectrometer from Thermo Scientific. (ESI)-MS 
were measured by using an Agilent 1100 series binary pump together with a reversed-phase 
HPLC column (Macherey-Nagel). Optical rotation was measured using a Schmidt & Hänsch 
Polartronic polarimeter in cuvettes with a path length of 10 cm.  CD-spectra were recorded on 
a J-815 CD-Spectrometer from Jasco. TLC was performed on Merck silica gel 60 F254 
aluminum sheet. For flash chromatography silica gel from Baker (40-70 µm) was used. MPLC 
was performed using an Isco sq16 with pre-packed cartridges (30 µm, spherical silica gel) 
from Interchim were used. 
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III.2. Experimental Part for Chapter 2 
III.2.1. Synthesis of Pyridinium Salts 39-42 
Compound 39: 
 
To a solution of the functionalized pyridine 40 (31.5 mg; 0.1 mmol; 1.0 eq) in 
dichloromethane (5 mL) was added 3-(2-bromoethyl)indole 41 (23.5 mg; 0.105 mmol; 1.05 
eq) and Et3N (15 µL; 0.11 mmol; 1.1 eq), and the solution was stirred at room temperature 
for 12h. Triethylamine and the solvent were removed under reduced pressure and the 
residue was dried in vacuo. TLC (cyclohexane/ethyl acetate, 2:4 v/v): RF = 0.30; 1H NMR (400 
MHz, CDCl3) δ 11.60 (s, 1H), 10.97 (s, 1H), 9.04 (d, J = 2.0 Hz, 1H), 8.46 (d, J = 2.0 Hz, 1H), 7.64  
– 7.56 (m, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.47 – 7.43 (m, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.15 – 7.09 
(m, 2H), 7.06 (s, 1H), 6.98 – 6.93 (m, 2H), 4.98 (t, J = 7.1 Hz, 2H), 4.04 (s, 3H), 3.97 (s, 3H), 
3.32 ppm (t, J = 7.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 191.8, 168.2, 166.8, 164.6, 153.8, 
151.3, 138.8, 136.4, 134.2, 133.1, 133.0, 127.8, 126.4, 122.7, 120.5, 119.7, 119.2, 118.8, 
118.2, 112.6, 112.1, 111.2, 109.0, 53.6, 53.5, 27.6 ppm. HRMS (m/z): [M]+ calcd for 
C26H23N2O6, 459.15506; found, 459.15492. 
 
Compound 42: 
 
To a solution of the functionalized pyridine 43 (25.3 mg; 0.1 mmol; 1.0 eq) in DCM (5 mL) 
was added 3-(2-bromoethyl)indole 44 (23.5 mg; 0.105 mmol; 1.05 eq)  and Et3N (15 µL; 0.11 
mmol; 1.1 eq), and the solution was stirred at room temperature for 12h. Triethylamine and 
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the solvent were removed under reduced pressure and the residue was dried under vacuum. 
TLC (cyclohexane/ethyl acetate, 2:4 v/v): RF = 0.30; 1H NMR (400 MHz, CDCl3) δ 11.21 (s, 1H), 
9.19 (d, J = 1.9 Hz, 1H), 8.51 (d, J = 1.9 Hz, 1H), 7.64 – 7.58 (m, 1H), 7.50 (d, J = 8.1 Hz, 1H), 
7.34 (d, J = 7.9 Hz, 1H), 7.17 – 7.12 (m, 1H), 7.04 (s, 1H), 7.00 (m, 1H), 4.89 (t, J = 7.1 Hz, 2H), 
4.03 (s, 3H), 4.02 (s, 3H), 3.98 (s,3H), 3.30 ppm (t, J = 7.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) 
δ 191.4, 169.2, 166.2, 163.9, 144.8, 143.5, 138.5, 137.8, 136.2, 134.6, 126.1, 122.3, 120.4, 
119.5, 118.4, 112.7, 111.4, 108.2, 57.0, 54.1, 54.0 ppm. HRMS (m/z): [M]+ calcd for 
C21H21N2O6, 397.13941; found, 397.13975. 
 
III.2.2. Synthesis of Indoloquinolizines 17 
General procedures for the synthesis of indoloquinolizines 
 Method Ia: General procedure for the cascade synthesis of indoloquinolizines using 
arylethylamines 
A 3-formylchromone-derivative 18 (1.0 eq.) was dissolved in toluene (10 ml/mmol) by 
heating to 80°C. Acetylenedicarboxylate 19 (1.3 eq.) was added followed by 
triphenylphosphine (0.6 eq.). Monitoring by TLC (dichloromethane/methanol 100:1) showed 
completion typically after 5-10 minutes. Tryptamine-derivative 23 (1.1 eq.) was added. After 
the tryptamine had dissolved camphorsulfonic acid (1.5 eq.) was added. Monitoring by TLC 
(cyclohexane/ethyl acetate 60:40) showed that the reaction was complete after 5-30 
minutes. The reaction mixture was directly subjected to column chromatography (30 g silica 
gel, cyclohexane/ethyl acetate 80:20). Removal of the solvent yielded the product as yellow 
solid. In case the purity was not sufficient the product was precipitated from methanol.  
 
 Method Ib: General procedure for the cascade synthesis of indoloquinolizines using 
arylethylamine hydrochlorides: 
To a solution of tricyclic benzopyrone 22 (1.0 eq.) and substituted tryptamine hydrochloride 
23 (1.05 eq.) in DMF (5 ml/mmol) was added triethylamine (1.1 eq.). After 30 minutes TLC 
(cyclohexane/ethyl acetate 3:2) showed that the starting material had been consumed. TFA 
(4 eq.) was added and after 30 minutes the formed intermediate could not be detected 
anymore in TLC (cyclohexane/ethyl acetate 3:2), the solution was diluted with ethyl acetate 
(30 ml/mmol) and washed with water (100 ml/ mmol), NaHCO3 (satd. 50 ml/mmol) and brine 
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(50 ml/mmol), dried over MgSO4 and the solvent was removed under reduced pressure. The 
crude product was coevaporated with methylene chloride and dissolved in methanol (5 
ml/mmol). After complete precipitation of the product the solvent was decanted and the 
product was washed with a small amount of methanol and dried in vacuo.  
 
 Method II: General procedure for the aza-Diels-Alder synthesis 
Tryptamine 23 (0.10 mmol; 1.0 eq.) was dissolved under argon in 5mL dry DMSO, and 3-
formylchromone 18 (0.10 mmol; 1.0 eq.) and molecular sieves 4Å were added. The mixture 
was left at 80°C for 2h and monitored by TLC (Cyclohexane/EtOAc 2:1). The 
acetylenedicarboxylate 19 (1.2 eq.; 0.12 mmol) and dry ZnCl2 (0.10 mmol; 1.0 eq) were 
added and the mixture was allowed to react for 12-24h at 80°C in a sealed tube under Ar. 
Disappearance of DMAD on TLC indicates complete reaction (cyclohexane/ethyl acetate 2:1). 
The reaction mixture is then diluted in 10 mL brine and extracted with 3x10mL DCM. The 
organic phase was dried over Na2SO4 evaporated to give a residue that is purified by flash 
chromatography as described in method Ia to yield a yellow solid, that can be recrystallized 
in methanol.  
 
Compound 17a: 
 
Compound 17a was synthesized according to method Ia. Yellow solid; m.p.: 237°C 
(decomposition); TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.43; 1H NMR (400 MHz, 
CDCl3) δ 11.25 (s, 1H), 9.05 (s, 1H), 7.92 (d, J = 1.5 Hz, 1H), 7.59 (d, J = 1.5 Hz, 1H), 7.45 (dd, J 
= 7.9, 1.6 Hz, 1H), 7.42 – 7.37 (m, 1H), 7.32 (d, J = 8.2 Hz, 1H), 7.16 (ddd, J = 8.2, 7.1, 1.1 Hz, 
1H), 7.05 (dd, J = 11.0, 3.9 Hz, 1H), 6.97 (dd, J = 8.3, 1.0 Hz, 1H), 6.89 – 6.81 (m, 1H), 3.84 (s, 
3H), 3.82 (s, 3H), 3.73 (dd, J = 13.2, 5.0 Hz, 2H), 3.09 (ddd, J = 15.6, 12.0, 5.7 Hz, 1H), 2.98 
(dd, J = 15.5, 3.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 192.0, 170.0, 168.7, 161.3, 153.5, 
136.3, 136.1, 134.5, 131.8, 130.4, 126.1, 123.0, 119.9, 119.9, 118.6, 118.4, 118.3, 113.4, 
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112.0, 108.2, 106.0, 68.0, 53.9, 52.6, 52.5, 23.2 ppm; HRMS (m/z): [M+H]+ calcd for 
C26H23O6N2, 459.15506; found, 459.15454. 
 
Compound 17b: 
 
Compound 17b was synthesized according to method Ia. Yellow solid; m.p.: 197°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.36; 1H NMR (400 MHz, CDCl3) δ 10.99 (s, 1H), 9.03 
(s, 1H), 7.93 (d, J = 1.4 Hz, 1H), 7.60 (d, J = 1.3 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.35 (d, J = 8.1 
Hz, 1H), 7.23 – 7.17 (m, 3H), 7.10 (dd, J = 11.0, 3.9 Hz, 1H), 6.94 – 6.85 (m, 1H), 3.86 (s, 3H), 
3.81 (s, 3H), 3.79 – 3.68 (m, 2H), 3.15 (ddd, J = 15.7, 11.9, 5.7 Hz, 1H), 2.93 (dd, J = 15.5, 3.6 
Hz, 1H), 2.28 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 192.1, 170.2, 168.9, 159.1, 153.5, 136.5, 
136.2, 135.5, 132.0, 130.4, 127.8, 126.1, 123.1, 120.0, 119.7, 118.4, 118.2, 113.4, 112.0, 
108.2, 106.1, 68.1, 54.0, 52.7, 52.5, 23.4, 20.8 ppm; HRMS (m/z): [M+H]+ calcd for 
C27H25O6N2, 473.17071; found, 473.17010. 
 
Compound 17c: 
 
Compound 17c was synthesized according to method Ia. Yellow solid; TLC (cyclohexane/ethyl 
acetate, 3:2 v/v): RF = 0.41; 1H NMR (400 MHz, CDCl3) δ 10.99 (s, 1H), 9.04 (s, 1H), 7.94 (d, J 
= 1.3 Hz, 1H), 7.66 (d, J = 1.2 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.27 – 
7.21 (m, J = 14.6 Hz, 2H), 7.20 – 7.15 (m, 1H), 7.09 (dd, J = 11.1, 3.8 Hz, 1H), 6.90 (d, J = 9.1 
Hz, 1H), 3.82 (s, 3H), 3.85 – 3.76 (m, J = 13.2 Hz, 1H), 3.79 (s, 3H), 3.70 (dd, J = 13.1, 5.3 Hz, 
1H), 3.15 (ddd, J = 17.5, 12.0, 5.6 Hz, 1H), 2.93 (dd, J = 15.5, 3.8 Hz, 1H), 2.89 – 2.77 (m, 1H), 
1.20 (d, J = 6.9 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 192.1, 170.1, 168.8, 159.2, 153.7, 138.9, 
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136.9, 136.1, 133.1, 132.0, 127.9, 126.1, 123.1, 120.0, 119.6, 118.4, 118.1, 112.9, 112.0, 
108.2, 105.9, 68.1, 54.0, 52.6, 33.4, 27.1, 24.3, 24.3, 23.4 ppm HRMS (m/z): [M+H]+ calcd for 
C29H29O6N2, 501.20201; found, 501.20134. 
 
Compound 17d: 
 
Compound 17d was synthesized according to method Ia. Yellow solid; m.p.: 209 °C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.44; 1H NMR (400 MHz, CDCl3) δ 11.26 (s, 1H), 9.11 
(s, 1H), 7.93 (d, J = 1.5 Hz, 1H), 7.59 (d, J = 1.5 Hz, 1H), 7.50 – 7.37 (m, J = 15.6, 9.9, 7.4, 1.2 
Hz, 3H), 7.33 (dt, J = 8.2, 0.9 Hz, 1H), 7.18 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.09 (ddd, J = 8.0, 
7.1, 1.0 Hz, 1H), 7.00 (dd, J = 8.3, 0.9 Hz, 1H), 6.85 (ddd, J = 7.8, 7.3, 1.2 Hz, 1H), 4.38 – 4.19 
(m, 4H), 3.93 – 3.78 (m, 1H), 3.71 (dd, J = 13.2, 4.9 Hz, 1H), 3.15 (ddd, J = 15.5, 12.0, 5.6 Hz, 
1H), 2.93 (dd, J = 15.5, 3.5 Hz, 1H), 1.34 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 192.0, 169.2, 168.3, 161.3, 153.6, 136.1, 135.8, 134.5, 131.9, 130.4, 
126.1, 123.0, 120.0, 119.9, 118.6, 118.4, 118.3, 114.2, 112.0, 108.2, 106.1, 68.2, 63.2, 61.8, 
52.4, 23.3, 14.5, 14.3 ppm; HRMS (m/z): [M+H]+ calcd for C28H27O6N2, 487.18636; found, 
487.18574. 
 
Compound 17e: 
 
Compound 17e was synthesized according to method Ia. Yellow solid; m.p.: 208°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.02 (s, 1H), 9.11 
(s, 1H), 7.93 (d, J = 1.5 Hz, 1H), 7.61 (d, J = 1.5 Hz 1H), 7.47 (dd, J = 7.9, 0.5 Hz, 1H), 7.38 – 
7.29 (m, 1H), 7.22 (s, 1H), 7.21 – 7.15 (m, 2H), 7.09 (ddd, J = 7.9, 7.1, 1.0 Hz, 1H), 6.90 (d, J = 
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8.5 Hz, 1H), 4.38 – 4.21 (m, 4H), 3.92 – 3.81 (m, 1H), 3.72 (dd, J = 13.2, 5.3 Hz, 1H), 3.15 (ddd, 
J = 15.5, 12.0, 5.6 Hz, 1H), 2.93 (dd, J = 15.5, 3.7 Hz, 1H), 2.28 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H), 
1.25 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 192.1, 169.3, 168.4, 159.1, 153.6, 136.1, 
136.0, 135.4, 132.1, 130.4, 127.7, 126.1, 123.0, 119.9, 119.7, 118.3, 118.2, 113.9, 112.0, 
108.1, 106.1, 68.2, 63.2, 61.7, 52.4, 23.4, 20.8, 14.5, 14.3 ppm; HRMS (m/z): [M+H]+ calcd for 
C29H29O6N2, 501.20201; found,: 501.20133. 
 
Compound 17f: 
 
Compound 17f was synthesized according to method II. Yellow solid; m.p.: 232 °C 
(decomposition); TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.38; 1H NMR (400 MHz, 
CDCl3) δ 11.09 (s, 1H), 9.02 (s, 1H), 7.90 (d, J = 1.5 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.47 (d, J 
= 7.9 Hz, 1H), 7.39 (d, J = 2.5 Hz, 1H), 7.37 – 7.30 (m, 2H), 7.21 – 7.17 (m, 1H), 7.17 – 7.05 (m, 
1H), 6.94 (d, J = 8.8 Hz, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 3.81 – 3.73 (m, 2H), 3.16 (ddd, J = 15.6, 
11.9, 5.8 Hz, 1H), 2.95 (dd, J = 15.6, 3.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.6, 170.0, 
168.7, 159.8, 153.6, 136.2, 135.8, 134.3, 131.7, 129.5, 126.0, 123.4, 123.2, 120.8, 120.0, 
120.0, 118.4, 114.0, 112.0, 108.2, 105.8, 68.2, 54.1, 52.8, 52.7, 23.4 ppm; HRMS (m/z): 
[M+H]+ calcd for C26H22O6N2Cl, 493.11609; found, 493.11565.  
 
Compound 17g: 
 
Compound 17g was synthesized according to method II. Yellow solid; m.p.: 163°C 
(decomposition); TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.26; 1H NMR (400 MHz, 
CDCl3) δ 11.25 (s, 1H), 8.92 (s, 1H), 7.93 – 7.92 (m, 1H), 7.61 (d, J = 1.4 Hz, 1H), 7.46 – 7.36 
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(m, 2H), 7.22 (s, 1H), 7.03 – 6.98 (m, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.88 – 6.81 (m, 2H), 3.85 (s, 
3H), 3.83 (s, 3H), 3.81 (s, 3H), 3.80 – 3.67 (m, 2H), 3.12 (ddd, J = 15.6, 12.0, 5.7 Hz, 1H), 2.88 
(dd, J = 15.4, 4.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 192.1, 170.1, 168.8, 161.5, 154.5, 
153.5, 136.3, 134.6, 132.5, 131.4, 130.4, 126.5, 120.0, 118.6, 118.5, 113.6, 113.3, 112.8, 
107.9, 106.1, 100.4, 68.1, 56.2, 54.0, 52.7, 52.6, 23.3 ppm; HRMS (m/z): [M+H]+ calcd for 
C27H25O7N2, 489.16563; found, 489.16500.  
 
Compound 17h: 
 
Compound 17h was synthesized according to method Ib. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.42; 1H NMR (400 MHz, CDCl3):  11.23 (s, 1H), 
9.17 (s, 1H), 7.95 (d, J = 1.5 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.45 – 7.40 (m, 2H), 7.29 – 7.27 
(m, 2H), 7.23 – 7.21 (m,1H), 7.02 – 7.00 (m, 1H), 6.85 – 6.89 (m 1H), 3.87 (s, 3H), 3.83 (s, 3H), 
3.80 – 3.72 (m, 2H), 3.16 – 3.08 (m, 1H) 2.90 – 2.86 (m, 1H).; 13C NMR (100 MHz, CDCl3):  
190.7, 169.8, 168.6, 161.2, 153.2, 136.4, 134.8, 134.4, 130.1, 127.6, 125.7, 120.8, 119.7, 
119.2, 118.5, 118.4, 118.3, 113.2, 112.9, 107.7, 106.0, 67.7, 53.8, 52.5, 52.1, 22.8 ppm; HRMS 
(ESI): calcd for C26H22O6N2Br [M+H+]: 537.06558, Found: 537.06527. 
 
Compound 17i: 
 
Compound 17i was synthesized according to method Ib. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3):  11.27 (s, 1H), 
8.94 (s, 1H), 7.96 (d, J = 1.5 Hz, 1H), 7.62 (d, J = 1.5 Hz, 1H), 7.45 (dd, J = 1.6, 7.8 Hz, 1H), 7.41 
(td, J = 1.6, 7.8 Hz, 1H), 7.26 (m, 1H), 7.23 (m, 1H), 7.02 (m, 2H), 6.87 (t, J =7.8 Hz, 1H), 3.87 
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(s, 3H), 3.81 (s, 3H), 3.78-3.71 (m, 2H), 3.17-3-09 (m, 1H) 2.93-2-88 (m, 1H), 2.44 (s, 3H); 13C 
NMR (100 MHz, CDCl3):  191.8, 169.9, 168.2, 161.1, 153.3, 136.0, 134.3, 131.6, 130.1, 129.0, 
126.1, 124.4, 119.7, 118.4, 118.2, 117.7, 113.3, 111.4, 107.4, 105.8, 67.9, 53.6, 52.4, 52.3, 
23.0, 21.4 ppm; HRMS (ESI): Calculated for C27H25O6N2 [M+H+]: 473.17126, Found: 
473.17160. 
 
Compound 17j: 
 
Compound 17j was synthesized according to method Ib Yellow solid; m.p. 230-235°C 
(decomposition); TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0,59; 1H NMR (400 MHz, 
CDCl3) δ 12.05 (s, 1H), 9.08 (s, 1H), 7.92 (d, J = 1.3 Hz, 1H), 7.56 (s, 1H), 7.49 – 7.31 (m, 8H), 
7.21 (s, 1H), 7.12 (d, J = 7.1 Hz, 1H), 6.47 (d, J = 8.9 Hz, 1H), 5.15 (s, 2H), 3.86 (d, J = 5.6 Hz, 
3H), 3.82 (s, 3H), 3.85 – 3.67 (m, 2H), 3.15 (ddd, J = 17.7, 12.1, 5.7 Hz, 1H), 2.93 (dd, J = 15.3, 
3.7 Hz, 1H), 2.20 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 192.0, 170.2, 168.8, 161.6, 161.4, 152.8, 
136.9, 136.9, 136.1, 131.9, 129.4, 128.8, 128.1, 127.2, 126.1, 123.0, 119.9, 118.3, 114.7, 
113.7, 113.0, 111.9, 108.3, 106.2, 102.5, 70.2, 68.0, 53.9, 52.5, 52.3, 23.1, 8.2 ppm; HRMS 
(m/z): [M+H]+ calcd for C34H31O7N2, 579.21258; found, 579.21214. 
 
Compound 17k: 
 
Compound 17k was synthesized according to method Ib. Yellow  solid; m.p.: 212°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3) δ 11.25 (s, 1H), 8.98 
(s, 1H), 7.92 (d, J = 1.5, 1H), 7.59 (d, J = 1.5, 1H), 7.43 (dd, J = 7.8, 1.6, 1H), 7.39 (ddd, J = 8.4, 
7.3, 1.7, 1H), 7.22 (dd, J = 8.8, 0.5, 1H), 7.00 (dd, J = 8.4, 1.0, 1H), 6.89 (d, J = 2.4, 1H), 6.87 – 
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6.82 (m, 2H), 4.37 – 4.20 (m, 4H), 3.90 – 3.78 (m, 1H), 3.83 (s, 3H), 3.71 (dd, J = 13.2, 5.0, 1H), 
3.11 (ddd, J = 15.5, 12.0, 5.7, 1H), 2.88 (dd, J = 15.4, 3.5, 1H), 1.34 (t, J = 7.1, 3H), 1.25 (t, J = 
7.1, 3H); 13C NMR (101 MHz, CDCl3) δ 192.1, 169.3, 168.3, 161.4, 154.4, 153.5, 135.7, 134.5, 
132.7, 131.3, 130.4, 126.5, 120.1, 118.6, 118.4, 114.2, 113.1, 112.8, 107.9, 106.1, 100.3, 68.2, 
63.2, 61.7, 56.1, 52.4, 23.4, 14.5, 14.3 ppm; HRMS (m/z): [M+H]+ calcd for C29H29O7N2, 
517.19693; found, 517.19623. 
 
Compound 17l: 
 
Compound 17l was synthesized according to method Ib. Yellow solid; m.p.: 180 °C 
(decomposition); TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.25 ; 1H NMR (400 MHz, 
CDCl3) δ 8.87 (s, 1H), 7.93 (s, 1H), 7.62 (s, 1H), 7.50 – 7.35 (m, 2H), 7.16 (d, J = 8.7 Hz, 1H), 
7.01 (d, J = 8.3 Hz, 1H), 6.91 – 6.81 (m, 2H), 6.80 – 6.70 (m, 1H), 3.86 (d, J = 1.9 Hz, 3H), 3.82 
(d, J = 1.9 Hz, 3H), 3.72 (ddd, J = 18.3, 12.4, 4.7 Hz, 2H), 3.09 – 2.94 (m, 1H), 2.78 (dd, J = 15.4, 
3.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 192.1, 170.1, 168.7, 161.3, 153.6, 149.9, 136.3, 
134.6, 132.7, 131.4, 130.4, 126.8, 119.9, 118.7, 118.4, 113.4, 112.9, 112.6, 107.6, 106.0, 
102.9, 68.0, 54.0, 52.6, 52.5, 23.1 ppm; HRMS (m/z): [M+H]+ calcd for C26H23O7N2, 475.14998; 
found, 475.14940. 
 
Compound 17m: 
 
Compound 17m was synthesized according to method Ia. Yellow solid; m.p.: 197°C 
(decomposition); TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.28; 1H NMR (400 MHz, 
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CDCl3) δ 11.11 (s, 1H), 8.89 (s, 1H), 7.89 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.53 (d, J 
= 2.4 Hz, 1H), 7.46 (dd, J = 8.8, 2.5 Hz, 1H), 7.24 (d, J = 8.8 Hz, 1H), 6.88 (ddd, J = 11.2, 6.3, 1.9 
Hz, 3H), 3.87 (s, 3H), 3.83 (s, 3H), 3.82 (s, 3H), 3.81 – 3.72 (m, 2H), 3.13 (ddd, J = 15.5, 11.8, 
5.8 Hz, 1H), 2.91 (dd, J = 15.5, 3.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 170.0, 168.7, 
160.2, 154.5, 153.6, 137.1, 135.6, 132.4, 132.4, 131.3, 126.4, 121.4, 120.4, 114.1, 113.4, 
112.8, 110.3, 107.8, 105.8, 100.2, 68.2, 56.1, 54.1, 52.8, 52.7, 23.4 ppm; HRMS (m/z): [M+H]+ 
calcd for C27H24O7N2Br, 567.07614; found, 567.07611.  
 
Compound 17n: 
 
Compound 17n was synthesized according to method Ia. Using the general procedure with 
1.1 eq. 1-(R)-(-)-camphorsulfonic acid and 5 ml/mmol toluene. Yellow solid; m.p.: 220°C 
(decomposition); TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.37; 1H NMR (400 MHz, 
CDCl3) δ 11.11 (s, 1H), 9.02 (s, 1H), 7.90 (d, J = 1.4 Hz, 1H), 7.60 (d, J = 1.4 Hz, 1H), 7.53 (d, J 
= 2.4 Hz, 1H), 7.50 – 7.42 (m, 2H), 7.35 (d, J = 8.1 Hz, 1H), 7.22 – 7.15 (m, 1H), 7.10 (t, J = 7.5 
Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 3.81 – 3.72 (m, 2H), 3.25 – 3.08 (m, 
1H), 2.95 (dd, J = 15.5, 3.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 170.0, 168.7, 160.2, 
153.7, 137.1, 136.2, 135.7, 132.4, 131.7, 126.0, 123.2, 121.4, 120.4, 120.0, 118.4, 114.0, 
112.0, 110.3, 108.2, 105.8, 68.2, 54.1, 52.8, 52.7, 23.4 ppm; HRMS (m/z): [M+H]+ calcd for 
C26H22O6N2Br, 537.06558; found, 537.06542. 
 
Compound 17o: 
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Compound 17o was synthesized according to method Ia with 1.1 eq. 1-(R)-(-)-
camphorsulfonic acid and 5 ml/mmol toluene. Yellow solid; m.p.: 238.2°C (decomposition); 
TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.59 (s, 1H), 
9.01 (s, 1H), 7.88 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 1.5 Hz, 1H), 7.53 – 7.43 (m, J = 7.1, 1.5 Hz, 
2H), 7.34 (d, J = 8.1 Hz, 1H), 7.32 (d, J = 2.5 Hz, 1H), 7.20 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.10 
(ddd, J = 7.9, 7.1, 1.0 Hz, 1H), 3.89 (s, 3H), 3.83 (d, J = 2.6 Hz, 3H), 3.81 (dd, J = 13.2, 5.2 Hz, 
2H), 3.16 (ddd, J = 15.6, 11.9, 5.8 Hz, 1H), 2.96 (dd, J = 15.6, 3.6 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 189.8, 169.9, 168.6, 155.7, 153.9, 136.2, 135.4, 134.0, 131.5, 128.0, 126.0, 124.0, 
123.3, 123.2, 121.5, 120.1, 118.4, 114.2, 112.0, 108.2, 105.6, 68.3, 54.2, 52.9, 52.9, 23.4 ppm; 
HRMS (m/z): [M+H]+ calcd for C26H21O7N2Cl2, 527.07712; found, 527.07684. 
 
Compound 17p: 
 
Compound 17p was synthesized according to method Ia with 1.1 eq. 1-(R)-(-)-
camphorsulfonic acid and 5 ml/mmol toluene. Yellow solid; m.p.: 131°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.75 (s, 1H), 9.01 
(s, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.63 (d, J = 1.5 Hz, 1H), 7.49 (d, J = 2.3 
Hz, 1H), 7.47 (dd, J = 7.9, 0.6 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 7.20 (ddd, J = 8.2, 7.1, 1.2 Hz, 
1H), 7.10 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 3.88 (s, 3H), 3.82 (d, J = 2.8 Hz, 3H), 3.80 – 3.70 (m, 
2H), 3.16 (ddd, J = 15.6, 11.8, 5.8 Hz, 1H), 2.96 (dd, J = 15.6, 3.5 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 189.7, 169.9, 168.6, 157.0, 153.9, 139.5, 136.2, 135.4, 131.6, 131.5, 126.0, 123.3, 
121.9, 120.1, 118.4, 114.2, 113.2, 112.0, 110.3, 108.2, 105.5, 68.3, 54.2, 52.9, 52.9, 23.4 ppm; 
HRMS (m/z): [M+H]+ calcd for C26H21O6N2Br2, 614.97609; found, 614.97638. 
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Compound 17q: 
 
Compound 17q was synthesized according to method Ia with 1.1 eq. 1-(R)-(-)-
camphorsulfonic acid and 5 ml/mmol toluene. Yellow solid; m.p.: 245°C (decomposition); 
TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.24 (s, 1H), 
9.06 (s, 1H), 7.94 (d, J = 1.4 Hz, 1H), 7.63 (d, J = 1.3 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.43 (s, 
1H), 7.39 (d, J = 8.1 Hz, 1H), 7.27 – 7.19 (m, 1H), 7.18 – 7.10 (m, 1H), 6.92 (s, 1H), 3.92 (s, 3H), 
3.86 (s, 3H), 3.85 – 3.75 (m, 2H), 3.20 (ddd, J = 15.8, 11.9, 5.8 Hz, 1H), 2.98 (dd, J = 15.5, 3.6 
Hz, 1H), 2.39 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 190.6, 170.1, 168.8, 159.9, 153.4, 143.4, 
136.2, 135.9, 131.8, 130.0, 126.1, 123.9, 123.1, 120.5, 120.0, 118.8, 118.4, 113.8, 112.0, 
108.2, 105.8, 68.1, 54.1, 52.8, 52.6, 23.4, 20.8 ppm; HRMS (m/z): [M+H]+ calcd for 
C27H24O6N2Cl, 507.13174; found, 507.13130. 
 
Compound 17r: 
 
Compound 17r was synthesized according to method Ia. 
17r: Diastereomer 1: Yellow solid mp 202°C; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 
0.37; 1H NMR (400 MHz, CDCl3):  11.36 (s, 1H), 9.31 (s, 1H), 7.90 (d, J = 1.4 Hz, 1H), 7.60 (d, 
J = 1.4 Hz, 1H), 7.57-7.55 (d, J = 7.8 Hz, 1H), 7.53-7.51 (d, J = 7.8 Hz, 1H), 7.44 (t, J = 7.7 Hz, 
1H), 7.38-7.36 (d, J = 7.8 Hz, 1H), 7.21 (t, J = 7.7 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 7.04-7.01 (d, 
J = 7.8 Hz, 1H), 6.90 (t, J = 7.5 Hz, 1H), 4.52-4.50 (dd, J = 6.2, 1.0 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 
3H), 3.67 (s, 3H), 3.58-3.53 (dd, J = 15.7, 1.0 Hz, 1H), 3.32-3-27 (dd, J = 15.7, 6.2 Hz, 1H).; 13C 
NMR (100 MHz, CDCl3):  192.4, 169.1, 168.5, 167.5, 161.4, 155.1, 136.1, 135.3, 134.7, 130.6, 
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128.2, 125.4, 123.0, 119.8, 119.6, 118.5, 118.3, 118.2, 116.6, 111.7, 108.3, 107.0, 66.2, 65.3, 
53.3, 53.0, 52.3, 22.9 ppm; Calculated for C28H25O8N2 [M+H+]: 517.16109, Found: 517.16119. 
17r: Diastereomer 2: Yellow solid; mp 209°C; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 
0.37; 1H NMR (400 MHz, CDCl3):  11.26 (s, 1H), 8.92 (s, 1H), 7.89 (d, J = 1.4 Hz, 1H), 7.64 (d, 
J = 1.4 Hz, 1H), 7.50-7.48 (d, J = 7.9 Hz, 1H), 7.47-7.45 (dd, J = 7.8, 1.6 Hz, 1H), 7.40 (td, J = .8, 
1.6 Hz, 1H), 7.36-7.34 (d, J = 7.9 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 7.01-
6.99 (d, J = 7.8 Hz, 1H), 6.87 (t, J = 7.5 Hz, 1H), 4.57 (t, J = 7.6 Hz, 1H), 3.91 (s, 3H), 3.85 (s, 
3H), 3.85 (s, 3H), 3.32-3-30 (d, Hz, J =7.6 Hz, 2H).; 13C NMR (100 MHz, CDCl3):  192.4, 170.0, 
168.4, 168.0, 161.4, 155.1, 136.2, 135.3, 134.7, 131.6, 130.4, 125.8, 123.0, 119.9, 119.4, 
118.4, 118.3, 118.1, 114.9, 111.8, 108.2, 107.9, 68.9, 65.3, 54.0, 53.2, 52.6, 22.9 ppm; 
Calculated for C28H25O8N2 [M+H+]: 517.16109, Found: 517.16129. 
 
Compound 17s: 
 
Compound 17s was synthesized according to method Ia with 1.1 eq. 1-(R)-(-)-
camphorsulfonic acid. Amorphous yellow solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF 
= 0.77; 1H-NMR (400 MHz, CDCl3) δ 11.31 (s, 1H), 9.14 (s, 1H), 7.81 (d, J = 1.6 Hz, 1H), 7.60 
(d, J = 1.5 Hz, 1H), 7.49 – 7.37 (m, 3H), 7.32 (dt, J = 8.2, 0.9 Hz, 1H), 7.18 (ddd, J = 8.2, 7.1, 1.2 
Hz, 1H), 7.09 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 7.01 (dd, J = 8.3, 0.8 Hz, 1H), 6.86 (ddd, J = 8.5, 
7.6, 1.2 Hz, 1H), 3.88 (ddd, J = 16.5, 12.2, 4.4 Hz, 1H), 3.72 (dd, J = 13.1, 5.1 Hz, 1H), 3.15 
(ddd, J = 15.4, 12.0, 5.6 Hz, 1H), 2.94 (dd, J = 15.5, 3.6 Hz, 1H), 1.58 (s, 9H), 1.48 (s, 9H); 13C-
NMR (101 MHz, CDCl3) δ = 191.9, 167.9, 161.3, 153.4, 136.1, 134.8, 134.4, 132.5, 130.3, 
126.1, 122.7, 120.2, 119.7, 118.4, 118.3, 118.2, 116.1, 111.9, 107.8, 105.9, 83.8, 82.3, 69.1, 
52.0, 28.4, 27.8, 23.3 ppm; HRMS (m/z): [M+H]+ calcd for C32H35O6N2, 543,24896; found, 
543,24858. 
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Compound 17t: 
 
Compound 17t was synthesized according to method Ia with 1.1 eq. 1-(R)-(-)-
camphorsulfonic acid. Yellow solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.29; 1H-
NMR (400 MHz, CDCl3) δ 9.11 (s, 1H), 7.77 (s, 1H), 7.63 (s, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.35 
(d, J = 8.1 Hz, 1H), 7.31 – 7.25 (m, 1H), 7.20 (t, J = 7.6 Hz, 1H), 7.11 (t, J = 7.5 Hz, 1H), 6.63 (d, 
J = 8.3 Hz, 1H), 6.45 (d, J = 8.3 Hz, 1H), 3.85 (s, 3H), 3.81 (s, 3H), 3.83 – 3.68 (m, 2H), 3.74 (s, 
3H), 3.24 – 3.06 (m, 1H), 2.94 (dd, J = 15.4, 4.1 Hz, 1H); 13C-NMR (101 MHz, CDCl3) δ 189.3, 
170.0, 169.0, 160.3, 158.2, 154.0, 137.3, 136.1, 133.5, 132.1, 126.1, 122.9, 119.8, 118.3, 
112.4, 112.1, 111.9, 110.7, 108.1, 107.7, 102.8, 68.1, 55.8, 53.8, 52.5, 52.5, 23.3 ppm; HRMS 
(m/z): [M+H]+ calcd for C27H25O7N2, 489.16563; found, 489.16490. 
 
Compound 17u: 
 
Compound 17u was synthesized according to method Ib. Yellow solid; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.58; 1H-NMR (400 MHz, CDCl3) δ 11.14 (s, 1H), 
9.08 (s, 1H), 7.96 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 1.4 Hz, 1H), 7.46 (dd, J = 7.8, 1.5 Hz, 1H), 7.42 
(ddd, J = 8.4, 7.3, 1.6 Hz, 1H), 7.33 (d, J = 7.3 Hz, 1H), 7.07 – 6.98 (m, 3H), 6.91 – 6.84 (m, 1H), 
3.88 (s, 3H), 3.90 – 3.82 (m, 1H), 3.84 (s, 3H), 3.79 – 3.68 (m, 1H), 3.16 (ddd, J = 15.8, 12.1, 
5.6 Hz, 1H), 2.93 (dd, J = 15.4, 4.1 Hz, 1H), 2.47 (s, 3H); 13C-NMR (101 MHz, CDCl3) δ 192.00, 
170.00, 168.87, 161.36, 153.52, 136.33, 135.79, 134.52, 131.41, 130.36, 125.55, 123.50, 
121.08, 120.15, 119.95, 118.58, 118.40, 115.95, 113.57, 108.69, 106.03, 68.07, 53.91, 52.62, 
52.58, 23.31, 16.61; HRMS (m/z): [M+H]+ calcd for C27H25O6N2, 473.17071; found, 473.17003. 
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Compound 17v: 
 
Compound 17v was synthesized according to method Ia. Yellow solid; m.p.: 215°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.71; 1H NMR (400 MHz, CDCl3) δ 11.16 (s, 1H), 9.09 
(s, 1H), 7.91 (d, J = 1.6 Hz, 1H), 7.62 (d, J = 1.6 Hz, 1H), 7.54 (d, J = 2.5 Hz, 1H), 7.49 – 7.44 (m, 
2H), 7.34 (dt, J = 8.2, 0.9 Hz, 1H), 7.19 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.09 (ddd, J = 7.9, 7.1, 
1.0 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 4.38 – 4.24 (m, 4H), 3.93 – 3.83 (m, 1H), 3.76 (dd, J = 13.5, 
5.4 Hz, 1H), 3.22 – 3.10 (m, 1H), 2.95 (dd, J = 15.6, 3.6 Hz, 1H), 1.36 (t, J = 7.1 Hz, 3H), 1.26 (t, 
J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 190.4, 169.1, 168.2, 160.3, 153.7, 137.0, 136.2, 
135.4, 132.5, 131.8, 126.1, 123.1, 121.5, 120.4, 120.0, 118.4, 114.5, 112.0, 110.2, 108.2, 
105.8, 68.4, 63.3, 61.8, 52.6, 23.4, 14.4, 14.3 ppm; HRMS (m/z): [M+H]+ calcd for 
C28H25O6N2Br, 565.09688; found, 565.09666. 
 
Compound 17w: 
 
Compound 17w was synthesized according to method Ia. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.72; 1H NMR (400 MHz, CDCl3) δ 11.65 (s, 1H), 9.09 
(s, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.65 (d, J = 1.5 Hz, 1H), 7.50 – 7.44 (m, 2H), 7.37 – 7.31 (m, J 
= 5.4 Hz, 2H), 7.19 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.09 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 4.42 – 
4.20 (m, 4H), 3.95 – 3.82 (m, 1H), 3.77 (dd, J = 13.2, 5.0 Hz, 1H), 3.16 (ddd, J = 17.6, 12.0, 5.6 
Hz, 1H), 2.96 (dd, J = 15.6, 3.6 Hz, 1H), 1.35 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 189.8, 169.0, 168.1, 155.7, 154.0, 136.2, 135.1, 133.9, 131.6, 128.0, 
126.1, 124.0, 123.2, 123.1, 121.6, 120.0, 118.4, 114.7, 112.0, 108.2, 105.6, 68.4, 63.4, 61.9, 
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52.8, 23.4, 14.4, 14.2 ppm; HRMS (m/z): [M+H]+ calcd for C28H25O6N2Cl2, 555.10842; found, 
555.10811. 
 
Compound 17x: 
 
Compound 17x was synthesized according to method Ia. Yellow solid; m.p.: 228°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.56; 1H NMR (400 MHz, CDCl3) δ 11.01 (s, 1H), 8.97 
(s, 1H), 7.92 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.24 – 7.19 (m, 3H), 6.92 – 6.88 (m, 
2H), 6.84 (dd, J = 8.8, 2.5 Hz, 1H), 4.34 – 4.23 (m, 4H), 3.89 – 3.80 (m, 1H), 3.83 (s, 3H), 3.71 
(dd, J = 13.3, 5.1 Hz, 1H), 3.11 (ddd, J = 15.5, 12.1, 5.6 Hz, 1H), 2.89 (dd, J = 15.5, 3.8 Hz, 1H), 
2.27 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 192.1, 
169.3, 168.4, 159.2, 154.4, 153.5, 136.0, 135.4, 132.8, 131.3, 130.4, 127.7, 126.5, 119.8, 
118.2, 113.9, 113.1, 112.8, 107.8, 106.1, 100.3, 68.3, 63.2, 61.7, 56.1, 52.4, 23.4, 20.8, 14.5, 
14.3 ppm; HRMS (m/z): [M+H]+ calcd for C30H31O7N2, 531.21258; found, 531.21189. 
 
Compound 17y: 
 
Compound 17y was synthesized according to method Ia. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.63; 1H NMR (400 MHz, CDCl3) δ 11.05 (s, 1H), 8.95 
(s, 1H), 7.89 (d, J = 1.5 Hz, 1H), 7.65 (d, J = 1.5 Hz, 1H), 7.21 (ddd, J = 8.8, 7.3, 3.1 Hz, 3H), 6.91 
– 6.85 (m, 2H), 6.82 (dd, J = 8.8, 2.5 Hz, 1H), 4.33 – 4.17 (m, 4H), 3.86 – 3.78 (m, 1H), 3.80 (s, 
3H), 3.67 (dd, J = 13.2, 5.1, 1H), 3.10 (ddd, J = 15.3, 12.0, 5.6 Hz, 1H), 2.87 (dd, J = 15.8, 4.0 
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Hz, 1H), 2.83 – 2.77 (m, 1H), 1.28 (t, J = 7.1 Hz, 3H), 1.23 – 1.17 (m, 9H); 13C NMR (101 MHz, 
CDCl3) δ 192.1, 169.2, 168.4, 159.3, 154.4, 153.6, 138.8, 136.2, 133.0, 132.9, 131.3, 127.9, 
126.5, 119.7, 118.1, 113.5, 113.2, 112.8, 107.9, 105.9, 100.3, 68.3, 63.2, 61.7, 56.1, 52.4, 
33.4, 24.4, 24.3, 23.4, 14.5, 14.3 ppm; HRMS (m/z): [M+H]+ calcd for C32H35O7N2, 559.24388; 
found, 559.24326. 
 
Compound 17z: 
 
Compound 17z was synthesized according to method Ia. Yellow solid; m.p.: 196°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF =  0.74; 1H NMR (400 MHz, CDCl3) δ 11.24 (s, 1H), 
9.10 (s, 1H), 7.90 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.47 (d, J = 7.7 Hz, 1H), 7.41 (s, 
1H), 7.34 (d, J = 8.1 Hz, 1H), 7.19 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.14 – 7.06 (m, 1H), 6.88 (d, J 
= 0.7 Hz, 1H), 4.38 – 4.22 (m, 4H), 3.93 – 3.80 (m, 1H), 3.74 (dd, J = 13.2, 4.9 Hz, 1H), 3.24 – 
3.07 (m, 1H), 2.94 (dd, J = 15.5, 3.5 Hz, 1H), 2.35 (s, 3H), 1.35 (t, J = 7.1 Hz, 3H), 1.26 (t, J = 
7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 190.5, 169.2, 168.3, 159.9, 153.4, 143.3, 136.2, 
135.5, 131.9, 130.0, 126.1, 123.8, 123.0, 120.5, 119.9, 118.9, 118.3, 114.3, 112.0, 108.2, 
105.8, 68.3, 63.3, 61.8, 52.5, 23.4, 20.7, 14.4, 14.3 ppm; HRMS (m/z): [M+H]+ calcd for 
C29H28O6N2Cl, 535.16304; found, 535.16262. 
 
Compound 17aa: 
 
Compound 17aa was synthesized according to method Ia. Yellow solid; m.p.: 216°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.71; 1H NMR (400 MHz, CDCl3) δ 11.13 (s, 1H), 9.09 
(s, 1H), 7.91 (d, J = 1.6 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.40 (d, J = 2.6 
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Hz, 1H), 7.35 – 7.34 (m, 1H), 7.32 (dd, J = 1.6, 0.7 Hz, 1H), 7.19 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 
7.09 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H), 4.42 – 4.21 (m, 4H), 3.95 – 3.81 
(m, 1H), 3.76 (dd, J = 13.0, 5.2 Hz, 1H), 3.16 (ddd, J = 15.5, 12.1, 5.7 Hz, 1H), 2.95 (dd, J = 15.6, 
3.5 Hz, 1H), 1.35 (t, J = 7.1 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 190.5, 
169.1, 168.2, 159.8, 153.7, 136.2, 135.4, 134.2, 131.8, 129.5, 126.1, 123.3, 123.0, 120.9, 
119.9 (2 C), 118.4, 114.5, 112.0, 108.2, 105.8, 68.3, 63.32, 61.8, 52.6, 23.4, 14.4, 14.3 ppm; 
HRMS (m/z): [M+H]+ calcd for C28H26O6N2Cl, 521.14739; found, 521.14689.  
 
Compound 17ab: 
 
 
Compound 17ab was synthesized according to method Ia. Yellow solid; m.p.: 230°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.62; 1H NMR (400 MHz, CDCl3) δ 11.13 (s, 1H), 8.97 
(s, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.40 (d, J = 2.6 Hz, 1H), 7.33 (dd, J = 
8.8, 2.6 Hz, 1H), 7.22 (d, J = 8.8 Hz, 1H), 6.94 (d, J = 8.8 Hz, 1H), 6.89 (d, J = 2.4 Hz, 1H), 6.85 
(dd, J = 8.8, 2.5 Hz, 1H), 4.39 – 4.21 (m, 4H), 3.93 – 3.80 (m, 1H), 3.83 (s, 3H), 3.75 (dd, J = 
13.1, 5.3 Hz, 1H), 3.13 (ddd, J = 15.5, 12.0, 5.7 Hz, 1H), 2.91 (dd, J = 15.5, 3.6 Hz, 1H), 1.35 (t, 
J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 190.5, 169.1, 168.2, 159.8, 
154.5, 153.6, 135.3, 134.2, 132.5, 131.4, 129.6, 126.5, 123.3, 120.9, 120.0, 114.6, 113.3, 
112.8, 107.8, 105.8, 100.3, 68.4, 63.3, 61.8, 56.1, 52.6, 23.5, 14.4, 14.3 ppm; HRMS (m/z): 
[M+H]+ calcd for C29H28O7N2Cl, 551.15796; found, 551.15757.  
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Compound 17ac: 
 
Compound 17ac was synthesized according to method Ia. Yellow solid; m.p.: 225°C; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.60; 1H NMR (400 MHz, CDCl3) δ 11.16 (s, 1H), 8.97 
(s, 1H), 7.90 (d, J = 1.5 Hz, 1H), 7.62 (d, J = 1.5 Hz, 1H), 7.54 (d, J = 2.5 Hz, 1H), 7.47 (dd, J = 
8.8, 2.5 Hz, 1H), 7.24 – 7.22 (m, 1H), 6.92 – 6.87 (m, 2H), 6.85 (dd, J = 8.8, 2.5 Hz, 1H), 4.40 – 
4.20 (m, 4H), 3.92 – 3.80 (m, 1H), 3.83 (s, 3H), 3.75 (dd, J = 13.1, 5.1 Hz, 1H), 3.13 (ddd, J = 
15.5, 12.0, 5.6 Hz, 1H), 2.91 (dd, J = 15.4, 3.7 Hz, 1H), 1.35 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 190.4, 169.1, 168.2, 160.3, 154.5, 153.7, 137.0, 135.3, 
132.5, 132.5, 131.4, 126.5, 121.5, 120.4, 114.5, 113.3, 112.8, 110.2, 107.8, 105.8, 100.3, 68.4, 
63.3, 61.9, 56.1, 52.7, 23.5, 14.5, 14.3 ppm; HRMS (m/z): [M+H]+ calcd for C29H28O7N2Br, 
595.10744; found, 595.10736.  
 
Compound 17ad: 
 
Compound 17ad was synthesized according to method Ia. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.57; 1H NMR (400 MHz, CDCl3) δ 11.39 (s, 1H), 9.01 
(s, 1H), 8.36 (dd, J = 8.3, 1.3 Hz, 1H), 7.91 (d, J = 1.5 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.61 (d, J 
= 1.5 Hz, 1H), 7.53 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.47 – 7.37 (m, 2H), 7.29 (dt, J = 8.2, 0.9 Hz, 
1H), 7.19 (d, J = 8.5 Hz, 2H), 7.14 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.04 (ddd, J = 8.0, 7.1, 1.0 Hz, 
1H), 3.80 (s, 3H), 3.79 – 3.76 (m, 1H), 3.76 (s, 3H), 3.69 (dd, J = 13.3, 4.9 Hz, 1H), 3.11 (ddd, J 
= 15.6, 11.9, 5.7 Hz, 1H), 2.88 (dd, J = 15.5, 3.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 192.4, 
170.2, 168.8, 161.5, 153.3, 136.7, 136.7, 136.2, 131.9, 129.6, 127.5, 126.1, 126.0, 125.7, 
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125.7, 124.3, 123.1, 119.9, 118.4, 117.8, 113.1, 112.8, 112.0, 108.3, 106.1, 68.1, 53.9, 52.7, 
52.5, 23.3 ppm; HRMS (m/z): [M+H]+ calcd for C30H25O6N2, 509.17071; found, 509.17005. 
 
Compound 17ae: 
 
Compound 17ae was synthesized according to method II. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 2:3 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.69 (s, 1H), 8.99 
(s, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.75 (d, J = 2.5 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.49 (d, J = 2.5 
Hz, 1H), 7.47 (dd, J = 7.9, 0.6 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.20 (ddd, J = 8.2, 7.1, 1.2 Hz, 
1H), 7.10 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 4.38 – 4.19 (m, 4H), 3.93 – 3.78 (m, 1H), 3.69 (dd, J = 
13.0, 4.9 Hz, 1H), 3.15 (ddd, J = 15.5, 11.8, 5.6 Hz, 1H), 2.95 (dd, J = 15.5, 3.5 Hz, 1H), 1.34 (t, 
J = 7.1 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 189.5, 170.2, 168.7, 
157.9, 153.0, 139.5, 136.3, 135.5, 131.8, 131.5, 126.5, 123.1, 121.8, 120.0, 118.4, 114.5, 
113.2, 111.1, 110.0, 108.3, 105.2, 68.6, 63.0, 61.8, 52.6, 23.3, 14.5, 14.4 ppm; HRMS (m/z): 
[M+H]+ calcd for C28H25Br2N2O6, 643.00739; found, 643.00765. 
 
Compound 17af: 
 
Compound 17af was synthesized according to method II. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 2:3 v/v): RF = 0.30; 1H NMR (400 MHz, CDCl3) δ 11.00 (s, 1H), 9.03 
(s, 1H), 7.85 (d, J = 1.5 Hz, 1H), 7.59 (d, J = 1.5 Hz, 1H), 7.52 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 
8.6, 2.3 Hz, 1H), 7.24 (d, J = 8.6 Hz, 1H), 6.84 (ddd, J = 11.4, 6.0, 2.0 Hz, 3H), 3.87 (s, 3H), 3.83 
(s, 3H), 3.82 (s, 3H), 3.81 – 3.72 (m, 2H), 3.18 (ddd, J = 15.5, 11.4, 6.0 Hz, 1H), 2.95 (dd, J = 
15.5, 3.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.5, 169.9, 168.4, 162.0, 154.4, 152.0, 137.0, 
135.5, 132.6, 132.4, 131.1, 126.3, 121.2, 119.9, 114.7, 113.6, 111.7, 110.2, 107.6, 106.1, 
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100.5, 68.4, 56.7, 54.2, 53.1, 52.5, 22.7 ppm; HRMS (m/z): [M+H]+ calcd for C27H24ClN2O7, 
523.12666; found, 523.12963. 
 
Compound 17ag: 
 
Compound 17ag was synthesized according to method II. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 2:3 v/v): RF = 0.25; 1H NMR (400 MHz, CDCl3) δ 11.01 (s, 1H), 8.90 
(s, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.51 (d, J = 2.5 Hz, 1H), 7.42 (dd, J = 
8.9, 2.5 Hz, 1H), 7.24 (d, J = 8.8 Hz, 1H), 6.90 – 6.84 (m, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.82 (s, 
3H), 3.81 – 3.72 (m, 2H), 3.13 (ddd, J = 15.5, 11.8, 5.8 Hz, 1H), 2.91 (dd, J = 15.5, 3.4 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 190.2, 170.1, 168.6, 160.3, 154.5, 154.3, 153.4, 137.2, 135.8, 
134.7, 132.1, 131.3, 126.4, 118.7, 114.0, 112.4, 110.4, 107.1, 105.2, 99.9, 68.0, 57.0, 55.3, 
54.2, 52.6, 52.4, 22.8 ppm; HRMS (m/z): [M+H]+ calcd for C27H23Cl2N2O7, 557.08768; found, 
557.08732. 
 
Compound 17ah: 
 
Compound 17ah was synthesized according to method II. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 2:3 v/v): RF = 0.25; 1H NMR (400 MHz, CDCl3) δ 11.16 (s, 1H), 8.91 
(s, 1H), 7.88 (d, J = 1.5 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.52 (d, J = 2.5 Hz, 1H), 7.44 (dd, J = 
8.8, 2.5 Hz, 1H), 7.28 (d, J = 8.8 Hz, 1H), 6.89 – 6.84 (m, 2H), 3.87 (s, 3H), 3.82 (s, 3H), 3.81 (s, 
3H), 3.81 – 3.72 (m, 2H), 3.13 (ddd, J = 15.5, 11.8, 5.8 Hz, 1H), 2.91 (dd, J = 15.5, 3.4 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 189.8, 179.4, 169.7, 161.7, 154.3, 153.8, 153.0, 137.3, 135.7, 
135.0, 132.4, 131.1, 126.9, 118.4, 114.3, 112.7, 110.1, 107.2, 105.9, 100.0, 67.9, 56.3, 55.0, 
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54.2, 52.6, 52.6, 22.9 ppm; HRMS (m/z): [M+H]+ calcd for C27H23Br2N2O7, 644.98665; found, 
644.98623. 
 
Compound 17ai: 
 
Compound 17ai was synthesized according to method II. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 2:3 v/v): RF = 0.25; 1H NMR (400 MHz, CDCl3) δ 11.08 (s, 1H), 8.89 
(s, 1H), 7.90 (d, J = 1.4 Hz, 1H), 7.61 (d, J = 1.4 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.45 (dd, J = 
8.8, 2.5 Hz, 1H), 7.21 (d, J = 8.8Hz, 1H), 6.87 – 6.81 (m, 2H), 4.36 – 4.20 (m, 4H), 3.93 – 3.88 
(m, 1H), 3.83 (s, 3H), 3.71 (dd, J = 13.0, 5.0 Hz, 1H), 3.18 (ddd, J = 15.7, 12.0, 5.6 Hz, 1H), 2.91 
(dd, J = 15.7, 4.8 Hz, 1H), 1.37 (t, J = 6.9 Hz, 3H), 1.25 (t, J = 6.9 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 191.0, 170.5, 169.0, 161.3, 154.2, 153.8, 153.0, 137.4, 135.6, 134.9, 132.4, 132.4, 
131.3, 126.4, 118.4, 114.0, 112.9, 110.2, 107.7, 105.2, 100.6, 68.1, 63.1, 61.8, 58.3, 52.5, 
23.3, 14.5, 14.3 ppm; HRMS (m/z): [M+H]+ calcd for C29H27Cl2N2O7, 585.11898; found, 
585.11914. 
 
Compound 17aj: 
 
Compound 17aj was synthesized according to method II. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 2:3 v/v): RF = 0.25; 1H NMR (400 MHz, CDCl3) δ 11.19 (s, 1H), 8.87 
(s, 1H), 7.88 (d, J = 1.5 Hz, 1H), 7.58 (d, J = 1.5 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.45 (dd, J = 
8.8, 2.4 Hz, 1H), 7.22 (d, J = 8.8Hz, 1H), 6.88 – 6.80 (m, 2H), 4.34 – 4.19 (m, 4H), 3.93 – 3.78 
(m, 1H), 3.82 (s, 3H), 3.71 (dd, J = 13.2, 5.3 Hz, 1H), 3.15 (ddd, J = 15.5, 12.0, 5.3 Hz, 1H), 2.93 
(dd, J = 15.5, 3.7 Hz, 1H), 1.32 (t, J = 7.0 Hz, 3H), 1.28 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 190.4, 172.6, 168.4, 162.2, 155.0, 154.5, 153.1, 137.6, 135.9, 134.4, 132.4, 132.3, 
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131.4, 126.4, 118.6, 114.6, 112.8, 110.3, 107.3, 105.2, 99.8, 68.0, 63.4, 61.7, 58.6, 52.1, 23.3, 
15.2, 14.8 ppm; HRMS (m/z): [M+H]+ calcd for C29H27Br2N2O7, 673.01795; found, 673.01823. 
 
III.2.3. Synthesis of Benzoquinolizines 47 and Imidazoquinolizines 49 
Compound 47a: 
 
Compound 47a was synthesized according to method Ib, dopamine hydrochloride 30a (63 
mg; 0.33 mol; 1.05 eq.), tricyclic benzopyrone 5a (100 mg; 0.32 mmol; 1.00 eq.), DIPEA (204 
mg; 1.58 mmol; 5.00 eq.) and trifluoroacetic acid (36 mg; 0.32 mmol; 1.05 eq.) were 
combined in DMF (3 ml). After aqueous workup, extraction with ethyl acetate and drying 
over magnesium sulfate the crude product was taken up in acetone (3 ml). To this solution 
were added potassium carbonate (219 mg; 1.58 mmol; 5.0 eq.), and dimethyl sulfate (199 
mg; 1.58 mmol; 5.0 eq.). The mixture was subjected to microwave irradiation (120°C; 20 
minutes). After washing with ammonium acetate solution and brine, and drying over 
magnesium sulfate the crude product was purified by HPLC (Nucleosil np column, isohexane/ 
(methylene chloride/ethanol 100:2) 9:1 to 0:1). The product (52 mg; 0.11 mmol; 35%) was 
obtained as amorphous yellow solid. TLC (dichloromethane/methanol, 95:5 v/v): RF = 0.58; 
1H-NMR (500 MHz, CDCl3) δ 7.93 (s, 1H), 7.42 – 7.32 (m, 2H), 7.22 (d, J = 7.4 Hz, 1H), 6.98 (t, 
J = 7.4 Hz, 1H), 6.95 (d, J = 8.3 Hz, 1H), 6.68 (s, 1H), 6.56 (s, 1H), 3.85 (s, 3H), 3.80 (d, J = 0.7 
Hz, 6H), 3.78 (s, 3H), 3.75 (s, 3H), 3.69 – 3.58 (m, 2H), 3.16 – 3.03 (m, 1H), 2.86 (dd, J = 16.5, 
3.3 Hz, 1H) ppm; HRMS (m/z): [M+H]+ calcd for C27H28O8N, 494.18094; found, 494.18028. 
 
Compound 47b: 
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Compound 47b was synthesized according to method Ia. TLC (dichloromethane/methanol, 
95:5 v/v): RF = 0.58; 1H-NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.43 – 7.32 (m, 2H), 7.21 (d, J = 
7.3 Hz, 1H), 6.97 (t, J = 7.3 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 6.67 (s, 1H), 6.57 (s, 1H), 3.80 (s, 
6H), 3.78 (s, 3H), 3.75 (s, 3H), 3.69 – 3.58 (m, 2H), 3.16 – 3.03 (m, 1H), 2.86 (dd, J = 16.5, 3.3 
Hz, 1H); 13C-NMR (101 MHz, CDCl3) δ 192.5, 173.4, 167.0, 163.5, 151.1, 148.2, 147.4, 135.2, 
134.5, 131.1, 131.1, 129.0, 126.4, 122.7, 122.0, 118.4, 115.7, 114.9, 112.0, 81.7, 56.4, 56.4, 
52.2, 52.1, 49.5, 29.7 ppm; HRMS (m/z): [M+H]+ calcd for C26H26O8N, 479.15802; found, 
479.15762. 
 
Compound 49a: 
 
Compound 49a was synthesized according to method Ib. Amorphous yellow solid; TLC (ethyl 
acetate): RF = 0.25; 1H NMR (400 MHz, CDCl3) δ 11.30 (s, 1H), 7.95 (d, J = 1.8 Hz, 1H), 7.56 (s, 
1H), 7.43 (dd, J = 8.2, 1.8 Hz, 1H), 7.40 – 7.33 (m, 1H), 7.11 (dd, J = 8.2, 7.1 Hz, 1H), 7.05 – 
6.99 (m, 1H),  6.86 – 6.81 (m, 1H),  4.09 (t, J =7.2 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.45 (dd, 
J = 13.2, 5.0Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 190.3, 175.2, 169,2, 168.1, 161.5, 153.2, 
138.2, 134.3, 134.0, 132.8, 132.4, 120.0, 118.0, 117.6, 108.0, 106.3, 65.9, 53.1, 51.4, 50.0, 
49.9, 24.5 ppm; HRMS (m/z): [M+H]+ calcd for C22H20N3O8, 454.12449; found, 454.12487. 
 
Compound 49b: 
 
Compound 49b was synthesized according to method Ib. Amorphous yellow solid; TLC (ethyl 
acetate): RF = 0.32; 1H NMR (400 MHz, CDCl3) δ 11.31 (s, 1H), 7.91 (d, J = 1.5 Hz, 1H), 7.56 (s, 
1H), 7.44 (dd, J = 7.9, 1.5 Hz, 1H), 7.40 – 7.36 (m, 1H), 7.16 (dd, J = 8.2, 7.1 Hz, 1H), 7.08 (dd, 
J = 11.6, 4.1 Hz, 1H),  6.86 – 6.83 (m, 1H), 4.11 (dd, J = 15.6, 12.0, 1H), 3.88 (s, 3H), 3.87 (s, 
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3H), 3.76 (s, 3H), 3.74 – 3.71 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 190.9, 174.0, 171.2, 167.8, 
161.5, 153.7, 136.0, 134.9, 134.7, 131.4, 130.2, 120.5, 120.5, 118.4, 118.2, 108.1, 106.4, 69.4, 
58.1, 52.5, 52.5, 51.9, 41.3 ppm; HRMS (m/z): [M+H]+ calcd for C23H22N3O8, 468.14014; 
found, 468.14236. 
 
Compound 49c: 
 
Compound 49c was synthesized according to method Ia. Amorphous yellow solid; TLC (ethyl 
acetate): RF = 0.55; 1H NMR (400 MHz, CDCl3) δ 11.19 (s, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.52 (s, 
1H), 7.43 (dd, J = 8.2, 2.0 Hz, 1H), 7.39 – 7.35 (m, 1H), 7.16 (dd, J = 8.2, 7.1 Hz, 1H), 7.02 (dd, 
J = 11.5, 4.9 Hz, 1H),  6.86 – 6.79 (m, 1H), 3.92 (s, 3H), 3.90-3.86 (m, 4H), 3.48 (dd, J = 13.2, 
5.0, 2H), 3.13 (ddd, J = 15.4, 12.2, 6.0 Hz, 1H), 2.98 (dd, J = 15.4, 4.4 Hz, 1H); 13C NMR (101 
MHz, CDCl3) δ 192.7, 171.2, 168.9, 161.5, 153.3, 135.9, 134.7, 134.3, 131.9, 130.3, 119.6, 
119.6, 118.8, 118.3, 107.9, 106.2, 68.2, 54.0, 52.8, 52.8, 23.0 ppm; HRMS (m/z): [M+H]+ calcd 
for C21H20N3O6, 410.13466; found, 410.13501. 
 
Compound 49d: 
 
Compound 49d was synthesized according to method Ia. Amorphous yellow solid; TLC (ethyl 
acetate):  RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.30 (s, 1H), 7.91 (d, J = 1.5 Hz, 1H), 7.55 (s, 
1H), 7.44 (dd, J = 7.9, 1.6 Hz, 1H), 7.41 – 7.36 (m, 1H), 7.15 (dd, J = 8.0, 7.1 Hz, 1H), 7.08 (dd, 
J = 12.0, 4.1 Hz, 1H),  6.86 – 6.83 (m, 1H), 4.54 (s, 3H), 4.10 (dd, J = 15.6, 12.0 Hz, 1H), 3.88 
(s, 3H), 3.87 (s, 3H), 3.77 (s, 3H), 3.52 (dd, J = 13.2, 5.0 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 
192.2, 173.3, 170.1, 167.8, 160.8, 153.6, 136.0, 134.7, 134.6, 131.9, 130.6, 120.0, 120.0, 
118.7, 118.5, 108.0, 105.9, 68.2, 60.2, 54.3, 53.0, 52.9, 52.0, 23.6 ppm; HRMS (m/z): [M+H]+ 
calcd for C24H24N3O8, 482.15579; found, 482.15556. 
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Compound 49e: 
 
Compound 49e was synthesized according to method Ia. Amorphous yellow solid; TLC 
(cyclohexane/ethyl acetate, 2:3 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.20 (s, 1H), 7.85 
(d, J = 2.1 Hz, 1H), 7.53 (s, 1H), 7.44 (dd, J = 8.0, 2.1 Hz, 1H), 7.40 – 7.35 (m, 1H), 7.16 (dd, J = 
8.3, 7.0 Hz, 1H), 7.04 (dd, J = 11.7, 5.0 Hz, 1H),  6.84 – 6.79 (m, 1H), 4.47 (s, 3H), 3.92 (s, 3H), 
3.91-3.88 (m, 4H), 3.43 (dd, J = 13.2, 5.1, 2H), 3.11 (ddd, J = 15.0, 12.5, 5.5 Hz, 1H); 13C NMR 
(101 MHz, CDCl3) δ 191.8, 171.6, 168.9, 161.0, 153.6, 136.1, 134.9, 134.5, 131.6, 130.3, 
119.8, 119.8, 118.5, 118.3, 108.4, 106.1, 67.7, 59.8, 53.6, 52.4, 52.4, 23.0 ppm; HRMS (m/z): 
[M+H]+ calcd for C22H21N3O8, 424.15031; found, 424.15023. 
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III.3. Experimental Part for Chapter 3 
III.3.1. Synthesis of the Cyclic Imines 69  
 General procedure for the preparation of non- substituted imines: 
A solution of 0.125 mol of tryptamine 23 in ethyl formate (150 mL) was refluxed for 6h. After 
evaporating the excess solvent in vacuum, the residue was dissolved in dry dichloromethane 
and POCl3 (11 mL, 0.132 mol) was added dropwise in ice-bath. The mixture was stirred for 
2h. After evaporating the excess solvent, the residue was dissolved in water, and washed 
with ether. The pH of the aqueous layer was asjusted by ammonium hydroxide to pH 10. 
The, the solution was extracted with dichloromethane, washed with brine and drier over 
sodium sulfate. The crude imines 69 were obtained by evaporating the solvent in vacuum 
followed by recrystallization from ethyl acetate. 
 
Compound 69a:  
 
Compound 69a was synthesized according to the general procedure for non- substituted 
imines. Dark red amorphous solid: 1H NMR (400 MHz, DMSO-d6)  11.32 (s, 1H), 8.36 (s, 1H), 
7.56 (d, J = 7.7Hz, 1H), 7.40 (d, J = 8.8 Hz, 1H), 7.19 (t, J = 7.2 Hz, 1H), 7.04 (t, J = 7.2 Hz, 1H), 
3.78 (t, J = 8.8 Hz, 2H), 2.80 (t, J = 8.8 Hz, 2H); 13C NMR (100 MHz, DMSO-d6):  151.6, 136.7, 
128.4, 124.8, 123.7, 119.7, 119.6, 113.8, 112.5, 48.1, 18.7 ppm; HRMS: Calcd for C11H11N2 
[M+H]+: 171.09174, Found: 171.09209. 
 
Compound 69b:  
 
Compound 69b was synthesized according to the general procedure for non- substituted 
imines. Dark red amorphous solid: 1H NMR (400 MHz, CDCl3)  8.35 (s, 1H), 7.28 (d, J = 8.4 
Hz, 1H), 6.93 (s, 1H), 6.91 (d, J = 8.4 Hz, 1H), 3.83 – 3.77 (m, 5H), 2.80 (t, J = 6.0 Hz, 2H); 13C 
NMR (100 MHz, DMSO-d6):  154.7, 151.6, 136.6, 128.4, 124.7, 123.7, 119.7, 113.7, 112.5, 
56.0, 48.2, 18.6 ppm; HRMS: Calcd for C12H13N2O [M+H]+: 200.09471, Found: 200.09592. 
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Compound 69c:  
 
Compound 69c was synthesized according to the general procedure for non- substituted 
imines. Dark red amorphous solid: 1H NMR (400 MHz, CDCl3)  8.22 (s, 1H), 7.40-7.26 (m, 
6H), 7.00-6.93 (m, 2H), 4.96 (s, 2H), 3.74 (t, J = 8.5 Hz, 2H), 2.75 (t, J = 8.5 Hz, 2H); 13C NMR 
(100 MHz, CDCl3):  153.6, 152.2, 137.4, 132.7, 128.5, 127.9, 127.6, 125.5, 116.3, 115.5, 
113.1, 112.2, 102.3, 70.8, 48.3, 19.2 ppm; HRMS: Calcd for C18H17N2O [M+H]+: 278.14191, 
Found: 278.14202. 
 
Compound 69d:  
 
Compound 69d was synthesized according to the general procedure for non- substituted 
imines. Dark red amorphous solid: 1H NMR (400 MHz, DMSO-d6)  11.41 (s, 1H), 8.34 (s, 1H), 
7.35 (s, 1H), 7.24 (d, J = 6.4 Hz, 1H), 7.08 (d, J = 6.4 Hz, 1H), 3.70 (t, J = 8.6 Hz, 2H), 2.84 (t, J = 
8.6 Hz, 2H), 2.61 (s, 3H); 13C NMR (100 MHz, DMSO-d6):  151.5, 136.7, 128.3, 124.8, 123.7, 
128.6, 120.6, 118.8, 113.5, 48.0, 22.0, 18.9 ppm; HRMS: Calcd for C12H13N2 [M+H]+: 
185.10732, Found: 185.10720. 
 
Compound 69e:  
 
Compound 69e was synthesized according to the general procedure for non- substituted 
imines. Dark red amorphous solid: RF = 0.35; 1H NMR (400 MHz, DMSO-d6)  11.46 (s, 1H), 
8.33 (s, 1H), 7.64 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 3.67 (t, J = 8.6 Hz, 
2H), 2.81 (t, J = 8.7 Hz, 2H); 13C NMR (100 MHz, DMSO-d6):  151.4, 136.6, 128.3, 124.7, 122.1, 
119.9, 119.5, 113.8, 110.3, 48.2, 18.8 ppm; HRMS: Calcd for C11H10N2 [M+H]+: 205.05270, 
Found: 205.05276. 
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 General procedure for the preparation of  substituted imines: 
Tryptamine 23 (5.0 mmol) was dissolved in dichloromethane (20 mL) at 0 °C and 
triethylamine (10.0 mmol, 2 eq., 0.67 mL) and the acyl chlroide 76 (6.0 mmol) were added 
to the solution.  The mixture was stirred for 2h. After evaporating the excess solvent in 
vacuum, the residue was dissolved in dry dichloromethane and POCl3 (11 mL, 0.132 mol) 
was added dropwise in ice-bath. The mixture was stirred for 2h. After evaporating the excess 
solvent, the residue was dissolved in water, and washed with ether. The pH of the aqueous 
layer was asjusted by ammonium hydroxide to pH 10. The, the solution was extracted with 
dichloromethane, washed with brine and drier over sodium sulfate. The crude imines 69 
were obtained by evaporating the solvent in vacuum followed by recrystallization from ethyl 
acetate. 
 
Compound 69f:  
 
Compound 69f was synthesized according to the general procedure for  substituted imines. 
Dark red amorphous solid: 1H NMR (400 MHz, CDCl3)  8.21 (s, 1H), 7.60 (d, J = 8.1 Hz, 1H), 
7.40 (d, J = 8.2 Hz, 1H), 7.28 (t, J = 7.5 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 3.87 (t, J = 8.4 Hz, 2H), 
2.87 (t, J = 8.8 Hz, 2H), 2.37 (s, 3H); 13C NMR (100 MHz, DMSO-d6):  158.1, 136.8, 129.1, 
125.5, 124.5, 120.3, 120.0, 116.6, 112.1, 48.1, 22.0, 19.4 ppm; HRMS: Calcd for C12H13N2 
[M+H]+: 185.10732, Found: 185.10744. 
 
Compound 69g:  
 
Compound 69g was synthesized according to the general procedure for  substituted imines. 
Dark red amorphous solid: 1H NMR (400 MHz, CDCl3)  8.21 (s, 1H), 7.29 (d, J = 8.3 Hz, 1H), 
6.97 (s, 1H), 6.93 (d, J = 8.43 Hz, 1H), 3.74 (m, 5H), 2.86 (t, J = 8.2 Hz, 2H), 2.34 (s, 3H); 13C 
NMR (100 MHz, DMSO-d6):  158.0, 154.4, 136.7, 129.1, 124.5, 122.5, 119.3, 113.6, 112.0, 
III. Experimental Part  128 
 
 
56.1, 48.1, 22.1, 19.4 ppm; HRMS: Calcd for C13H15N2O [M+H]+: 215.11789, Found: 
215.11791. 
 
Compound 69h:  
 
Compound 69h was synthesized according to the general procedure for  substituted 
imines. Dark red amorphous solid: 1H NMR (400 MHz, DMSO-d6)  11.11 (s, 1H), 7.78 – 7.75 
(m, 2H), 7.63 – 7.45 (m, 5H), 7.21 – 7.18 (m, 1H), 7.10 – 7.07 (m, 1H), 3.98 (t, J = 8.2 Hz, 2H), 
2.86 (t, J = 8.2 Hz, 2H); 13C NMR (100 MHz, DMSO-d6):  159.4, 137.6, 136.5, 129.9, 128.8, 
127.8, 124.6, 120.4, 119.9, 117.9, 111.9, 48.8, 19.2 ppm; HRMS: Calcd for C17H15N2 [M+H]+: 
247.12297, Found: 247.12311. 
 
Compound 69i:  
 
Compound 69i was synthesized according to the general procedure for  substituted imines. 
Dark red amorphous solid: 1H NMR (400 MHz, DMSO-d6)  8.21 (s, 1H), 7.26 – 7.14 (m, 5H), 
6.97 (s, 1H), 6.93 (d, J = 8.43 Hz, 1H), 3.74 (m, 5H), 2.86 (t, J = 8.2 Hz, 2H); 13C NMR (100 MHz, 
DMSO-d6):  159.4, 153.2, 137.6, 136.5, 129.9, 128.8, 124.6, 119.9, 117.9, 111.9, 113.8, 
112.7, 56.1, 48.8, 19.2 ppm; HRMS: Calcd for C18H17N2O [M+H]+: 277.13354, Found: 
277.13333. 
 
Compound 69j:  
 
Compound 69j was synthesized according to the general procedure for  substituted imines. 
Dark red amorphous solid: 1H NMR (400 MHz, CDCl3)  8.80 (s, 1H), 7.62 – 7.43 (m, 3H), 3.90 
(t, J = 8.4 Hz, 2H), 3.87 (s, 3H), 2.87 (t, J = 8.4 Hz, 2H), 2.71 (q, J = 7.4 Hz, 2H), 1.29 (t, J, = 7.4 
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Hz, 3H); 13C NMR (100 MHz, DMSO-d6):  161.7, 136.6, 128.6, 125.6, 124.4, 120.3, 120.0, 
118.0, 116.8, 111.9, 48.2, 28.4, 19.3, 10.9 ppm; HRMS: Calcd for C14H17N2O [M+H]+: 
229.13354, Found: 229.13367. 
 
III.3.2. Synthesis of the Chromone Dienes 70  
Compound 70a:  
 
Compound 70a was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.24 (dd, J = 8.0, 
1.6 Hz, 1H), 8.09 (s, 1H), 7.67 (td, J = 7.2, 1.6 Hz, 1H), 7.37 (d, J = 15.6 Hz, 1H), 7.26 (d, J = 15.6 
Hz, 1H), 3.77 (s, 3H); 13C NMR (100 MHz, CDCl3):  176.0, 168.0, 157.6, 155.7, 135.8, 134.2, 
126.5, 126.0, 124.4, 121.9, 119.5, 118.3, 51.8 ppm; HRMS: Calcd for C13H10O4Na [M+Na]+: 
253.04712, Found: 253.04793.  
 
Compound 70b:  
 
Compound 70b was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.17 (s, 1H), 8.08 
(d, J = 8.2 Hz, 1H), 7.73 – 7.69 (m, 2H), 7.45 (d, J = 7.8 Hz, 1H), 7.01 (d, J = 11.8 Hz, 1H), 3.79 
(s, 3H); 13C NMR (100 MHz, CDCl3):  173.4, 166.7, 160.0, 153.7, 148.7, 134.8, 131.4, 127.0, 
124.6, 124.4, 121.2, 118.0, 52.0 ppm; HRMS: Calcd for C13H10O4F [M+H]+: 249.05576, Found: 
249.05563.  
 
Compound 70c:  
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Compound 70c was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.29 (s, 1H), 8.07 
(d, J = 8.4 Hz, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.45 (d, J = 12.1 Hz, 1H), 
7.01 (d, J = 12.1 Hz, 1H), 3.79 (s, 3H); 13C NMR (100 MHz, CDCl3):  175.5, 166.8, 160.2, 153.7, 
148.9, 135.8, 131.5, 127.4, 124.8, 120.9, 119.3, 118.1, 52.1 ppm; HRMS: Calcd for C13H10O4Cl 
[M+H]+: 265.02621, Found: 265.02644.  
 
Compound 70d:  
 
Compound 70d was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.28 (s, 1H), 7.91 
(d, J = 8.5 Hz, 1H), 7.83 (t, J = 7.8 Hz, 1H), 7.48 (d, J = 12.3 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H) 7.01 
(d, J = 12.3 Hz, 1H), 3.79 (s, 3H); 13C NMR (100 MHz, CDCl3):  175.5, 166.8, 156.2, 148.9, 
135.8, 134.5, 126.2, 124.5, 121.3, 120.9, 118.1, 114.7, 52.1 ppm; HRMS: Calcd for C13H10O4Br 
[M+H]+: 308.97570, Found: 308.97549.  
 
Compound 70e:  
 
Compound 70e was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.19 (dd, J = 8.0, 
1.8 Hz, 1H), 8.08 (s, 1H), 7.74 (td, J = 7.2, 1.8 Hz, 1H), 7.51 (q, J = 7.9 Hz, 1H), 7.32 (d, J = 14.6 
Hz, 1H), 7.24 (d, J = 14.6 Hz, 1H), 3.79 (s, 3H), 2.51 (s, 3H); 13C NMR (100 MHz, CDCl3):  175.5, 
168.4, 156.2, 154.8, 135.9, 134.2, 126.4, 125.8, 124.3, 122.0, 119.6, 118.7, 52.4, 21.6 ppm; 
HRMS: Calcd for C14H13O4 [M+H]+: 245.08084, Found: 245.08066.  
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Compound 70f:  
 
Compound 70f was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.22 (dd, J = 7.8, 
1.8 Hz, 1H), 8.09 (s, 1H), 7.70 (td, J = 7.2, 1.8 Hz, 1H), 7.52 (q, J = 7.9 Hz, 1H), 7.34 (d, J = 14.3 
Hz, 1H), 7.26 (d, J = 14.3 Hz, 1H), 3.78 (s, 3H), 2.72 (q, J = 8.0 Hz, 2H), 1.91 (t, J = 8.0 Hz; 3H); 
13C NMR (100 MHz, CDCl3):  175.4, 167.1, 156.7, 154.0, 138.7, 134.2, 126.5, 125.7, 124.1, 
119.9, 119.3, 118.7, 52.3, 28.4, 14.6 ppm; HRMS: Calcd for C15H15O4 [M+H]+: 259.09649, 
Found: 259.09629.  
 
Compound 70g:  
 
Compound 70g was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.24 (dd, J = 8.0, 
1.9 Hz, 1H), 8.11 (s, 1H), 7.71 (td, J = 7.3, 1.8 Hz, 1H), 7.47 (q, J = 8.0 Hz, 1H), 7.30 (d, J = 13.0 
Hz, 1H), 7.19 (d, J = 13.0 Hz, 1H), 3.80 (s, 3H), 2.90 (q, J = 6.8 Hz, 1H), 1.25 (d, J = 6.8 Hz; 6H); 
13C NMR (100 MHz, CDCl3):  175.3, 167.0, 156.4, 154.1, 137.9, 134.1, 128.1, 125.6, 123.9, 
120.2, 119.1, 118.8, 52.3, 35.6, 22.4, 22.4 ppm; HRMS: Calcd for C16H17O4 [M+H]+: 273.11214, 
Found: 273.11200.  
 
Compound 70h:  
 
Compound 70h was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.29 (s, 1H), 8.19 
(d, J = 9.0 Hz, 1H), 7.75 (t, J = 8.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.46 (d, J = 12.0 Hz, 1H), 
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6.98 (d, J = 11.9 Hz, 1H), 3.80 (s, 3H); 13C NMR (100 MHz, CDCl3):  177.0, 166.7, 160.1, 153.5, 
142.1, 135.7, 131.8, 125.3, 124.7, 120.7, 121.3, 118.1, 52.1 ppm; HRMS: Calcd for C13H10O6N 
[M+H]+: 276.05026, Found: 276.05009.  
 
Compound 70i:  
 
Compound 70i was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.27 (dd, J = 8.3, 
1.7 Hz, 1H), 8.07 (s, 1H), 7.75 – 7.72 (m, 1H), 7.52 – 7.48 (m, 2H), 7.13 (d, J = 17.1 Hz, 1H), 
7.01 (d, J = 15.7 Hz, 1H); 13C NMR (100 MHz, CDCl3):  176.1, 158.1, 155.6, 141.7, 134.7, 
126.5, 126.4, 124.3, 118.6, 118.4, 113.4, 101.7 ppm; HRMS: Calcd for C12H8O2N [M+H]+: 
198.05495, Found: 198.05508.  
 
Compound 70j:  
 
Compound 70j was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.20 (s, 1H), 8.10 
(d, J = 8.0 Hz, 1H), 7.64 – 7.59 (m, 2H), 7.35 (d, J = 15.8 Hz, 1H), 6.94 (d, J = 15.8 Hz, 1H); 13C 
NMR (100 MHz, CDCl3):  173.7, 159.7, 153.8, 148.7, 131.3, 127.1, 124.6, 124.4, 121.2, 119.8, 
113.8, 101.9 ppm; HRMS: Calcd for C12H7O2NF [M+H]+: 216.04553, Found: 216.04538.  
 
Compound 70k:  
 
Compound 70k was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.27 (s, 1H), 8.05 
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(d, J = 8.4 Hz, 1H), 7.82 (t, J = 7.6 Hz, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.47 (d, J = 12.0 Hz, 1H), 
6.99 (d, J = 12.1 Hz, 1H); 13C NMR (100 MHz, CDCl3):  175.5, 160.2, 153.7, 148.9, 135.8, 
131.5, 127.4, 124.8, 120.9, 119.3, 113.6, 101.8 ppm; HRMS: Calcd for C12H7O2NCl [M+H]+: 
232.01598, Found: 232.01605.  
 
Compound 70l:  
 
Compound 70l was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.29 (s, 1H), 7.90 
(d, J = 8.6 Hz, 1H), 7.82 (t, J = 7.9 Hz, 1H), 7.47 (d, J = 12.5 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H) 7.00 
(d, J = 12.5 Hz, 1H); 13C NMR (100 MHz, CDCl3):  175.4, 156.3, 148.8, 135.4, 134.3, 126.2, 
124.5, 121.7, 119.9, 114.6, 113.9, 101.4 ppm; HRMS: Calcd for C12H7O2NBr [M+H]+: 
275.96547, Found: 275.96548.  
 
Compound 70m:  
 
Compound 70m was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.22 (dd, J = 7.9, 
1.9 Hz, 1H), 8.13 (s, 1H), 7.67 (td, J = 7.4, 1.9 Hz, 1H), 7.52 (q, J = 7.9 Hz, 1H), 7.32 (d, J = 14.6 
Hz, 1H), 7.21 (d, J = 14.6 Hz, 1H), 2.50 (s, 3H); 13C NMR (100 MHz, CDCl3):  175.5, 156.2, 
154.7, 135.9, 134.3, 126.4, 124.2, 122.0, 119.7, 118.4, 112.1, 101.7, 21.6  ppm; HRMS: Calcd 
for C13H10O2N [M+H]+: 212.07060, Found: 212.07071.  
 
Compound 70n:  
 
III. Experimental Part  134 
 
 
Compound 70n was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.20 (dd, J = 7.9, 
2.1 Hz, 1H), 8.07 (s, 1H), 7.73 (td, J = 7.2, 2.0  Hz, 1H), 7.50 (q, J = 7.9 Hz, 1H), 7.34 (d, J = 14.7 
Hz, 1H), 7.25 (d, J = 14.7 Hz, 1H), 2.72 (q, J = 8.0 Hz, 2H), 1.91 (t, J = 8.0 Hz; 3H); 13C NMR (100 
MHz, CDCl3):  175.4, 167.1, 156.7, 154.0, 138.7, 134.2, 126.5, 124.1, 119.9, 119.3, 118.7, 
113.4, 28.4, 14.6  ppm; HRMS: Calcd for C14H12O2N [M+H]+: 226.08626, Found: 226.08603.  
 
Compound 70o:  
 
Compound 70o was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.23 (dd, J = 7.6, 
1.8 Hz, 1H), 8.09 (s, 1H), 7.69 (td, J = 7.6, 1.8 Hz, 1H), 7.45 (q, J = 8.0 Hz, 1H), 7.30 (d, J = 12.9 
Hz, 1H), 7.21 (d, J = 12.9 Hz, 1H), 2.91 (q, J = 6.8 Hz, 1H), 1.27 (d, J = 6.8 Hz; 6H); 13C NMR (100 
MHz, CDCl3):  175.3, 156.4, 154.1, 137.9, 134.1, 128.1, 125.7, 123.9, 120.2, 119.1, 118.8, 
113.7, 35.6, 22.4, 22.3 ppm; HRMS: Calcd for C15H14O2N [M+H]+: 240.10191, Found: 
240.10184.  
 
Compound 70p:  
 
Compound 70p was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.30 (s, 1H), 7.92 
(d, J = 8.5 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.35 (d, J = 12.7 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H) 7.00 
(d, J = 12.7 Hz, 1H); 13C NMR (100 MHz, CDCl3):  175.3, 156.3, 148.6, 135.3, 134.4, 130.1, 
126.3, 124.5, 119.9, 114.7, 113.9, 101.3 ppm; HRMS: Calcd for C12H7O4N2 [M+H]+: 243.04003, 
Found: 243.03991.  
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Compound 70q:  
 
Compound 70q was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.29 (dd, J = 7.3, 
1.2 Hz, 1H), 8.12 (s, 1H), 7.72 – 7.69 (m, 1H), 7.49 – 7.44 (m,  2H), 7.42 (d, J = 16.0 Hz, 1H), 
7.29 (d, J = 16.3 Hz, 1H), 4.26 (q, J = 6.9 Hz, 2H), 1.33 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz, 
CDCl3):  176.1, 167.5, 157.5, 155.7, 135.5, 134.2, 126.5, 126.0, 124.4, 122.4, 119.6, 118.3, 
60.7, 14.5 ppm; HRMS: Calcd for C14H13O4 [M+H]+: 245.08084, Found: 245.08088.  
 
Compound 70r:  
 
Compound 70r was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.19 (s, 1H), 8.09 
(d, J = 8.2 Hz, 1H), 7.72 – 7.67 (m, 2H), 7.43 (d, J = 7.8 Hz, 1H), 6.99 (d, J = 12.0 Hz, 1H), 4.26 
(q, J = 7.0 Hz, 2H), 1.34 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3):  173.4, 166.7, 160.0, 
153.7, 148.7, 134.8, 131.4, 127.0, 124.6, 124.4, 120.9, 118.0, 60.8, 14.4 ppm; HRMS: Calcd 
for C14H12O4F [M+H]+: 263.07141, Found: 263.07137.  
 
Compound 70s:  
 
Compound 70s was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.27 (s, 1H), 8.08 
(d, J = 8.3 Hz, 1H), 7.82 (t, J = 7.6 Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.46 (d, J = 12.0 Hz, 1H), 
7.01 (d, J = 12.0 Hz, 1H), 4.28 (q, J = 6.9 Hz, 2H), 1.37 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, 
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CDCl3):  175.4, 166.9, 160.0, 153.7, 148.9, 135.7, 131.4, 127.4, 124.7, 124.1, 121.0, 118.1, 
61.0, 14.5 ppm; HRMS: Calcd for C14H12O4Cl [M+H]+: 279.04186, Found: 279.04169.  
 
Compound 70t:  
 
Compound 70t was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, DMSO-d6)  12.41 (s, 1H), 
8.88 (s, 1H), 8.11 (d, J = 8.1 Hz, 1H), 7.83 (t, J = 8.1 Hz, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.53 (t, J = 
7.8 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.12 (d, J = 9.2 Hz, 1H); 13C NMR (100 MHz, DMSO-d6):  
174.2, 164.0, 159.1, 156.8, 148.4, 137.1, 128.8, 126.2, 123.7, 122.7, 121.4, 118.7 ppm; HRMS: 
Calcd for C12H8O4Na [M+Na]+: 239.03148, Found: 239.03140.  
 
Compound 70u:  
 
Compound 70u was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  12.49 (s, 1H), 8.92 
(s, 1H), 8.03 (d, J = 8.1 Hz, 1H), 7.84 (t, J = 7.9 Hz, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 9.0 
Hz, 1H), 7.03 (d, J = 10.2 Hz, 1H); 13C NMR (100 MHz, DMSO-d6):  174.1, 164.9, 159.3, 154.0, 
148.1, 135.2, 131.0, 128.4, 124.9, 124.2, 121.7, 121.1, 118.1 ppm; HRMS: Calcd for 
C13H7O4FNa [M+Na]+: 257.02206, Found: 257.02198.  
 
Compound 70v:  
 
Compound 70v was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, DMSO-d6)  12.51 (s, 1H), 
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8.91 (s, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.83 (t, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.43 (d, J 
= 10.2 Hz, 1H), 7.01 (d, J = 10.2 Hz, 1H); 13C NMR (100 MHz, DMSO-d6):  174.4, 164.8, 160.1, 
153.8, 148.3, 135.1, 130.7, 128.4, 124.8, 124.5, 121.9, 121.2, 118.1 ppm; HRMS: Calcd for 
C13H7O4ClNa [M+Na]+: 273.99251, Found: 273.99261.  
 
Compound 70w:  
 
Compound 70w was synthesized according to the general procedure. White solid; TLC 
(cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.55; 1H NMR (400 MHz, CDCl3)  8.70 (d, J = 16.4 
Hz, 1H), 8.32 (d, J = 7.9 Hz, 1H), 8.21 (s, 1H), 8.11 (d, J = 7.4 Hz, 2H), 7.72 (t, J = 7.4 Hz, 1H), 
7.59 (t, J = 7.0 Hz, 1H), 7.52–7.47 (m, 5H); 13C NMR (100 MHz, CDCl3):  190.8, 176.5, 159.1, 
155.7, 138.1, 135.5, 134.3, 133.2, 128.9, 128.8, 126.5, 126.2, 126.0, 124.5, 119.9, 118.4 ppm; 
HRMS: Calcd for C18H13O3 [M+H]+: 277.08592, Found: 277.08571.  
 
III.3.3. Synthesis of the Indoloquinolizines 72 
General procedure for the racemic synthesis of ring-fused quinolizines:  
The cyclic imine (0.10 mmol; 1.0 eq.) was dissolved under argon in 5mL dry DMSO, and dry 
ZnCl2 (0.10 mmol; 1.0 eq) was added and stirred for 5min. Chromone diene 70 (0.10 mmol; 
1.0 eq.) was added and the reaction mixture was allowed to react for 1h at 80°C in a sealed 
tube under Ar. Disappearance of the chromone on TLC indicates complete reaction 
(cyclohexane/ethyl acetate 1:1). The reaction mixture is then diluted in 10 mL brine and 
extracted with 3x10mL DCM. The organic phase was dried over Na2SO4 evaporated to give a 
residue that is purified by flash chromatography to yield the ring-fused quinolizines as 
colorful solids. 
 
General procedure for the asymmetric imino-Diels-Alder synthesis of ring-fused 
quinolizines:  
ZnEt2 (0.01 mmol; 20 mol%) and (R)-Binol (R)-80a or (R)-dianthracenylbinol (R)-80e (0.02 
mmol; 40 mol%) were dissolved under argon in 5mL dry toluene and stirred for 15 minutes, 
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then the cyclic imine (0.05 mmol; 1.0 eq) was added to the reaction mixture which is 
subsequently cooled to -78°C. Chromone diene 70 (0.10 mmol; 1.0 eq.) was added and the 
reaction mixture was allowed to react for 12-24h at -78°C in a sealed tube under Ar. 
Disappearance of the chromone on TLC indicates complete reaction (cyclohexane/ethyl 
acetate 1:1). The reaction mixture is then evaporated to give a residue that is purified by 
flash chromatography to yield the ring-fused quinolizines as colorful solids. 
 
Compound 72a:  
 
Compound 72a was synthesized according to the general procedures. Red amorphous solid; 
TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3): δ 11.21 (s, 1H), 
8.72 (s, 1H), 7.80 (s, 1H), 7.74 (s, 1H), 7.44 – 7.31 (m, 3H), 7.23 – 7.16 (m, 1H), 6.97 – 6.85 (m, 
3H), 3.91 (dd, J = 12.3, 6.3 Hz, 1H), 3.87 (s, 3H), 3.68 (td, J = 12.4, 6.3 Hz, 1H), 3.61 (s, 3H), 
3.53 (s, 3H), 3.16 (dd, J = 13.8, 3.2 Hz, 1H), 3.02 (dd, J = 13.8, 3.2 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 191.6, 164.5, 164.2, 150.8, 135.8, 135.1, 132.5, 131.7, 131.5, 127.7, 123.4, 121.5, 120.4, 
119.6, 117.4, 116.5, 116.0, 113.2, 111.7, 104.2, 70.2, 67.7, 55.4, 49.8, 24.3, 22.6 ppm; HRMS: 
Calcd for C26H25O4N2 [M+H]+: 445.17580, Found: 445.17561; [α]D20 -8.4 ° (c 0.002 in ethanol). 
 
Compound 72b:  
 
Compound 72b was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H), 9.73 (s, 1H), 7.78 (s, 1H), 7.70 (s, 1H), 7.34 – 7.27 (m, 2H), 7.18 – 7.10 
(m, 3H), 7.03 – 6.99 (m, 1H), 6.90 – 6.84 (m, 2H), 6.31 (s, 1H), 4.15 – 4.10 (m, 3H), 3.50 – 3.46 
(m, 1H), 3.05 – 2.97 (m, 1H), 2.88 – 2.83 (m, 1H), 1.32 (t, J = 6.5 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 188.3, 170.8, 155.0, 153.7, 136.1, 134.3, 132.1, 131.5, 131.3, 129.3, 125.8, 125.6, 
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121.2, 119.0, 117.9, 116.2, 112.3, 111.6, 106.7, 106.1, 67.1, 61.2, 49.8, 22.4, 16.2 ppm; 
HRMS: Calcd for C25H23O4N2 [M+H]+: 415.16523, Found: 415.16511 
 
Compound 72c:  
 
Compound 72c was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 11.24 (s, 1H), 9.74 (s, 1H), 7.79 (s, 1H), 7.69 (s, 1H), 7.33 
– 7.28 (m, 2H), 7.17 – 7.10 (m, 3H), 7.04 – 6.98 (m, 1H), 6.91 – 6.84 (m, 2H), 6.31 (s, 1H), 4.02 
– 3.99 (m, 1H), 3.49 – 3.44 (m, 1H), 3.04 – 2.97 (m, 1H), 2.89 – 2.83 (m, 1H), 1.47 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ 188.3, 170.9, 155.0, 153.7, 136.1, 134.3, 132.1, 131.5, 131.4, 129.3, 
125.8, 125.6, 121.2, 119.0, 117.9, 116.2, 112.3, 111.6, 106.7, 106.1, 81.5, 67.1, 49.8, 28.8, 
21.6 ppm; HRMS: Calcd for C27H27O4N2 [M+H]+: 443.19653, Found: 449.19670. 
 
Compound 72d:  
 
Compound 72d was synthesized according to the general procedures. Red amorphous solid; 
TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.30; 1H NMR (400 MHz, CDCl3) 11.31 (s, 1H), 
9.14 (s, 1H), 7.81 (s, 1H), 7.60 (s, 1H), 7.48 – 7.40 (m, 3H), 7.25 – 7.18 (m, 1H), 7.33 – 7.31 (m, 
1H), 7.09 – 7.00 (m, 2H), 6.86 (m, 1H), 6.29 (s, 1H), 3.83 – 3.79 (m, 1H), 3.20 – 3.13 (m, 1H), 
2.96 – 2.91 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 191.9, 153.4, 136.1, 134.8, 132.5, 130.3, 126.1, 
122.7, 120.2, 119.7, 118.4, 118.3, 118.2, 118.1, 116.1, 111.9, 107.8, 105.9, 83.8, 82.3, 69.1, 52.0, 
23.4 ppm; HRMS: Calcd for C23H18O2N3 [M+H]+: 368.13935, Found: 368.13932; [α]D20 -7.4 ° (c 
0.002 in ethanol). 
 
Compound 72e:  
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Compound 72e was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 12.14 (s, 1H), 11.22 (s, 1H), 9.74 (s, 1H), 7.74 (s, 1H), 7.68 (s, 1H), 7.33 – 7.27 (m, 
2H), 7.17 – 7.10 (m, 3H), 7.05 – 7.00 (m, 1H), 6.91 – 6.84 (m, 2H), 6.31 (s, 1H), 4.16 – 4.11 (m, 
1H), 3.49 – 3.45 (m, 1H), 3.03 – 2.96 (m, 1H), 2.86 – 2.82 (m, 1H) ; 13C NMR (101 MHz, DMSO-
d6) δ 188.3, 173.1, 155.3, 153.7, 136.2, 132.1, 132.0, 131.5, 131.3, 129.3, 125.7, 125.5, 121.1, 
119.0, 118.0, 116.3, 112.3, 111.6, 106.8, 106.1, 67.0, 49.8, 22.1 ppm; HRMS: Calcd for 
C23H19O4N2 [M+Na]+: 409.11588, Found: 4019.11574. 
 
Compound 72f:  
 
Compound 72f was synthesized according to the general procedures. Red amorphous solid; 
TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.24 (s, 1H), 
9.76 (s, 1H), 7.75 (s, 1H), 7.70 (s, 1H), 7.32 – 7.27 (m, 2H), 7.18 – 7.10 (m, 3H), 7.03 – 7.00 (m, 
1H), 6.90 – 6.84 (m, 2H), 6.30 (s, 1H), 4.15 – 4.11 (m, 1H), 3.72 (s, 3H), 3.51 – 3.48 (m, 1H), 
3.03 – 2.97 (m, 1H), 2.86 – 2.82 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ 188.5, 170.1, 155.2, 
153.9, 136.2, 134.4, 132.1, 131.6, 131.4, 129.3, 125.8, 125.7, 121.2, 119.0, 117.9, 116.3, 
112.3, 111.6, 106.8, 106.1, 67.1, 53.5, 50.0, 49.8, 22.4 ppm; HRMS: Calcd for C24H21O4N2 
[M+H]+: 401.14958, Found: 401.14950; [α]D20 -8.1 ° (c 0.002 in ethanol). 
 
Compound 72g:  
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Compound 72g was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.35 (s, 1H), 8.60 (s, 1H), 7.83 (s, 1H), 7.70 (s, 1H), 7.45 – 7.32 (m, 3H), 7.23 – 7.17 
(m, 1H), 6.93 – 6.85 (m, 3H), 6.28 (s, 1H), 3.91 – 3.87 (m, 4H), 3.68 – 3.60 (m, 4H), 3.14 (dd, J 
= 14.0, 3.2 Hz, 1H), 2.93 (dd, J = 14.0, 3.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 191.4, 165.0, 
164.5, 150.7, 135.8, 135.1, 132.4, 131.5, 131.3, 127.6, 123.4, 121.6, 120.4, 119.5, 117.3, 116.5, 
116.2, 113.2, 111.8, 104.2, 70.4, 67.8, 55.4, 50.0, 22.7 ppm; HRMS: Calcd for C25H23O5N2 
[M+H]+: 431.16015, Found: 431.16007. 
 
Compound 72h:  
 
Compound 72h was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.20 (s, 1H), 8.79 (s, 1H), 7.80 (s, 1H), 7.72 (s, 1H), 7.44 – 7.32 (m, 4H), 7.23 – 7.18 
(m, 3H), 5.99 (s, 1H), 4.02 (q, J = 7.6 Hz, 2H), 3.91 – 3.87 (m, 4H), 3.68 – 3.60 (m, 1H), 3.13 
(dd, J = 13.6, 3.1 Hz, 1H), 3.00 (dd, J = 13.7, 3.1 Hz, 1H), 1.48 (t, J = 7.6 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 191.2, 165.2, 164.5, 150.6, 135.8, 135.2, 132.4, 131.5, 131.1, 127.4, 123.4, 121.7, 
120.3, 119.6, 117.3, 116.6, 116.2, 114.2, 111.7, 104.2, 70.3, 67.7, 61.7, 50.2, 22.6, 14.2 ppm; 
HRMS: Calcd for C26H25O5N2 [M+H]+: 445.17580, Found: 445.17593. 
 
Compound 72i:  
 
Compound 72i was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.25 
(s, 1H), 8.91 (s, 1H), 7.93 – 7.90 (m, 1H), 7.61 (d, J = 1.4 Hz, 1H), 7.46 – 7.38 (m, 2H), 7.22 (s, 
1H), 7.03 – 6.99 (m, 1H), 6.88 (d, J = 2.4 Hz, 1H), 6.88 – 6.80 (m, 2H), 6.01 (s, 1H), 3.81 – 3.67 
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(m, 5H), 3.12 (ddd, J = 15.6, 12.0, 5.7 Hz, 1H), 2.88 (dd, J = 15.4, 4.0 Hz, 1H), 1.48 (s, 9H); 13C 
NMR (126 MHz, CDCl3) δ 192.1, 168.8, 161.5, 154.5, 153.5, 136.3, 134.6, 132.5, 131.4, 130.4, 
126.5, 120.0, 118.6, 118.5, 113.6, 113.3, 112.8, 107.9, 106.1, 100.4, 82.3, 68.1, 54.0, 52.7, 
29.3, 29.3, 29.2, 21.7 ppm; HRMS: Calcd for C28H29O5N2 [M+H]+: 473.20710, Found: 
473.20688. 
 
Compound 72j:  
 
Compound 72j was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.17 
(s, 1H), 8.75 (s, 1H), 7.80 (s, 1H), 7.72 (s, 1H), 7.46 – 7.33 (m, 3H), 7.23 – 7.16 (m, 1H), 6.96 – 
6.87 (m, 3H), 6.01 (s, 1H), 3.91 – 3.86 (m, 1H), 3.75 (s, 3H), 3.67 – 3.61 (m, 1H), 3.13 (dd, J = 
13.9, 3.0 Hz, 1H), 2.98 (dd, J = 13.9, 3.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 191.3, 164.2, 
150.6, 135.7, 135.0, 132.3, 131.7, 131.4, 127.6, 123.4, 121.5, 120.4, 119.7, 117.4, 117.3, 116.6, 
116.2, 113.4, 111.8, 104.6, 70.5, 67.9, 52.4, 22.5 ppm; HRMS: Calcd for C24H20O3N3 [M+H]+: 
398.14992, Found: 398.14974. 
 
Compound 72k:  
 
Compound 72k was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 12.14 (s, 1H), 11.09 (s, 1H), 8.93 (s, 1H), 7.84 (s, 1H), 7.72 (s, 1H), 7.46 – 7.34 (m, 
3H), 7.23 – 7.17 (m, 1H), 6.95 – 6.87 (m, 3H), 6.17 (s, 1H), 3.91 – 3.86 (m, 4H), 3.68 – 3.63 (m, 
1H), 3.12 (dd, J = 13.9, 3.2 Hz, 1H), 2.97 (dd, J = 13.9, 3.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
δ 191.0, 173.7, 164.4, 150.9, 135.5, 135.4, 133.0, 131.4, 131.3, 127.7, 123.4, 121.5, 120.7, 119.9, 
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117.4, 116.3, 116.2, 113.2, 111.7, 104.0, 70.7, 67.7, 52.9, 22.3 ppm; HRMS: Calcd for 
C24H21O5N2 [M+Na]+: 439.12644, Found: 439.12657. 
 
Compound 72l:  
 
Compound 72l was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.24 
(s, 1H), 8.73 (s, 1H), 7.81 (s, 1H), 7.73 (s, 1H), 7.47 – 7.32 (m, 4H), 7.24 – 7.18 (m, 3H), 4.14 
(q, J = 6.7 Hz, 2H), 3.90 (dd, J = 12.3, 6.3 Hz, 1H), 3.77 (s, 3H), 3.66 (td, J = 12.0, 6.2 Hz, 1H), 
3.53 (s, 3H), 3.14 (dd, J = 13.8, 3.3 Hz, 1H), 2.98 (dd, J = 13.8, 3.3 Hz, 1H), 1.44 (t, J = 6.7 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 190.4, 164.0, 163.7, 150.7, 135.6, 135.1, 132.5, 131.7, 131.5, 
127.6, 123.4, 121.5, 120.3, 119.9, 119.7, 117.1, 116.4, 113.0, 111.9, 104.1, 70.5, 67.6, 62.7, 55.9, 
24.3, 22.6, 14.9 ppm; HRMS: Calcd for C27H27O5N2 [M+H]+: 459.19145, Found: 459.19115. 
 
Compound 72m:  
 
Compound 72m was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.14 (s, 1H), 8.92 (s, 1H), 7.82 (s, 1H), 7.72 (s, 1H), 7.48 – 7.32 (m, 4H), 7.23 – 7.18 
(m, 3H), 3.93 (dd, J = 12.7, 6.5 Hz, 1H), 3.79 (s, 3H), 3.65 (td, J = 12.1, 6.3 Hz, 1H), 3.51 (s, 3H), 
3.12 – 3.08 (m, 1H), 2.97 (dd, J = 13.9, 3.2 Hz, 1H), 1.48 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 
189.7, 165.3, 163.4, 151.2, 135.2, 135.1, 132.7, 131.8, 131.4, 128.0, 123.5, 121.4, 120.4, 119.7, 
119.5, 118.0, 116.4, 113.2, 111.8, 104.0, 81.2, 70.2, 67.6, 55.8, 29.1, 24.4, 22.6 ppm; HRMS: 
Calcd for C29H31O5N2 [M+H]+: 498.22275, Found: 498.22268. 
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Compound 72n:  
 
Compound 72n was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.30; 1H NMR (400 MHz, 
CDCl3):  11.26 (s, 1H), 9.12 (s, 1H), 7.94 (s, 1H), 7.62 (s, 1H), 7.47 – 7.44 (m, 2H), 7.30 – 7.23 
(m, 3H), 6.99 – 6.91 (m, 2H), 3.86 (s, 3H), 3.81 – 3.74 (m, 2H), 3.64 (s, 3H), 3.16 – 3.07 (m, 
1H), 2.91 – 2.86 (m, 1H); 13C NMR (101 MHz, CDCl3) 13C NMR (100 MHz, CDCl3):  191.1, 
161.3, 153.0, 136.5, 134.7, 134.4, 130.0, 127.5, 125.8, 120.8, 119.6, 119.1, 118.5, 118.4, 
118.2, 116.8, 113.5, 112.7, 107.6, 106.2, 67.0, 53.2, 52.4, 26.9, 22.8 ppm; HRMS: Calcd for 
C25H22O3N3 [M+H]+: 412.16557, Found: 412.16550; [α]D20 -7.9 ° (c 0.002 in ethanol). 
 
Compound 72o:  
 
Compound 72o was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 12.14 (s, 1H), 11.24 (s, 1H), 8.85 (s, 1H), 7.79 (s, 1H), 7.73 (s, 1H), 7.46 – 7.34 (m, 
3H), 7.23 – 7.17 (m, 1H), 6.95 – 6.87 (m, 3H), 3.93 (dd, J = 12.4, 6.4 Hz, 1H), 3.88 (s, 3H), 3.69 
(td, J = 12.3, 6.3 Hz, 1H), 3.56 (s, 3H), 3.14 (dd, J = 13.4, 3.2 Hz, 1H), 3.00 (dd, J = 13.4, 3.2 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 191.0, 173.4, 164.7, 151.2, 135.7, 135.0, 132.6, 131.8, 131.7, 
127.7, 123.3, 121.5, 120.3, 119.7, 117.4, 116.0, 115.8, 113.9, 111.6, 104.1, 70.2, 67.8, 52.1, 24.4, 
22.4 ppm; HRMS: Calcd for C25H23O5N2 [M+Na]+: 453.14209, Found: 453.14187. 
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Compound 72p:  
 
Compound 72p was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.18 (s, 1H), 9.02 (s, 1H), 7.94 (d, J = 2.0 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.43 (d, J 
= 8.0 Hz, 1H), 7.40 – 7.30 (m, 3H), 7.22 – 7.12 (m, 2H), 6.97 (d, J = 8.5 Hz, 1H), 6.00 (s, 1H), 
3.83 – 3.75 (m, 5H), 3.20 (m, 1H), 2.99 (dd, J = 14.0, 4.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 
190.4, 167.2, 159.5, 153.4, 136.2, 135.1, 134.3, 131.6, 129.6, 125.9, 122.3, 121.2, 120.9, 
120.1, 119.7, 118.3, 114.6, 112.0, 108.2, 105.9, 68.4, 52.6, 50.6, 23.6 ppm; HRMS: Calcd for 
C24H20O4N2F [M+H]+: 419.14016, Found: 419.13999. 
 
Compound 72q:  
 
Compound 72q was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.10 (s, 1H), 8.99 (s, 1H), 7.92 (d, J = 1.5 Hz, 1H), 7.59 (d, J = 1.5 Hz, 1H), 7.46 (d, J 
= 8.0 Hz, 1H), 7.38 – 7.31 (m, 3H), 7.22 – 7.12 (m, 2H), 6.98 (d, J = 8.7 Hz, 1H), 6.02 (s, 1H), 
3.83 – 3.73 (m, 5H), 3.16 (m, 1H), 2.97 (dd, J = 15.6, 3.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 
190.5, 168.9, 159.7, 153.6, 136.2, 135.6, 134.3, 131.6, 129.5, 125.9, 122.4, 121.2, 120.8, 
120.0, 119.7, 118.3, 114.5, 112.0, 108.3, 105.8, 68.4, 52.7, 50.6, 23.4 ppm; HRMS: Calcd for 
C24H20O4N2Cl [M+H]+: 435.11061, Found: 435.11066. 
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Compound 72r:  
 
Compound 72r was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.21 
(s, 1H), 9.02 (s, 1H), 7.95 (d, J = 1.5 Hz, 1H), 7.50 (d, J = 1.5 Hz, 1H), 7.42 – 7.31 (m, 4H), 7.22 
– 7.12 (m, 2H), 6.99 (d, J = 8.6 Hz, 1H), 6.00 (s, 1H), 3.80 – 3.70 (m, 5H), 3.14 (m, 1H), 2.98 
(dd, J = 15.5, 3.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.6, 168.3, 159.4, 154.0, 136.2, 
135.4, 134.3, 131.1, 129.5, 125.8, 122.6, 121.0, 120.7, 120.0, 119.7, 118.4, 114.6, 112.0, 
108.7, 105.8, 68.4, 52.6, 50.6, 23.2 ppm; HRMS: Calcd for C24H20O4N2Br [M+H]+: 479.06010, 
Found: 479.05979. 
 
Compound 72s:  
 
Compound 72s was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.00 (s, 1H), 9.02 (s, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.59 (d, J = 2.0 Hz, 1H), 7.47 (d, J 
= 7.8 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.20 – 7.10 (m, 4H), 6.94 – 6.90 (m, 1H), 6.01 (s, 1H), 
3.86 (s, 3H), 3.79 – 3.68 (m, 2H), 3.15 (ddd, J = 15.7, 11.9, 5.7, 9.9 Hz, 1H), 2.93 (dd, J = 15.5, 
3.6 Hz, 1H), 2.28 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 192.0, 169.0, 159.2, 153.4, 136.7, 136.0, 
135.4, 132.5, 130.2, 127.7, 126.0, 123.1, 120.4, 119.6, 118.4, 118.2, 113.4, 112.0, 108.5, 
106.1, 68.0, 54.2, 52.7, 23.6, 20.5 ppm; HRMS: Calcd for C25H23O4N2 [M+H]+: 415.16523, 
Found: 415.16504. 
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Compound 72t:  
 
Compound 72t was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.07 
(s, 1H), 9.03 (s, 1H), 7.92 (d, J = 2.3 Hz, 1H), 7.60 (d, J = 2.4 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 
7.35 (d, J = 7.9 Hz, 1H), 7.20 – 7.12 (m, 4H), 6.95 – 6.91 (m, 1H), 6.00 (s, 1H), 3.84 (s, 3H), 3.78 
– 3.71 (m, 2H), 3.17 – 3.14 (m, 1H), 2.93 – 2.87 (m, 1H), 2.72 (q, J = 8.0 Hz, 2H), 1.31 (t, J = 
8.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 191.7, 169.4, 159.3, 153.5, 136.7, 136.0, 135.3, 
132.5, 130.2, 127.8, 126.0, 123.2, 120.5, 119.5, 118.4, 118.2, 113.3, 111.7, 108.4, 106.0, 67.9, 
54.3, 52.7, 27.1, 23.5, 14.7 ppm; HRMS: Calcd for C26H25O4N2 [M+H]+: 429.18088, Found: 
429.18057. 
 
Compound 72u:  
 
Compound 72u was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 10.99 (s, 1H), 9.03 (s, 1H), 7.92 (d, J = 1.8 Hz, 1H), 7.67 (d, J = 1.8 Hz, 1H), 7.47 (d, J 
= 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.27 - 7.16 (m, 3H), 7.09 (m, 1H), 6.90 (d, J = 9.0 Hz, 1H), 
5.97 (s, 1H), 3.85 – 3.76 (m, 4H), 3.65 (dd, J = 13.1, 5.3 Hz, 1H), 3.15 – 3.19 (m, 1H), 2.96 (dd, 
J = 14.9, 4.0 Hz, 1H), 2.87 – 2.79 (m, 1H), 1.31 (d, J = 7.0 Hz, 6H); 13C NMR (101 MHz, CDCl3) 
δ 192.0, 168.7, 159.4, 154.0, 138.7, 136.8, 136.6, 133.4, 132.2, 127.8, 126.1, 123.1, 120.4, 
119.6, 118.7, 118.1, 112.9, 112.3, 108.2, 105.9, 68.4, 53.2, 33.7, 27.1, 24.2, 24.1, 23.2 ppm; 
HRMS: Calcd for C27H27O4N2 [M+H]+: 443.19653, Found: 443.19626). 
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Compound 72v:  
 
Compound 72v was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H), 8.99 (s, 1H), 7.87 (d, J = 2.7 Hz, 1H), 7.68 (d, J = 2.7 Hz, 1H), 7.46 (d, J 
= 7.8 Hz, 1H), 7.41 – 7.32 (m, 3H), 7.22 – 7.13 (m, 2H), 6.97 (d, J = 8.1 Hz, 1H), 6.03 (s, 1H), 
3.83 – 3.76 (m, 5H), 3.19 (m, 1H), 2.98 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 190.2, 167.4, 
159.7, 153.1, 136.4, 134.9, 134.3, 131.8, 129.6, 125.7, 122.4, 121.3, 121.0, 120.1, 119.7, 
118.2, 114.7, 112.3, 108.2, 105.9, 68.7, 52.4, 50.4, 23.7 ppm; HRMS: Calcd for C24H20O6N3 
[M+H]+: 446.13466, Found: 446.13438. 
 
Compound 72w:  
 
Compound 72w was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.04 (s, 1H), 8.99 (s, 1H), 7.78 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 2.0 Hz, 1H), 7.53 – 7.49 
(m, 2H), 7.29 (d, J = 8.6 Hz, 1H), 6.92 – 6.88 (m, 3H), 6.00 (s, 1H), 3.85 (s, 3H), 3.81 - 3.74 (m, 
5H), 3.15 – 3.11 (m, 1H), 2.93 (dd, J = 15.7, 3.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.3, 
168.4, 160.0, 154.4, 153.6, 137.2, 135.7, 132.8, 132.0, 131.2, 126.5, 121.6, 120.7, 114.3, 
113.2, 112.7, 110.1, 107.8, 105.6, 100.1, 68.7, 55.1, 53.0, 52.1, 23.4 ppm; HRMS: Calcd for 
C25H22O5N2F [M+H]+: 449.15073, Found: 449.15047. 
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Compound 72x:  
 
Compound 72x was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.05 (s, 1H), 9.02 (s, 1H), 7.83 (d, J = 1.7 Hz, 1H), 7.58 (d, J = 1.7 Hz, 1H), 7.51 (d, J 
= 2.3 Hz, 1H), 7.49 (dd, J = 8.6, 2.5 Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 6.84 – 6.80 (m, 3H), 6.04 
(s, 1H), 3.88 (s, 3H), 3.81 – 3.72 (m, 5H), 3.21 (ddd, J = 15.7, 11.4, 6.1 Hz, 1H), 2.98 (dd, J = 
15.7, 3.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.3, 169.7, 162.1, 154.4, 152.5, 137.0, 135.9, 
132.6, 132.1, 131.0, 126.3, 121.4, 119.9, 114.7, 113.6, 111.7, 110.2, 107.6, 106.1, 100.9, 68.3, 
56.6, 53.1, 52.7, 22.4 ppm; HRMS: Calcd for C25H22O5N2Cl [M+H]+: 465.12118, Found: 
465.12098. 
 
Compound 72y:  
 
Compound 72y was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.16 (s, 1H), 8.93 (s, 1H), 7.87 (d, J = 1.9 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.52 – 7.48 
(m, 2H), 7.25 (d, J = 8.7 Hz, 1H), 6.97 – 6.90 (m, 3H), 6.01 (s, 1H), 3.86 (s, 3H), 3.81 – 3.72 (m, 
5H), 3.15 – 3.11 (m, 1H), 2.94 (dd, J = 15.8, 3.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.2, 
168.9, 160.2, 154.3, 153.6, 137.1, 135.7, 132.9, 132.7, 131.1, 126.4, 121.6, 120.4, 113.8, 
113.1, 112.5, 110.1, 107.7, 105.6, 100.2, 68.5, 55.0, 53.1, 52.2, 23.8 ppm; HRMS: Calcd for 
C25H22O5N2Br [M+H]+: 509.07066, Found: 509.07085. 
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Compound 72z:  
 
Compound 72z was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.01 (s, 1H), 8.97 (s, 1H), 7.93 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 1.6 Hz, 1H), 7.24 – 7.19 
(m, 3H), 6.92 – 6.88 (m, 2H), 6.85 (dd, J = 8.8, 2.5 Hz, 1H), 5.98 (s, 1H), 3.89 – 3.80 (m, 4H), 
3.78 (s, 3H), 3.71 (dd, J = 13.3, 5.1 Hz, 1H), 3.11 (ddd, J = 15.5, 12.1, 5.5 Hz, 1H), 2.89 (dd, J = 
15.5, 3.7 Hz, 1H), 2.29 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 192.1, 169.3, 168.4, 159.2, 154.4, 
153.5, 136.0, 135.4, 132.8, 131.3, 130.4, 127.7, 126.5, 119.8, 118.2, 113.9, 113.1, 112.8, 
107.8, 100.3, 68.3, 56.1, 52.8, 52.4, 23.6, 21.2 ppm; HRMS: Calcd for C26H25O5N2 [M+H]+: 
445.17580, Found: 445.17575. 
 
Compound 72aa:  
 
Compound 72aa was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.04 (s, 1H), 8.99 (s, 1H), 7.91 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.23 – 7.18 
(m, 3H), 6.93 – 6.87 (m, 3H), 5.99 (s, 1H), 3.89 – 3.82 (m, 4H), 3.77 (s, 3H), 3.70 (dd, J = 13.2, 
5.2 Hz, 1H), 3.09 (ddd, J = 15.6, 12.0, 5.2 Hz, 1H), 2.92 – 2.87 (m, 3H), 1.32 (t , J = 7.9 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ 191.1, 169.4, 168.4, 159.5, 154.4, 153.6, 136.0, 135.5, 132.7, 
131.2, 130.4, 127.7, 126.5, 119.8, 118.2, 113.9, 113.1, 112.8, 107.8, 100.3, 68.0, 56.1, 52.8, 
52.5, 28.3, 23.5, 17.3 ppm; HRMS: Calcd for C27H27O5N2 [M+H]+: 459.19145, Found: 
459.19137. 
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Compound 72ab:  
 
Compound 72ab was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 8.95 (s, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.57 (d, J = 1.5 Hz, 1H), 7.26 – 7.20 
(m, 3H), 6.92 – 6.82 (m, 3H), 6.03 (s, 1H), 3.89 – 3.80 (m, 4H), 3.78 (s, 3H), 3.70 (dd, J = 13.4, 
5.0 Hz, 1H), 3.17 – 3.13 (m, 1H), 2.95 – 2.90 (m, 2H), 1.31 (d, J = 7.0 Hz, 6H); 13C NMR (101 
MHz, CDCl3) δ 192.1, 169.3, 168.4, 159.2, 154.4, 153.5, 136.0, 135.4, 132.8, 131.3, 130.4, 
127.7, 126.5, 119.8, 118.2, 113.9, 113.1, 107.8, 106.1, 100.3, 68.3, 56.1, 52.8, 52.4, 34.1, 
23.6, 21.8, 21.7 ppm; HRMS: Calcd for C28H29O5N2 [M+H]+: 437.20710, Found: 437.20687. 
 
Compound 72ac:  
 
Compound 72ac was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.11 (s, 1H), 8.99 (s, 1H), 7.87 (s, 1H), 7.63 (s, 1 H), 7.51 (s, 1H), 7.36 – 7.31 (m, 2H), 
7.26 – 7.22 (m, 2H), 6.98 (d, J = 9.0 Hz, 1H), 3.88 (s, 3H), 3.81 (m, 4H), 3.53 – 3.46 (m, 4H), 
3.22 – 3.17 (m, 1H), 3.01 (dd, J = 15.3, 3.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) 191.2, 176.8, 
159.7, 153.5, 136.0, 135.8, 134.3, 131.7, 129.3, 126.0, 123.5, 123.1, 120.7, 120.2, 119.0, 
118.4, 115.1, 112.0, 108.2, 105.7, 68.1, 54.2, 52.8, 52.6, 23.8, 22.4 ppm; HRMS: Calcd for 
C26H24O5N2F [M+H]+: 463.16638, Found: 463.16611. 
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Compound 72ad:  
 
Compound 72ad was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.30; 1H NMR (400 MHz, 
CDCl3)  11.23 (s, 1H), 9.03 (s, 1H), 7.91 (s, 1H), 7.62 (s, 1 H), 7.58 (s, 1H), 7.37 – 7.30 (m, 2H), 
7.20 – 7.14 (m, 2H), 6.95 (d, J = 8.7 Hz, 1H), 3.87 (s, 3H), 3.84 – 3.80 (m, 4H), 3.54 – 3.46 (m, 
4H), 3.22 – 3.16 (m, 1H), 2.95 ppm (dd, J = 15.6, 3.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
190.5, 170.1, 159.8, 153.5, 136.1, 135.8, 134.2, 131.7, 129.4, 126.0, 123.4, 123.1, 120.8, 
120.0, 119.1, 118.4, 114.0, 112.1, 108.2, 105.8, 68.1, 54.3, 52.8, 52.6, 23.7, 22.5 ppm; HRMS: 
Calcd for C26H24O5N2Cl [M+H]+: 479.13683, Found: 479.13677; [α]D20 -8.8 ° (c 0.002 in 
ethanol). 
 
Compound 72ae:  
 
Compound 72ae was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.23 (s, 1H), 9.03 (s, 1H), 7.91 (s, 1H), 7.62 (s, 1 H), 7.58 (s, 1H), 7.37 – 7.30 (m, 2H), 
7.20 – 7.14 (m, 2H), 6.95 (d, J = 8.7 Hz, 1H), 3.87 (s, 3H), 3.82 – 3.78 (m, 4H), 3.54 – 3.46 (m, 
4H), 3.22 – 3.16 (m, 1H), 2.95 ppm (dd, J = 15.6, 3.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
190.5, 170.1, 159.8, 153.5, 136.1, 135.8, 134.2, 131.7, 129.4, 126.0, 123.4, 123.1, 120.8, 
120.0, 119.1, 118.4, 114.0, 112.1, 108.2, 105.8, 68.1, 54.3, 52.8, 52.6, 23.7, 22.5 ppm; HRMS: 
Calcd for C26H24O5N2Br [M+H]+: 523.08631, Found: 523.08614. 
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Compound 72af:  
 
Compound 72af was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3)  11.27 (s, 1H), 9.02 (s, 1H), 7.91 (s, 1H), 7.58 (s, 1H), 7.46 – 7.39 (m, 2H), 7.27 – 7.23 
(m, 2H), 7.04 (m, 1H), 6.89 (t, J =7.8 Hz, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.69 – 3.64 (m, 2H), 
3.39 (s, 3H), 3.18 – 3.13 (m, 1H) 2.93 – 2.87 (m, 1H), 2.51 (s, 3H); 13C NMR (100 MHz, CDCl3): 
 191.7, 169.9, 168.2, 161.1, 153.2, 136.8, 134.2, 131.8, 129.2, 126.2, 124.7, 119.6, 118.4, 
118.2, 117.6, 113.3, 111.4, 107.7, 105.7, 70.0, 67.9, 53.6, 52.5, 52.3, 23.1, 22.7, 21.5 ppm; 
HRMS: Calcd for C27H27O5N2 [M+H]+: 459.19145, Found: 459.19139; [α]D20 -10.1 ° (c 0.002 in 
ethanol). 
 
Compound 72ag:  
 
Compound 72ag was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.24 (s, 1H), 9.01 (s, 1H), 7.92 (s, 1H), 7.59 (s, 1H), 7.46 – 7.40 (m, 2H), 7.28 – 7.23 
(m, 2H), 7.04 – 7.01 (m, 1H), 6.92 (t, J =7.8 Hz, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.69 – 3.64 (m, 
2H), 3.49 (s, 3H), 3.18 – 3.12 (m, 1H) 2.92 – 2.87 (m, 1H), 2.79 (q, J = 7.9 Hz, 2H), 1.32 (t , J = 
7.9 Hz, 3H); 13C NMR (100 MHz, CDCl3):  192.0, 169.9, 165.2, 161.0, 153.2, 136.9, 134.3, 
131.7, 129.2, 126.1, 124.7, 119.6, 118.3, 118.2, 117.6, 113.4, 111.4, 107.8, 105.7, 69.9, 67.8, 
53.7, 52.5, 52.2, 28.1, 23.3, 22.8, 17.1 ppm; HRMS: Calcd for C28H29O5N2 [M+H]+: 473.20710, 
Found: 473.20685. 
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Compound 72ah:  
 
Compound 72ah was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.08 (s, 1H), 8.99 (s, 1H), 7.87 (s, 1H), 7.59 (s, 1H), 7.26 – 7.19 (m, 3H), 6.92 – 6.84 
(m, 3H), 3.88 – 3.80 (m, 4H), 3.77 – 3.72 (m, 4H), 3.55 (s, 3H), 3.18 – 3.13 (m, 1H), 2.93 – 2.87 
(m, 2H), 1.31 (d, J = 7.0 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 192.0, 169.5, 168.3, 159.4, 
154.3, 153.6, 136.1, 135.5, 132.7, 131.2, 130.6, 127.8, 126.4, 119.7, 118.4, 113.8, 113.2, 
107.7, 106.3, 100.3, 68.3, 56.2, 52.6, 52.1, 34.0, 27.5, 23.8, 21.7, 21.4 ppm; HRMS: Calcd for 
C29H31O5N2 [M+H]+: 487.22275, Found: 487.22255. 
 
Compound 72ai:  
 
Compound 72ai was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.24 (s, 1H), 9.00 (s, 1H), 7.88 (d, J = 3.0 Hz, 1H), 7.70 (d, J = 3.0 Hz, 1H), 7.49 (d, J 
= 8.0 Hz, 1H), 7.40 – 7.32 (m, 2H), 7.23 – 7.12 (m, 2H), 6.99 – 6.93 (d, J = 8.0 Hz, 1H), 3.84 – 
3.75 (m, 8H), 3.61 (s, 3H), 3.29 – 3.26 (m, 1H), 2.95 – 2.90 (m, 1H); 13C NMR (101 MHz, CDCl3) 
δ 189.8, 166.4, 160.7, 153.2, 136.4, 135.9, 134.3, 131.6, 129.5, 125.4, 122.4, 121.2, 121.0, 
120.0, 119.9, 118.1, 114.7, 112.4, 110.2, 108.2, 68.7, 54.0, 52.4, 52.3, 50.3, 23.4 ppm; HRMS: 
Calcd for C26H24O7N3 [M+H]+: 490.16088, Found: 490.16084. 
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Compound 72aj:  
 
Compound 72aj was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.10 (s, 1H), 8.97 (s, 1H), 7.93 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.47 (d, J 
= 7.9 Hz, 1H), 7.39 – 7.30 (m, 3H), 7.25 – 7.19 (m, 1H), 7.17 – 7.10 (m, 1H), 6.00 (s, 1H), 6.91 
(d, J = 8.6 Hz, 1H), 3.80 – 3.73 (m, 2H), 3.16 (dd, J = 15.6, 12.0 Hz, 1H), 2.98 (dd, J = 15.6, 7.4 
Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 159.7, 153.6, 136.3, 135.8, 134.4, 131.7, 129.6, 
126.0, 123.3, 123.2, 120.7, 121.0, 120.0, 118.2, 115.3, 114.1, 112.0, 108.1, 105.7, 68.2, 54.1, 
23.4 ppm; HRMS: Calcd for C23H17O2N3F [M+H]+: 386.12993, Found: 386.12981. 
 
Compound 72ak:  
 
Compound 72ak was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.10 (s, 1H), 8.97 (s, 1H), 7.93 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.47 (d, J 
= 7.9 Hz, 1H), 7.39 – 7.30 (m, 3H), 7.25 – 7.19 (m, 1H), 7.17 – 7.10 (m, 1H), 6.00 (s, 1H), 6.91 
(d, J = 8.6 Hz, 1H), 3.80 – 3.73 (m, 2H), 3.16 (dd, J = 15.6, 12.0 Hz, 1H), 2.98 (dd, J = 15.6, 7.4 
Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 159.7, 153.6, 136.3, 135.8, 134.4, 131.7, 129.6, 
126.0, 123.3, 123.2, 120.7, 121.0, 120.0, 118.2, 115.3, 114.1, 112.0, 108.1, 105.7, 68.2, 54.1, 
23.4 ppm; HRMS: Calcd for C23H17O2N3 [M+H]+: 402.10038, Found: 402.10005. 
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Compound 72al:  
 
Compound 72al was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.10 (s, 1H), 8.97 (s, 1H), 7.93 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.47 (d, J 
= 7.9 Hz, 1H), 7.39 – 7.30 (m, 3H), 7.25 – 7.19 (m, 1H), 7.17 – 7.10 (m, 1H), 6.00 (s, 1H), 6.91 
(d, J = 8.6 Hz, 1H), 3.80 – 3.73 (m, 2H), 3.16 (dd, J = 15.6, 12.0 Hz, 1H), 2.98 (dd, J = 15.6, 7.4 
Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 159.7, 153.6, 136.3, 135.8, 134.4, 131.7, 129.6, 
126.0, 123.3, 123.2, 120.7, 121.0, 120.0, 118.2, 115.3, 114.1, 112.0, 108.1, 105.7, 68.2, 54.1, 
23.4 ppm; HRMS: Calcd for C23H17O2N3Br [M+H]+: 446.04987, Found: 446.04961. 
 
Compound 72am:  
 
Compound 72am was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.04 (s, 1H), 9.01 (s, 1H), 7.92 (d, J = 2.0 Hz, 1H), 7.59 (d, J = 1.7 Hz, 1H), 7.48 (d, J 
= 7.7 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.23 – 7.13 (m, 4H), 6.94 – 6.90 (m, 1H), 6.00 (s, 1H), 
3.83 – 3.77 (m, 2H), 3.18 (dd, J = 15.8, 3.7 Hz, 1H), 2.95 (dd, J = 15.7, 3.6 Hz, 1H), 2.26 (s, 3H); 
13C NMR (101 MHz, CDCl3) δ 192.9, 160.2, 153.7, 136.4, 136.1, 135.4, 132.3, 130.5, 127.9, 
126.0, 123.4, 120.3, 119.5, 118.3, 118.2, 113.7, 112.1, 111.5, 108.4, 106.2, 68.0, 53.7, 23.6, 
21.0 ppm; HRMS: Calcd for C24H20O2N3 [M+H]+: 382.15500, Found: 382.15467. 
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Compound 72an:  
 
Compound 72an was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.08 (s, 1H), 9.00 (s, 1H), 7.90 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 1.8 Hz, 1H), 7.48 (d, J 
= 7.6 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.24 – 7.15 (m, 4H), 6.98 – 6.94 (m, 1H), 6.01 (s, 1H), 
3.80 – 3.73 (m , 2H), 3.17 (dd, J = 15.8, 3.8 Hz, 1H), 2.96 (dd, J = 15.7, 3.8 Hz, 1H), 2.79 (q, J = 
7.9 Hz, 2H), 1.32 (t , J = 7.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 192.0, 160.3, 153.8, 136.4, 
136.1, 135.7, 132.1, 130.5, 127.8, 126.0, 123.3, 120.4, 119.5, 118.2, 118.1, 113.8, 112.0, 
111.6, 108.7, 106.2, 68.4, 53.4, 27.5, 23.3, 17.5 ppm; HRMS: Calcd for C25H22O2N3 [M+H]+: 
396.17065, Found: 396.17044. 
 
Compound 72ao:  
 
Compound 72ao was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.02 (s, 1H), 8.99 (s, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 1.7 Hz, 1H), 7.48 (d, J 
= 7.7 Hz, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.23 – 7.14 (m, 4H), 6.95 – 6.90 (m, 1H), 5.99 (s, 1H), 
3.84 – 3.78 (m, 2H), 3.19 (dd, J = 15.6, 3.8 Hz, 1H), 2.96 – 2.91 (m, 2H), 1.31 (d, J = 7.0 Hz, 
6H); 13C NMR (101 MHz, CDCl3) δ 192.9, 160.2, 153.7, 136.4, 136.1, 135.4, 132.3, 130.5, 
127.9, 126.0, 123.4, 120.3, 119.5, 118.3, 118.2, 113.7, 112.1, 111.5, 108.4, 106.2, 68.0, 34.0, 
27.5, 23.7, 21.4 ppm; HRMS: Calcd for C26H24O2N3 [M+H]+: 410.18630 Found: 410.18604. 
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Compound 72ap:  
 
Compound 72ap was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 8.95 (s, 1H), 7.85 (d, J = 3.5 Hz, 1H), 7.59 – 7.53 (m, 3H), 7.31 (d, J = 7.7 
Hz, 1H), 6.97 (ddd, J = 12.0, 8.0, 2.4 Hz, 3H), 5.95 (s, 1H), 3.81 – 3.72 (m, 5H), 3.15 – 3.11 (m, 
1H), 2.98 (dd, J = 14.9, 3.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 189.7, 160.3, 154.3, 153.4, 
137.0, 135.7, 132.8, 132.7, 131.0, 126.4, 121.8, 120.4, 113.8, 113.0, 112.5, 111.8, 110.1, 
107.6, 105.6, 102.4, 68.9, 53.8, 52.1, 23.9 ppm; HRMS: Calcd for C24H19O3N3F [M+H]+: 
416.14050, Found: 416.14021. 
 
Compound 72aq:  
 
Compound 72aq was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.08 (s, 1H), 9.01 (s, 1H), 7.89 (d, J = 3.6 Hz, 1H), 7.54 – 7.48 (m, 3H), 7.25 (d, J = 6.7 
Hz, 1H), 7.02 – 6.96 (m, 3H), 6.04 (s, 1H), 3.82 – 3.71 (m, 5H), 3.15 – 3.10 (m, 1H), 3.02 (dd, J 
= 13.8, 4.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.2, 160.8, 156.1, 151.4, 137.5, 135.7, 
132.6, 132.4, 131.5, 126.3, 121.7, 120.4, 113.9, 113.0, 112.4, 111.8, 110.2, 107.5, 105.6, 
102.7, 68.9, 53.7, 52.0, 23.8 ppm; HRMS: Calcd for C24H19O3N3Cl [M+H]+: 432.11095, Found: 
432.11060. 
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Compound 72ar:  
 
Compound 72ar was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.06 (s, 1H), 8.99 (s, 1H), 7.87 (d, J = 3.7 Hz, 1H), 7.56 – 7.49 (m, 3H), 7.24 (d, J = 6.7 
Hz, 1H), 7.00 – 6.94 (m, 3H), 5.98 (s, 1H), 3.81 – 3.73 (m, 5H), 3.16 – 3.12 (m, 1H), 3.02 – 2.98 
(m, 1H); 13C NMR (101 MHz, CDCl3) δ 190.5, 160.7, 156.6, 151.1, 137.7, 135.7, 132.6, 132.5, 
131.1, 126.0, 121.7, 120.4, 113.8, 113.0, 112.7, 111.8, 110.3, 107.5, 105.7, 102.8, 68.9, 53.6, 
52.4, 23.8 ppm; HRMS: Calcd for C24H19O3N3Cl [M+H]+: 476.06043, Found: 476.06029. 
 
Compound 72as:  
 
Compound 72as was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H), 9.04 (s, 1H), 7.88 (s, 1H), 7.57 (s, 1H), 7.47 – 7.40 (m, 2H), 7.27 – 7.23 
(m, 2H), 7.02 (m, 1H), 6.97 (d, J = 8.8 Hz, 1H), 6.00 (s, 1H), 3.87 (s, 3H), 3.69 – 3.64 (m, 2H), 
3.17 – 3.12 (m, 1H), 2.93 – 2.89 (m, 1H), 2.53 (s, 3H); 13C NMR (100 MHz, CDCl3):  191.4, 
168.3, 161.4, 153.2, 136.5, 134.3, 131.8, 129.4, 126.4, 124.8, 119.5, 118.5, 118.0, 117.5, 
113.7, 111.4, 111.1, 107.5, 105.8, 67.8, 53.4, 52.3, 22.7, 21.7 ppm; HRMS: Calcd for 
C25H22O3N3 [M+H]+: 412.16557, Found: 412.16551. 
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Compound 72at:  
 
Compound 72at was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.17 (s, 1H), 9.02 (s, 1H), 7.90 (s, 1H), 7.56 (s, 1H), 7.46 – 7.41 (m, 2H), 7.26 – 7.23 
(m, 2H), 7.04 – 6.96 (m, 2H), 5.99 (s, 1H), 3.85 (s, 3H), 3.67 – 3.63 (m, 2H), 3.17 – 3.12 (m, 
1H), 2.90 – 2.86 (m, 1H), 2.77 (q, J = 7.8 Hz, 2H), 1.38 (t , J = 7.8 Hz, 3H); 13C NMR (100 MHz, 
CDCl3):  190.7, 165.4, 161.2, 153.7, 136.7, 134.2, 131.5, 129.5, 126.2, 124.6, 119.7, 118.5, 
118.2, 117.4, 113.7, 111.7, 111.3, 107.7, 105.7, 100.8, 67.9, 53.3, 52.2, 28.2, 22.6, 17.1  ppm; 
HRMS: Calcd for C26H24O3N3 [M+H]+: 426.18122, Found: 426.18100. 
 
Compound 72au:  
 
Compound 72au was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.09 (s, 1H), 9.04 (s, 1H), 7.87 (s, 1H), 7.63 (s, 1H), 7.25 – 7.20 (m, 3H), 6.97 – 6.92 
(m, 3H), 6.00 (s, 1H), 3.86 – 3.80 (m, 4H), 3.78 – 3.72 (m, 1H), 3.18 – 3.12 (m, 1H), 2.93 – 2.87 
(m, 2H), 1.37 (d, J = 7.4 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 192.4, 168.0, 159.6, 154.2, 
153.7, 136.0, 135.7, 132.8, 131.2, 130.6, 127.5, 126.4, 119.6, 118.3, 113.1, 113.2, 111.7, 
107.5, 106.0, 100.3, 68.4, 53.6, 52.1, 34.0, 27.6, 21.8, 21.4 ppm; HRMS: Calcd for C27H26O3N3 
[M+H]+: 440.19687, Found: 440.19658. 
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Compound 72av:  
 
Compound 72av was synthesized according to racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.18 
(s, 1H), 8.99 (s, 1H), 7.90 (s, 1H), 7.67 (s, 1 H), 7.59 (s, 1H), 7.36 – 7.30 (m, 2H), 7.20 – 7.13 
(m, 2H), 7.01 (d, J = 8.5 Hz, 1H), 3.78 – 3.74 (m, 4H), 3.55 – 3.47 (m, 4H), 3.23 – 3.17 (m, 1H), 
2.98 (dd, J = 15.7, 4.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) 190.1, 157.9, 153.3, 136.0, 135.9, 
134.2, 131.9, 129.4, 126.3, 123.4, 123.0, 120.8, 120.2, 119.1, 118.3, 114.0, 113.2, 112.0, 
108.2, 105.9, 68.1, 54.4, 53.1, 23.6, 22.3 ppm; HRMS: Calcd for C25H21O3N3F [M+H]+: 
430.15615, Found: 430.15586. 
 
Compound 72aw:  
 
Compound 72aw was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.09 (s, 1H), 9.00 (s, 1H), 7.87 (s, 1H), 7.64 (s, 1 H), 7.51 (s, 1H), 7.36 – 7.30 (m, 2H), 
7.26 – 7.22 (m, 2H), 6.98 (d, J = 8.9 Hz, 1H), 3.76 – 3.72 (m, 4H), 3.54 – 3.47 (m, 4H), 3.23 – 
3.17 (m, 1H), 2.98 (dd, J = 15.2, 3.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) 190.7, 158.4, 153.7, 
136.0, 135.7, 134.3, 131.7, 129.4, 126.0, 123.7, 123.0, 120.7, 120.4, 119.0, 118.4, 115.4, 
113.7, 112.0, 108.7, 105.7, 68.0, 54.2, 53.5, 24.7, 22.7 ppm; HRMS: Calcd for C25H21O3N3Cl 
[M+H]+: 446.12660, Found: 446.12635. 
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Compound 72ax:  
 
Compound 72ax was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.07 (s, 1H), 9.02 (s, 1H), 7.86 (s, 1H), 7.67 (s, 1 H), 7.50 (s, 1H), 7.35 – 7.30 (m, 2H), 
7.26 – 7.21 (m, 2H), 7.01 (d, J = 8.7 Hz, 1H), 3.75 – 3.70 (m, 4H), 3.55 – 3.50 (m, 4H), 3.23 - 
3.18 (m, 1H), 2.96 – 2.91 (m, 1H); 13C NMR (101 MHz, CDCl3) 192.1, 158.3, 153.8, 136.2, 
135.7, 134.1, 131.5, 129.3, 126.1, 123.4, 123.0, 120.8, 120.7, 119.1, 118.2, 115.3, 113.8, 
112.0, 108.6, 105.7, 68.1, 54.3, 53.6, 24.8, 22.6 ppm; HRMS: Calcd for C25H21O3N3Br [M+H]+: 
490.07608, Found: 490.07589. 
 
Compound 72ay:  
 
Compound 72ay was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.26 (s, 1H), 9.00 (s, 1H), 7.89 (s, 1H), 7.57 (s, 1H), 7.47 – 7.40 (m, 2H), 7.28 – 7.23 
(m, 2H), 7.03 (m, 1H), 6.95 (d, J = 8.7 Hz, 1H), 3.87 (s, 3H), 3.69 – 3.64 (m, 2H), 3.38 (s, 3H), 
3.18 – 3.12 (m, 1H), 2.94 – 2.89 (m, 1H), 2.50 (s, 3H); 13C NMR (100 MHz, CDCl3):  191.6, 
168.1, 161.4, 153.0, 136.7, 134.2, 131.8, 129.3, 126.2, 124.7, 119.5, 118.4, 118.1, 117.6, 
113.0, 111.5, 111.4, 107.7, 105.8, 100.8, 67.8, 53.0, 52.8, 52.3, 22.7, 21.4 ppm; HRMS: Calcd 
for C26H24O3N3 [M+H]+: 426.18122, Found: 426.18097. 
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Compound 72az:  
 
Compound 72az was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.23 (s, 1H), 8.99 (s, 1H), 7.90 (s, 1H), 7.57 (s, 1H), 7.46 – 7.41 (m, 2H), 7.27 – 7.23 
(m, 2H), 7.04 – 7.00 (m, 1H), 6.93 (t, J =7.9 Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.68 – 3.63 (m, 
2H), 3.17 – 3.12 (m, 1H) 2.92 – 2.87 (m, 1H), 2.78 (q, J = 8.0 Hz, 2H), 1.34 (t , J = 8.0 Hz, 3H); 
13C NMR (100 MHz, CDCl3):  190.7, 165.2, 161.2, 153.2, 136.8, 134.2, 131.7, 129.5, 126.1, 
124.8, 119.7, 118.3, 118.1, 117.5, 114.5, 113.3, 111.4, 107.7, 105.7, 100.5, 67.7, 53.3, 52.4, 
52.1, 28.0, 22.7, 17.0 ppm; HRMS: Calcd for C27H26O3N3 [M+H]+: 440.19687, Found: 
440.19649. 
 
Compound 72ba:  
 
Compound 72ba was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.07 (s, 1H), 9.00 (s, 1H), 7.86 (s, 1H), 7.62 (s, 1H), 7.26 – 7.20 (m, 3H), 6.93 – 6.86 
(m, 3H), 3.87 – 3.80 (m, 4H), 3.78 – 3.73 (m, 1H), 3.57 (s, 3H), 3.18 – 3.13 (m, 1H), 2.94 – 2.87 
(m, 2H), 1.34 (d, J = 7.2 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 192.2, 168.2, 159.7, 154.1, 
153.6, 136.0, 135.5, 132.8, 131.3, 130.6, 127.6, 126.4, 119.7, 118.3, 114.5, 113.7, 113.2, 
107.6, 106.2, 100.5, 100.3, 68.4, 52.6, 52.2, 33.2, 25.4, 23.3 ppm; HRMS: Calcd for C28H28O3N3 
[M+H]+: 454.21252, Found: 454.21239. 
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Compound 72bb:  
 
Compound 72bb was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H), 8.72 (s, 1H), 7.80 (s, 1H), 7.68 (s, 1H), 7.46 – 7.32 (m, 4H), 7.26 – 7.17 
(m, 3H), 6.00 (s, 1H), 3.91 – 3.86 (m, 1H), 3.67 – 3.59 (m, 4H), 3.12 (dd, J = 13.8, 4.0 Hz, 1H), 
2.99 (dd, J = 12.0, 3.8 Hz, 1H), 1.47 – 1.43 (m, 3H), 1.02 – 0.95 (d, J = 6.4 Hz, 18H); 13C NMR 
(101 MHz, CDCl3) δ 190.1, 165.9, 164.3, 150.6, 135.9, 135.2, 132.3, 131.8, 131.5, 127.1, 123.2, 
121.4, 120.3, 119.4, 117.3, 116.7, 116.2, 113.2, 111.0, 104.1, 70.4, 67.7, 55.3, 50.7, 26.3, 26.2, 
22.7, 18.0, 17.9 ppm; HRMS: Calcd for C33H41O5N2Si [M+H]+: 573.27793, Found: 573.27765. 
 
Compound 72bc:  
 
Compound 72bc was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.20 (s, 1H), 9.04 (s, 1H), 7.91 (d, J = 2.1 Hz, 1H), 7.66 (d, J = 2.2 Hz, 1H), 7.42 (d, J 
= 8.2 Hz, 1H), 7.37 – 7.29 (m, 2H), 7.22 – 7.13 (m, 2H), 7.00 – 6.94 (m, 1H), 5.98 (s, 1H), 3.82 
– 3.75 (m, 5H), 3.21 – 3.17 (m, 1H), 3.01 (dd, J = 13.9, 4.0 Hz, 1H), 1.47 – 1.43 (m, 3H), 0.99 
(d, J = 6.4 Hz, 18H); 13C NMR (101 MHz, CDCl3) δ 190.0, 167.5, 159.3, 154.0, 136.1, 135.6, 
134.2, 131.7, 129.6, 125.9, 122.4, 121.0, 120.8, 120.1, 119.7, 118.4, 114.6, 112.6, 108.1, 
105.9, 68.3, 55.3, 50.9, 26.2, 26.1, 23.5, 18.0, 17.9 ppm; HRMS: Calcd for C33H40O5N2Si 
[M+H]+: 591.26850, Found: 591.26813. 
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Compound 72bd:  
 
Compound 72bd was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.09 (s, 1H), 8.99 (s, 1H), 7.93 (d, J = 2.2 Hz, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.46 (d, J 
= 8.0 Hz, 1H), 7.36 – 7.29 (m, 2H), 7.23 – 7.13 (m, 2H), 6.99 – 6.93 (m, 1H), 6.00 (s, 1H), 3.83 
– 3.75 (m, 5H), 3.20 – 3.16 (m, 1H), 3.00 (dd, J = 14.0, 4.0 Hz, 1H), 2.46 (s, 3H), 1.47 – 1.42 
(m, 3H), 1.04 (d, J = 6.5 Hz, 18H); 13C NMR (101 MHz, CDCl3) δ 190.2, 167.0, 160.0, 153.9, 
136.2, 135.4, 134.2, 130.4, 129.7, 123.6, 122.4, 121.1, 120.7, 120.1, 119.0, 118.4, 113.5, 
112.5, 108.3, 105.4, 69.1, 55.4, 50.8, 26.2, 26.1, 23.7, 22.2, 18.0, 17.9 ppm; HRMS: Calcd for 
C34H43O5N2Si [M+H]+: 597.29358, Found: 597.29319. 
 
Compound 72be:  
 
Compound 72be was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.09 (s, 1H), 9.00 (s, 1H), 7.84 (s, 1H), 7.71 (s, 1H), 7.42 – 7.30 (m, 4H), 7.23 – 7.17 
(m, 3H), 5.99 (s, 1H), 3.89 – 3.84 (m, 1H), 3.67 – 3.61 (m, 1H), 3.10 (dd, J = 14.0, 3.0 Hz, 1H), 
2.96 (dd, J = 14.0, 3.0 Hz, 1H), 1.47 – 1.42 (m, 3H), 1.01 (d, J = 6.4 Hz, 18H); 13C NMR (101 
MHz, CDCl3) δ 190.8, 163.4, 153.4, 135.8, 132.2, 131.7, 131.5, 127.5, 123.4, 121.7, 120.6, 119.5, 
118.9, 117.3, 117.2, 116.6, 116.3, 113.4, 111.7, 104.6, 70.2, 68.0, 52.4, 26.2, 26.1, 22.6, 18.0, 
17.9 ppm; HRMS: Calcd for C32H38O3N3Si [M+H]+: 540.26770, Found: 540.26749. 
 
 
 
 
III. Experimental Part  166 
 
 
Compound 72bf:  
 
Compound 72bf was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.14 (s, 1H), 9.02 (s, 1H), 7.89 (d, J = 2.2 Hz, 1H), 7.68 (d, J = 2.2 Hz, 1H), 7.41 (d, J 
= 8.1 Hz, 1H), 7.37 – 7.30 (m, 2H), 7.23 – 7.13 (m, 2H), 6.98 (d, J = 8.2 Hz, 1H), 6.00 (s, 1H), 
3.82 – 3.75 (m, 2H), 3.21 – 3.16 (m, 1H), 2.99 (dd, J = 13.8, 4.0 Hz, 1H), 1.47 – 1.42 (m, 3H), 
1.00 (d, J = 6.3 Hz, 18H); 13C NMR (101 MHz, CDCl3) δ 191.2, 167.6, 159.2, 154.8, 136.2, 135.4, 
134.2, 131.8, 129.6, 125.8, 122.4, 121.2, 120.8, 120.0, 119.7, 118.9, 114.3, 112.5, 108.3, 
105.8, 68.3, 51.2, 26.2, 26.1, 23.4, 18.0, 17.9 ppm; HRMS: Calcd for C32H37O3N3Si [M+H]+: 
558.25827, Found: 558.25804. 
 
Compound 72bg:  
 
Compound 72bg was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 8.99 (s, 1H), 7.88 (d, J = 2.2 Hz, 1H), 7.68 (d, J = 2.2 Hz, 1H), 7.43 (d, J 
= 8.1 Hz, 1H), 7.37 – 7.29 (m, 2H), 7.23 – 7.13 (m, 2H), 6.97 (d, J = 8.2 Hz, 1H), 6.04 (s, 1H), 
3.80 – 3.74 (m, 2H), 3.22 – 3.16 (m, 1H), 3.02 (dd, J = 14.0, 4.0 Hz, 1H), 2.46 (s, 3H), 1.47 – 
1.41 (m, 3H), 1.02 (d, J = 6.4 Hz, 18H); 13C NMR (101 MHz, CDCl3) δ 191.5, 166.4, 159.3, 154.3, 
136.7, 135.2, 131.8, 129.4, 125.7, 122.4, 121.6, 120.8, 120.4, 120.1, 119.7, 118.7, 115.0, 
112.7, 108.1, 105.7, 68.3, 50.9, 26.2, 26.1, 23.5, 22.5, 18.0, 17.9 ppm; HRMS: Calcd for 
C33H40O3N3 [M+H]+: 554.28335, Found: 554.28311. 
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Compound 72bh:  
 
Compound 72bh was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.24 (s, 1H), 8.79 (s, 1H), 7.84 (s, 1H), 7.71 (s, 1H), 7.45 – 7.31 (m, 3H), 7.23 – 7.17 
(m, 1H), 6.94 – 6.85 (m, 3H), 6.08 (s, 1H), 4.04 (q, J = 7.9 Hz, 2H), 3.91 – 3.86 (m, 1H), 3.68 – 
3.61 (m, 4H), 3.12 (dd, J = 14.0, 3.0 Hz, 1H), 2.94 (dd, J = 14.0, 3.0 Hz, 1H), 1.37 (t, J = 7.9 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 191.3, 167.2, 164.4, 150.7, 135.9, 135.0, 132.4, 131.5, 131.4, 
127.5, 123.4, 121.7, 120.5, 119.3, 117.3, 116.4, 116.2, 113.2, 111.7, 104.2, 70.4, 67.7, 54.4, 50.8, 
22.4, 14.7 ppm; HRMS: Calcd for C26H25O5N2 [M+H]+: 445.17580, Found: 445.17547. 
 
Compound 72bi:  
 
Compound 72bi was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.14 (s, 1H), 9.0 (s, 1H), 7.79 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.53 – 7.48 
(m, 2H), 7.28 (d, J = 8.6 Hz, 1H), 6.92 – 6.88 (m, 3H), 6.02 (s, 1H), 4.03 (q, J = 8.0 Hz, 2H), 3.81 
- 3.75 (m, 5H), 3.16 – 3.11 (m, 1H), 2.95 (dd, J = 15.8, 3.8 Hz, 1H), 1.38 (t, J = 7.9 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 190.7, 168.5, 160.0, 154.3, 153.6, 137.4, 135.7, 132.7, 132.1, 131.1, 
126.4, 121.6, 120.8, 114.3, 113.7, 112.6, 110.4, 107.8, 105.7, 100.4, 70.1, 68.9, 53.2, 52.1, 
23.3, 14.5 ppm; HRMS: Calcd for C26H24O5N2F [M+H]+: 463.16638, Found: 463.16651. 
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Compound 72bj:  
 
Compound 72bj was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 8.99 (s, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.63 (d, J = 1.6 Hz, 1H), 7.24 – 7.18 
(m, 3H), 6.93 – 6.85 (m, 3H), 6.01 (s, 1H), 4.05 (q, J = 7.9 Hz, 2H), 3.85 – 3.80 (m, 4H), 3.70 
(dd, J = 13.5, 5.1 Hz, 1H), 3.10 (ddd, J = 15.3, 12.3, 5.6 Hz, 1H), 2.90 (dd, J = 15.3, 3.7 Hz, 1H), 
2.31 (s, 3H), 1.37 (t, J = 7.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 190.1, 168.4, 166.4, 158.7, 
154.2, 153.4, 136.3, 135.7, 132.8, 131.4, 130.4, 127.8, 126.5, 119.6, 118.2, 113.4, 113.1, 
112.7, 107.8, 100.8, 70.2, 68.3, 52.7, 52.4, 23.7, 21.2, 14.8 ppm; HRMS: Calcd for C27H27O5N2 
[M+H]+: 459.19145, Found: 459.19111. 
 
Compound 72bk:  
 
Compound 72bk was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.18 (s, 1H), 8.89 (s, 1H), 7.82 (s, 1H), 7.73 (s, 1H), 7.46 – 7.33 (m, 3H), 7.23 – 7.16 
(m, 1H), 6.96 – 6.88 (m, 3H), 6.02 (s, 1H), 4.04 (q, J = 8.0 Hz, 2H), 3.90 – 3.86 (m, 1H), 3.67 – 
3.62 (m, 1H), 3.12 – 3.08 (m, 1H), 2.99 (dd, J = 14.0, 3.0 Hz, 1H), 1.38 (t, J = 8.0 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 191.5, 164.1, 150.9, 135.6, 135.1, 132.3, 131.4, 131.2, 127.5, 123.4, 
121.7, 120.4, 119.6, 117.4, 117.2, 116.6, 116.2, 113.4, 111.7, 104.6, 70.3, 67.7, 51.2, 22.4, 14.9 
ppm; HRMS: Calcd for C25H22O3N3 [M+H]+: 412.16557, Found: 412.16519. 
 
 
 
 
III. Experimental Part  169 
 
 
Compound 72bl:  
 
Compound 72bl was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.09 (s, 1H), 8.99 (s, 1H), 7.92 (d, J = 2.0 Hz, 1H), 7.62 (d, J = 2.0 Hz, 1H), 7.48 (d, J 
= 7.9 Hz, 1H), 7.39 – 7.29 (m, 2H), 7.25 – 7.19 (m, 1H), 7.16 – 7.10 (m, 1H), 6.91 (d, J = 8.6 Hz, 
1H), 5.99 (s, 1H), 4.04 (q, J = 7.9 Hz, 2H), 3.81 – 3.75 (m, 2H), 3.18 – 3.14 (m, 1H), 2.97 (dd, J 
= 15.8, 7.5 Hz, 1H), 1.36 (t, J = 7.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 190.3, 159.9, 153.5, 
136.4, 135.8, 134.4, 131.6, 129.6, 126.4, 123.3, 123.1, 121.7, 121.4, 120.0, 118.3, 115.2, 
114.2, 112.9, 108.1, 105.9, 70.1, 68.8, 52.4, 23.2, 14.7 ppm; HRMS: Calcd for C25H21O3N3F 
[M+H]+: 430.15615, Found: 430.15598. 
 
Compound 72bm:  
 
Compound 72bm was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 9.02 (s, 1H), 7.86 (s, 1H), 7.58 (s, 1H), 7.47 – 7.39 (m, 2H), 7.27 – 7.20 
(m, 2H), 7.02 – 6.95 (m, 2H), 6.01 (s, 1H), 4.07 (q, J = 8.0 Hz, 2H), 3.69 – 3.64 (m, 2H), 3.17 – 
3.12 (m, 1H), 2.93 – 2.88 (m, 1H), 2.51 (s, 3H), 1.39 (t, J = 8.0 Hz, 3H); 13C NMR (100 MHz, 
CDCl3):  190.7, 167.2, 161.9, 153.3, 136.7, 134.3, 131.7, 129.4, 126.0, 124.8, 119.6, 118.4, 
118.0, 117.8, 113.7, 111.3, 111.1, 107.2, 105.8, 69.9, 68.2, 52.6, 23.7, 21.3, 14.6 ppm; HRMS: 
Calcd for C26H24O3N3 [M+H]+: 426.18122, Found: 426.18104. 
 
 
 
 
III. Experimental Part  170 
 
 
Compound 72bn:  
 
Compound 72bn was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.03 (s, 1H), 9.07 (s, 1H), 7.94 (d, J = 1.7 Hz, 1H), 7.61 (d, J = 1.7 Hz, 1H), 7.45 – 7.40 
(m, 2H), 7.29 – 7.23 (m, 3H), 7.02 – 7.00 (m, 1H), 6.89 – 6.85 (m 1H), 6.01 (s, 1H), 3.81 – 3.72 
(m, 5H), 3.16 – 3.07 (m, 1H), 2.90 – 2.86 (m, 1H); 13C NMR (100 MHz, CDCl3):  190.8, 168.5, 
161.1, 153.2, 136.4, 134.9, 134.7, 130.1, 127.5, 125.7, 120.7, 119.7, 119.2, 118.4, 118.3, 
118.2, 113.1, 112.7, 107.6, 106.0, 67.6, 53.8, 52.7, 22.4 ppm; HRMS: Calcd for C24H20O4N2Cl 
[M+H]+: 435.11061, Found: 435.11037. 
 
Compound 72bo:  
 
Compound 72bo was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.10 (s, 1H), 8.99 (s, 1H), 7.88 (d, J = 1.5 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.54 (d, J 
= 2.5 Hz, 1H), 7.45 (dd, J = 8.7, 2.5 Hz, 1H), 7.23 (d, J = 8.8 Hz, 1H), 6.93 – 6.89 (m, 3H), 6.02 
(s, 1H), 3.82 (s, 3H), 3.81 – 3.74 (m, 2H), 3.12 (ddd, J = 15.6, 11.6, 5.8 Hz, 1H), 2.90 (dd, J = 
15.6, 3.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 191.0, 168.6, 160.2, 154.3, 153.2, 137.0, 135.5, 
132.4, 132.3, 131.2, 126.4, 121.5, 120.4, 114.0, 113.7, 112.8, 110.2, 107.8, 105.6, 100.2, 68.1, 
53.5, 52.8, 23.3 ppm; HRMS: Calcd for C24H19O4N2F [M+H]+: 453.10119, Found: 453.10111. 
 
 
 
 
 
III. Experimental Part  171 
 
 
Compound 72bp:  
 
Compound 72bp was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ δ 11.09 (s, 1H), 8.98 (s, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.53 (d, 
J = 2.5 Hz, 1H), 7.44 – 7.40 (m, 1H), 7.22 (d, J = 8.7 Hz, 1H), 6.93 – 6.88 (m, 3H), 6.01 (s, 1H), 
3.82 – 3.74 (m, 5H), 3.15 – 3.10 (m, 1H), 2.93 (dd, J = 15.7, 3.4 Hz, 1H), 2.52 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 190.0, 168.4, 166.5, 158.8, 154.2, 153.3, 136.3, 135.8, 132.6, 131.5, 
130.4, 127.9, 126.5, 119.5, 118.2, 113.7, 113.2, 112.5, 107.8, 100.7, 69.8, 52.6, 52.4, 23.6, 
21.5 ppm; HRMS: Calcd for C25H22O4N2Cl [M+H]+: 449.12626, Found: 449.12626. 
 
Compound 72bq:  
 
Compound 72bq was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.10 (s, 1H), 9.04 (s, 1H), 7.93 (d, J = 1.8 Hz, 1H), 7.59 (d, J = 1.8 Hz, 1H), 7.45 – 7.40 
(m, 2H), 7.29 – 7.22 (m, 3H), 7.02 – 6.97 (m, 2H), 6.01 (s, 1H), 3.81 – 3.75 (m, 2H), 3.15 – 3.09 
(m, 1H), 2.91 – 2.86 (m, 1H); 13C NMR (100 MHz, CDCl3):  190.4, 161.0, 153.2, 136.7, 134.7, 
134.6, 130.1, 127.4, 125.7, 120.7, 119.8, 119.2, 118.4, 118.0, 116.9, 114.0, 113.7, 112.4, 
107.6, 106.4, 67.9, 52.6, 22.8 ppm; HRMS: Calcd for C23H17O2N3Cl [M+H]+: 402.10038, Found: 
402.10014. 
 
 
 
 
 
III. Experimental Part  172 
 
 
Compound 72br:  
 
Compound 72br was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 8.97 (s, 1H), 7.85 (d, J = 1.7 Hz, 1H), 7.60 (d, J = 1.7 Hz, 1H), 7.52 (d, J 
= 2.4 Hz, 1H), 7.47 (dd, J = 8.9, 2.5 Hz, 1H), 7.27 (d, J = 8.9 Hz, 1H), 6.98 – 6.93 (m, 3H), 6.04 
(s, 1H), 3.81 – 3.74 (m, 2H), 3.15 (ddd, J = 15.7, 11.4, 6.0 Hz, 1H), 2.94 (dd, J = 15.8, 3.3 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 160.2, 154.3, 153.6, 137.2, 135.6, 132.7, 132.4, 
131.3, 126.3, 121.4, 120.4, 114.4, 114.0, 113.4, 112.7, 110.3, 107.6, 105.8, 100.1, 69.0, 52.9, 
23.6 ppm; HRMS: Calcd for C23H16O2N3ClF [M+H]+: 420.09096, Found: 420.09081. 
 
Compound 72bs:  
 
Compound 72bs was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.15 (s, 1H), 8.99 (s, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.51 (d, J 
= 2.5 Hz, 1H), 7.46 – 7.42 (m, 1H), 7.28 (d, J = 8.7 Hz, 1H), 6.98 – 6.93 (m, 3H), 6.01 (s, 1H), 
3.81 – 3.75 (m, 2H), 3.18 – 3.13 (m, 1H), 2.97 (dd, J = 15.4, 3.2 Hz, 1H), 2.54 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 190.3, 161.4, 154.7, 153.5, 137.7, 135.5, 132.6, 132.7, 131.2, 126.4, 
121.5, 120.2, 114.7, 114.0, 113.1, 112.7, 110.9, 107.6, 105.7, 100.1, 70.0, 52.4, 23.7, 21.9 
ppm; HRMS: Calcd for C24H19O2N3Cl [M+H]+: 416.11603, Found: 416.11571. 
 
 
 
 
 
III. Experimental Part  173 
 
 
Compound 72bt:  
 
Compound 72bt was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.17 (s, 1H), 9.01 (s, 1H), 7.95 (d, J = 1.9 Hz, 1H), 7.60 (d, J = 1.9 Hz, 1H), 7.42 (dd, J 
= 1.7, 7.9 Hz, 1H), 7.41 (td, J = 7.8, 1.6 Hz, 1H), 7.26 – 7.23 (m, 2H), 7.03 – 6.98 (m, 2H), 6.90 
(t, J =7.9 Hz, 1H), 5.99 (s, 1H), 3.81 (s, 3H), 3.78 – 3.71 (m, 2H), 3.17 – 3.09 (m, 1H), 2.93 – 
2.88 (m, 1H), 2.44 (s, 3H); 13C NMR (100 MHz, CDCl3):  191.7, 168.2, 161.2, 153.4, 136.7, 
134.2, 131.4, 130.0, 129.1, 126.1, 124.5, 119.8, 118.4, 118.3, 116.9, 113.3, 111.5, 109.8, 
107.3, 105.8, 67.8, 52.7, 51.9, 23.1, 21.7 ppm; HRMS: Calcd for C25H23O4N2 [M+H]+: 
415.16523, Found: 415.16523. 
 
Compound 72bu:  
 
Compound 72bu was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.04 (s, 1H), 9.02 (s, 1H), 7.89 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.55 (d, J 
= 2.6 Hz, 1H), 7.46 (dd, J = 8.5, 2.4 Hz, 1H), 7.22 (d, J = 8.6 Hz, 1H), 6.94 – 6.89 (m, 3H), 6.00 
(s, 1H), 3.81 – 3.74 (m, 5H), 3.14 (ddd, J = 15.8, 11.5, 5.6 Hz, 1H), 2.95 (dd, J = 15.8, 3.5 Hz, 
1H), 2.41 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 191.4, 168.7, 161.3, 154.5, 153.0, 138.2, 135.6, 
132.5, 132.0, 131.3, 126.5, 121.5, 120.7, 114.4, 113.8, 112.9, 110.2, 107.6, 105.5, 100.7, 68.4, 
53.7, 52.7, 26.4, 23.5 ppm; HRMS: Calcd for C25H22O4N2F [M+H]+: 433.15581, Found: 
433.15569. 
 
 
 
III. Experimental Part  174 
 
 
Compound 72bv:  
 
Compound 72bv was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 8.99 (s, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.56 (d, J 
= 2.2 Hz, 1H), 7.43 – 7.38 (m, 1H), 7.21 (d, J = 8.4 Hz, 1H), 6.95 – 6.89 (m, 3H), 6.03 (s, 1H), 
3.81 – 3.74 (m, 5H), 3.12 – 3.07 (m, 1H), 2.99 – 2.94 (m, 1H), 2.54 (s, 3H), 2.49 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 190.8, 168.6, 161.1, 154.9, 153.2, 138.2, 135.5, 132.9, 131.9, 131.3, 
126.4, 121.5, 120.6, 114.9, 113.8, 112.8, 110.2, 107.5, 105.5, 100.6, 68.4, 53.5, 52.7, 26.2, 
24.1, 23.9 ppm; HRMS: Calcd for C26H25O4N2 [M+H]+: 429.18088, Found: 429.18059. 
 
Compound 72bw:  
 
Compound 72bw was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.09 (s, 1H), 8.99 (s, 1H), 7.90 (d, J = 1.9 Hz, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.47 (d, J 
= 7.7 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.22 – 7.15 (m, 4H), 6.94 – 6.91 (m, 1H), 6.03 (s, 1H), 
3.78 (dd, J = 15.7, 3.7 Hz , 2H), 3.24 (dd, J = 15.7, 3.7 Hz, 1H), 3.00 (dd, J = 15.6, 3.5 Hz, 1H), 
2.30 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 192.5, 160.7, 153.9, 136.4, 136.2, 135.4, 132.4, 
130.6, 127.9, 126.4, 123.4, 120.2, 119.5, 118.4, 118.2, 113.9, 112.2, 111.4, 108.4, 106.7, 68.2, 
53.6, 23.6, 21.7 ppm; HRMS: Calcd for C24H20O2N3 [M+H]+: 382.15500, Found: 382.15476. 
 
 
 
 
  
III. Experimental Part  175 
 
 
Compound 72bx:  
 
Compound 72bx was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.02 (s, 1H), 8.99 (s, 1H), 7.86 (d, J = 1.8 Hz, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.54 (d, J 
= 2.5 Hz, 1H), 7.48 (dd, J = 8.8, 2.5 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 6.97 – 6.92 (m, 3H), 6.03 
(s, 1H), 3.80 – 3.75 (m, 2H), 3.16 (ddd, J = 15.6, 11.4, 6.0 Hz, 1H), 2.93 (dd, J = 15.6, 3.3 Hz, 
1H), 2.41 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 190.7, 160.4, 154.2, 137.2, 135.4, 132.7, 132.5, 
131.2, 126.3, 121.3, 120.2, 114.3, 114.0, 113.2, 112.7, 110.1, 109.8, 107.6, 105.7, 100.1, 69.7, 
54.6, 52.5, 23.8 ppm; HRMS: Calcd for C24H19O2N3F [M+H]+: 400.14558, Found: 400.14517. 
 
Compound 72by:  
 
Compound 72by was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.08 (s, 1H), 9.02 (s, 1H), 7.83 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.55 (d, J 
= 2.2 Hz, 1H), 7.47 – 7.43 (m, 1H), 7.26 – 7.22 (m, 1H), 6.97 – 6.90 (m, 3H), 6.02 (s, 1H), 3.80 
– 3.75 (m, 2H), 3.18 – 3.13 (m, 1H), 2.96 – 2.91 (m, 1H), 2.53 (s, 3H), 2.40 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 192.0, 161.2, 153.8, 137.5, 135.3, 132.9, 132.8, 131.2, 126.3, 121.4, 
120.2, 114.4, 114.0, 113.9, 112.6, 110.5, 109.6, 107.6, 105.8, 100.4, 69.8, 54.5, 52.5, 24.6, 
23.7 ppm; HRMS: Calcd for C25H22O2N3 [M+H]+: 396.17065, Found: 396.17033. 
 
 
 
 
 
III. Experimental Part  176 
 
 
Compound 72bz:  
 
Compound 72bz was synthesized according to the general procedures. Red amorphous solid; 
TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3)  11.20 (s, 1H), 
8.95 (s, 1H), 7.96 (d, J = 1.7Hz, 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.49 – 7.43 (m, 2H), 7.25 – 7.21 
(m, 2H), 7.03 – 6.98 (m, 2H), 6.88 (t, J =7.8 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.78 – 3.70 (m, 
2H), 3.47 (s, 3H), 3.18 – 3.11 (m, 1H), 2.91 – 2.86 (m, 1H); 13C NMR (100 MHz, CDCl3):  191.5, 
170.2, 168.5, 161.4, 153.2, 136.3, 134.5, 131.8, 130.1, 129.2, 126.3, 124.6, 119.9, 118.6, 
118.4, 117.9, 113.5, 111.6, 107.6, 106.0, 68.1, 53.9, 52.6, 52.5, 23.2, 21.6 ppm; HRMS: Calcd 
for C26H24O5N2 [M+H]+: 445.17580, Found: 445.17577; [α]D20 -8.6 ° (c 0.002 in ethanol).  
 
Compound 72ca:  
 
Compound 72ca was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H), 8.99 (s, 1H), 7.81 (s, 1H), 7.62 (s, 1 H), 7.58 (s, 1H), 7.37 – 7.30 (m, 2H), 
7.26 – 7.21 (m, 2H), 6.97 (d, J = 8.9 Hz, 1H), 3.74 – 3.69 (m, 7H), 3.53 – 3.47 (m, 4H), 3.22 – 
3.17 (m, 1H), 3.02 – 2.98 (m, 1H); 13C NMR (101 MHz, CDCl3) 189.4, 160.2, 153.6, 136.4, 
135.8, 134.2, 131.7, 129.3, 126.0, 123.7, 123.1, 120.7, 120.3, 119.0, 118.3, 115.4, 113.8, 
112.4, 108.8, 105.7, 68.0, 54.3, 53.4, 24.7, 24.6, 22.4 ppm; HRMS: Calcd for C26H24O5N2F 
[M+H]+: 463.16638, Found: 463.16614. 
 
 
 
 
 
III. Experimental Part  177 
 
 
Compound 72cb:  
 
Compound 72cb was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.19 (s, 1H), 9.00 (s, 1H), 7.83 (s, 1H), 7.61 (s, 1 H), 7.55 (s, 1H), 7.37 – 7.31 (m, 2H), 
7.26 – 7.20 (m, 2H), 6.98 (d, J = 8.8 Hz, 1H), 3.76 – 3.71 (m, 7H), 3.53 – 3.46 (m, 4H), 3.22 – 
3.16 (m, 1H), 3.00 – 2.96 (m, 1H), 2.54 (s, 3H); 13C NMR (101 MHz, CDCl3) 190.1, 163.4, 
153.8, 137.2, 135.8, 134.3, 131.6, 129.3, 126.2, 123.8, 123.5, 120.7, 120.4, 118.9, 118.4, 
115.2, 113.8, 112.3, 108.7, 105.7, 68.2, 54.4, 53.2, 24.6, 24.5, 23.2, 22.7 ppm; HRMS: Calcd 
for C27H27O5N2 [M+H]+: 459.19145, Found: 459.19111. 
 
Compound 72cc:  
 
Compound 72cc was synthesized according to the general procedures. Red amorphous solid; 
TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.30; 1H NMR (400 MHz, CDCl3) 1H NMR (400 
MHz, CDCl3):  11.23 (s, 1H), 9.17 (s, 1H), 7.95 (d, J = 1.5 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.45 
– 7.40 (m, 2H), 7.29 – 7.27 (m, 2H), 7.23 – 7.21 (m, 1H), 7.02 – 7.00 (m, 1H), 6.89 – 6.85 (m 
1H), 3.87 (s, 3H), 3.80 – 3.70 (m, 5H), 3.16 – 3.08 (m, 1H), 2.90 – 2.86 (m, 1H); 13C NMR (101 
MHz, CDCl3) 13C NMR (100 MHz, CDCl3):  192.0, 161.4, 153.4, 136.6, 134.7, 134.6, 130.3, 
127.8, 125.8, 120.8, 119.9, 118.6, 118.5, 118.4, 116.9, 113.4, 113.2, 112.9, 107.9, 106.1, 70.0, 
54.1, 52.4, 26.9, 23.0 ppm; HRMS: Calcd for C25H22O3N3 [M+H]+: 412.16557, Found: 
412.16552; [α]D20 -9.5 ° (c 0.002 in ethanol). 
 
 
 
 
III. Experimental Part  178 
 
 
Compound 72cd:  
 
Compound 72cd was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.17 (s, 1H), 9.01 (s, 1H), 7.83 (s, 1H), 7.64 (s, 1 H), 7.57 (s, 1H), 7.37 – 7.31 (m, 2H), 
7.27 – 7.21 (m, 2H), 7.00 – 6.96 (m, 1H), 3.75 – 3.70 (m, 4H), 3.53 – 3.47 (m, 4H), 3.23 – 3.17 
(m, 1H), 3.03 – 2.98 (m, 1H); 13C NMR (101 MHz, CDCl3) 189.7, 153.5, 136.7, 135.8, 134.3, 
131.6, 129.3, 126.2, 123.6, 123.1, 120.9, 120.3, 119.0, 118.7, 115.4, 114.3, 113.5, 112.4, 
108.9, 105.0, 69.1, 53.3, 24.7, 24.6, 22.7 ppm; HRMS: Calcd for C25H21O3N3F [M+H]+: 
430.15615, Found: 430.15590. 
 
Compound 72ce:  
 
Compound 72ce was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.18 (s, 1H), 9.02 (s, 1H), 7.82 (s, 1H), 7.61 (s, 1 H), 7.53 (s, 1H), 7.37 – 7.30 (m, 2H), 
7.26 – 7.21 (m, 2H), 6.98 (d, J = 8.9 Hz, 1H), 3.76 – 3.71 (m, 4H), 3.53 – 3.47 (m, 4H), 3.22 – 
3.16 (m, 1H), 3.00 – 2.95 (m, 1H), 2.53 (s, 3H); 13C NMR (101 MHz, CDCl3) 189.9, 154.2, 
136.9, 135.6, 134.3, 131.6, 129.5, 126.2, 123.9, 123.5, 120.8, 120.4, 119.0, 118.4, 115.5, 
115.7, 113.8, 112.5, 108.7, 105.8, 68.7, 53.2, 24.6, 24.5, 23.7, 22.8 ppm; HRMS: Calcd for 
C26H24O3N3 [M+H]+: 426.18122, Found: 426.18098. 
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Compound 72cf:  
 
Compound 72cf was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.22 (s, 1H), 9.74 (s, 1H), 7.74 (s, 1H), 7.68 (s, 1H), 7.33 – 7.27 (m, 2H), 7.17 – 7.10 
(m, 3H), 7.05 – 7.00 (m, 1H), 6.91 – 6.84 (m, 2H), 6.01 (s, 1H), 3.78 – 3.73 (m, 4H), 3.49 – 3.45 
(m, 1H), 3.03 – 2.96 (m, 1H), 2.86 – 2.82 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ 188.3, 
173.1, 155.3, 153.7, 136.2, 132.1, 132.0, 131.3, 129.3, 125.7, 125.5, 121.1, 119.0, 118.0, 
116.3, 112.3, 111.6, 110.7, 106.8, 106.1, 67.0, 52.1, 51.8, 51.7, 22.1 ppm; HRMS: Calcd for 
C25H24O5N2 [M+H]+: 431.16015, Found: 431.15979. 
 
Compound 72cg:  
 
Compound 72cg was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.17 (s, 1H), 9.04 (s, 1H), 7.88 (s, 1H), 7.64 (s, 1 H), 7.53 (s, 1H), 7.37 – 7.31 (m, 2H), 
7.26 – 7.22 (m, 2H), 6.99 – 6.95 (m, 1H), 6.01 (s, 1H), 3.89 (s, 3H), 3.82 (m, 4H), 3.55 – 3.48 
(m, 1H), 3.23 – 3.17 (m, 1H), 2.98 (dd, J = 15.2, 3.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) 
190.7, 176.9, 159.5, 153.3, 136.2, 135.9, 134.1, 131.6, 129.4, 126.2, 123.9, 123.2, 120.5, 
120.0, 119.9, 118.3, 115.1, 112.7, 108.3, 105.5, 68.2, 54.3, 52.8, 52.6, 22.7 ppm; HRMS: Calcd 
for C25H22O5N2F [M+H]+: 449.15073, Found: 449.15047. 
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Compound 72ch:  
 
Compound 72ch was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.18 (s, 1H), 9.01 (s, 1H), 7.93 (s, 1H), 7.63 (s, 1H), 7.49 – 7.38 (m, 2H), 7.28 – 7.23 
(m, 2H), 7.01 (m, 1H), 6.88 (t, J = 8.0 Hz, 1H), 3.87 (s, 3H), 3.82 (s, 3H), 3.68 – 3.63 (m, 2H), 
3.20 – 3.15 (m, 1H) 2.93 – 2.87 (m, 1H), 2.53 (s, 3H); 13C NMR (100 MHz, CDCl3):  191.0, 
170.2, 167.4, 161.7, 153.3, 136.5, 134.9, 131.4, 129.7, 126.1, 124.6, 119.5, 118.7, 118.5, 
117.4, 113.5, 111.3, 107.8, 105.8, 69.9, 67.8, 53.8, 52.3, 22.7, 21.9 ppm; HRMS: Calcd for 
C26H25O5N2 [M+H]+: 445.17580, Found: 445.17559. 
 
Compound 72ci:  
 
Compound 72ci was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.20 (s, 1H), 9.72 (s, 1H), 7.73 (s, 1H), 7.65 (s, 1H), 7.30 – 7.23 (m, 2H), 7.18 – 7.10 
(m, 3H), 7.04– 7.00 (m, 1H), 6.91 – 6.87 (m, 2H), 5.98 (s, 1H), 3.77 – 3.73 (m, 4H), 3.51 – 3.47 
(m, 1H), 3.03 – 2.98 (m, 1H), 2.85 – 2.80 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ 190.5, 
165.2, 153.8, 136.7, 132.8, 132.0, 131.4 129.5, 125.8, 125.5, 121.9, 119.0, 118.5, 116.2, 
116.0, 112.7, 111.5, 110.9, 106.7, 106.2, 67.2, 51.7, 51.6, 22.8  ppm; HRMS: Calcd for 
C24H20O3N3 [M+H]+: 398.14992, Found: 398.14961. 
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Compound 72cj:  
 
Compound 72cj was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.29 (s, 1H), 9.22 (s, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.52 (d, J 
= 7.8 Hz, 1H), 7.43 (s, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.27 – 7.19 (m, 1H), 7.18 – 7.10 (m, 1H), 
6.92 (s, 1H), 6.07 (s, 1H), 3.85 – 3.79 (m, 5H), 3.23 – 3.18 (m, 1H), 3.02 – 2.97 (m, 1H), 2.44 
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 190.4, 171.4, 159.7, 153.4, 143.0, 136.6, 135.8, 131.8, 
130.0, 126.3, 123.7, 123.1, 120.6, 120.1, 118.8, 113.7, 112.4, 111.0, 108.2, 105.7, 68.1, 53.7, 
52.7, 23.2, 21.1 ppm; HRMS: Calcd for C25H22O4N2Cl [M+H]+: 449.12626, Found: 449.12640. 
 
Compound 72ck:  
 
Compound 72ck was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.20 (s, 1H), 9.18 (s, 1H), 7.92 (d, J = 1.9 Hz, 1H), 7.64 (d, J = 1.9 Hz, 1H), 7.52 (d, J 
= 7.9 Hz, 1H), 7.47 (s, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.26 – 7.20 (m, 1H), 7.16 – 7.12 (m, 1H), 
6.95 (s, 1H), 6.04 (s, 1H), 3.82 – 3.78 (m, 2H), 3.21 (ddd, J = 14.0, 10.9, 6.0 Hz, 1H), 2.95 (dd, 
J = 14.0, 5.6 Hz, 1H), 2.46 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 191.2, 159.9, 153.4, 143.7, 
136.2, 135.7, 131.6, 130.1, 126.4, 123.9, 123.1, 120.5, 120.1, 118.9, 113.7, 112.3, 111.2, 
111.1, 108.9, 104.3, 67.4, 52.9, 24.2, 21.4 ppm; HRMS: Calcd for C24H19O2N3Cl [M+H]+: 
416.11603, Found: 416.11597. 
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Compound 72cl:  
 
Compound 72cl was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.23 (s, 1H), 9.03 (s, 1H), 7.88 (d, J = 2.0 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.53 (d, J 
= 7.9 Hz, 1H), 7.42 – 7.37 (d, J = 8.3 Hz, 1H), 7.27 – 7.21 (m, 2H), 6.92 (s, 1H), 3.86 – 3.75 (m, 
8H), 3.69 (s, 3H), 3.24 (ddd, J = 15.7, 11.6, 5.9 Hz, 1H), 2.96 (dd, J = 15.7, 3.4 Hz, 1H), 2.47 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 190.4, 170.3, 159.9, 153.5, 143.4, 136.4, 135.9, 131.7, 
129.7, 126.1, 123.8, 123.1, 120.5, 120.1, 118.8, 118.3, 114.7, 112.0, 108.1, 105.8, 68.2, 54.0, 
53.2, 52.3, 28.1, 23.5, 20.4 ppm; HRMS: Calcd for C27H26O5N2Cl [M+H]+: 493.15248, Found: 
493.15211. 
 
Compound 72cm:  
 
Compound 72cm was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.84 (s, 1H), 9.05 (s, 1H), 7.87 (d, J = 1.8 Hz, 1H), 7.56 (s, 1H), 7.49 – 7.31 (m, 3H), 
7.21 (s, 1H), 6.63 (d, J = 7.9 Hz, 1H), 3.72 (s, 3H), 3.65 – 3.57 (m, 5H), 3.18 (ddd, J = 17.7, 12.0, 
5.6 Hz, 1H), 2.98 (dd, J = 15.2, 4.0 Hz, 1H), 2.43 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 189.4, 
160.4, 153.7, 136.7, 135.8, 134.3, 132.1, 130.3, 129.7, 126.4, 123.2, 120.8, 119.7, 119.1, 
118.9, 113.5, 114.2, 112.2, 108.7, 105.8, 68.2, 54.3, 53.3, 25.7, 23.6, 22.5  ppm; HRMS: Calcd 
for C26H23O3N3Cl [M+H]+: 460.14225, Found: 460.14214. 
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Compound 72cn:  
 
Compound 72cn was synthesized according to the racemic general procedure.Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.85 (s, 1H), 9.06 (s, 1H), 7.87 (d, J = 1.8 Hz, 1H), 7.78 (d, J = 2.0 Hz, 1H), 7.64 (d, J 
= 1.7 Hz, 1H), 7.49 – 7.47 (m, 2H), 7.33 (d, J = 8.0 Hz, 1H), 7.18 – 7.12 (m, 2H), 6.00 (s, 1H),  
3.80 – 3.72 (m, 5H), 3.19 (ddd, J = 15.6, 11.9, 5.9 Hz, 1H), 2.98 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 189.4, 168.8, 157.2, 153.8, 139.6, 136.1, 135.4, 131.6, 131.4, 126.7, 123.3, 121.8, 
120.1, 118.4, 114.2, 113.1, 112.0, 110.0, 108.2, 105.7, 68.3, 53.8, 52.1, 23.3 ppm; HRMS: 
Calcd for C24H19O4N2Cl2 [M+H]+: 469.07164, Found: 469.07133. 
 
Compound 72co:  
 
Compound 72co was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.29 (s, 1H), 9.01 (s, 1H), 7.88 (d, J = 1.5 Hz, 1H), 7.64 (d, J = 1.5 Hz, 1H), 7.52 – 7.44 
(m, 2H), 7.34 (d, J = 8.1 Hz, 1H), 7.32 (d, J = 2.5 Hz, 1H), 7.20 (dd, J = 8.2, 7.1 Hz, 1H), 7.13 
(ddd, J = 7.9, 7.1 Hz, 1H), 5.98 (s, 1H), 3.76 (dd, J = 13.4, 5.0 Hz, 2H), 3.21 (ddd, J = 14.0, 10.9, 
6.0 Hz, 1H), 2.95 (dd, J = 14.0, 5.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 191.2, 155.9, 153.8, 
136.1, 135.4, 133.9, 131.5, 128.4, 126.3, 124.0, 123.2, 123.1, 121.6, 120.0, 118.4, 114.3, 
113.5, 112.1, 108.2, 105.7, 68.1, 53.0, 23.5 ppm; HRMS: Calcd for C23H16O2N3Cl2 [M+H]+: 
436.06141, Found: 436.06104. 
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Compound 72cp:  
 
Compound 72cp was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.30; 1H NMR (400 MHz, 
CDCl3)  11.17 (s, 1H), 8.99 (s, 1H), 7.89 (s, 1H), 7.65 (s, 1H), 7.58 (s, 1H), 7.42 – 7.31 (m, 3H), 
7.04 (d, J = 8.7 Hz, 1H), 3.82 (s, 3H), 3.79 (s, 3H), 3.52 – 3.44 (m, 5H), 3.31 – 3.23 (m, 1H), 3.00 
– 2.97 ppm (m, 1H); 13C NMR (101 MHz, CDCl3) 189.9, 170.4, 159.8, 153.6, 136.2, 135.9, 
134.2, 132.1, 131.1, 129.7, 126.2, 123.2, 120.8, 120.0, 119.7, 118.5, 114.2, 112.2, 108.5, 
105.9, 68.2, 54.5, 52.8, 52.7, 23.3, 22.4 ppm; HRMS: Calcd for C26H23O5N2Cl2 [M+H]+: 
513.09785, Found: 513.09781; [α]D20 -6.7 ° (c 0.002 in ethanol). 
 
Compound 72cq:  
 
Compound 72cq was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.24 (s, 1H), 9.01 (s, 1H), 7.87 (s, 1H), 7.66 (s, 1H), 7.57 (s, 1H), 7.42 – 7.31 (m, 3H), 
7.07 (d, J = 8.6 Hz, 1 H), 3.69 (s, 3H), 3.51 – 3.43 (m, 5H), 3.20 (ddd, J = 13.9, 10.9, 5.7 Hz, 1H), 
2.89 (ddd, J = 13.9, 11.0, 5.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) 189.9, 160.2, 153.7, 136.7, 
135.9, 134.3, 132.1, 130.4, 129.7, 126.3, 123.1, 120.8, 119.9, 119.2, 118.6, 114.2, 113.7, 
112.3, 108.6, 105.9, 68.2, 54.4, 53.0, 23.7, 22.3 ppm; HRMS: Calcd for C25H20O3N3Cl2 [M+H]+: 
480.08762, Found: 480.08771. 
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III.4. Experimental Part for Chapter 4 
III.4.1. Synthesis of the Indolopyridiniums 87 
The cyclic imine (0.10 mmol; 1.0 eq.) was dissolved under argon in 5mL dry DMSO, and dry 
ZnCl2 (0.10 mmol; 1.0 eq) was added and stirred for 5min. Chromone diene 70 (0.10 mmol; 
1.0 eq.) was added and the reaction mixture was allowed to react for 24h at 80°C in a sealed 
tube under Ar. The reaction mixture is then diluted in 10 mL brine and extracted with 3x10mL 
DCM. The organic phase was dried over Na2SO4 evaporated to give a residue that is purified 
by flash chromatography to yield the indolopyridiniums as red amorphous solids. 
 
Compound 87a: 
 
Compound 87a was synthesized according to the general procedure. Red amorphous solid; 
TLC (ethyl acetate): RF = 0.40; 1H NMR (400 MHz, CDCl3): δ 11.03 (s, 1H), 9.44 (s, 1H), 9.08 (s, 
1H), 7.74 (s, 1H), 7.46 – 7.30 (m, 4H), 7.27 – 7.20 (m, 3H), 5.21 (t, J = 9.5 Hz, 2H), 3.95 – 3.90 
(m, 3H), 3.43 (t, J = 9.5 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 196.8, 165.5, 164.6, 153.7, 150.9, 
138.2, 135.4, 132.3, 131.5, 131.4, 127.6, 123.7, 122.0, 121.6, 120.4, 119.5, 117.3, 116.8, 113.2, 
111.4, 104.9, 70.7, 60.2, 22.6 ppm; HRMS: Calcd for C24H19O4N2 [M+H]+: 399.13393, Found: 
399.13385. 
 
Compound 87b:  
 
Compound 87b was synthesized according to the general procedure. Red amorphous solid; 
TLC (ethyl acetate): RF = 0.40; 1H NMR (400 MHz, CDCl3): δ 10.96 (s, 1H), 9.45 (s, 1H), 9.07 (s, 
1H), 7.75 (s, 1H), 7.48 – 7.32 (m, 4H), 7.26 – 7.20 (m, 3H), 5.18 (t, J = 9.6 Hz, 2H), 3.41 (t, J = 
9.5 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 196.8, 165.5, 153.6, 150.9, 138.3, 135.4, 132.2, 131.5, 
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131.4, 127.7, 124.0, 123.6, 122.0, 121.5, 120.4, 119.4, 117.3, 116.8, 113.1, 111.4, 104.8, 65.2, 
22.5 ppm; HRMS: Calcd for C23H16O4N3 [M+H]+: 366.12370, Found: 366.12375. 
 
Compound 87c:  
 
Compound 87c was synthesized according to the general procedure. Red amorphous solid; 
TLC (ethyl acetate): RF = 0.40; 1H NMR (400 MHz, CDCl3): δ 11.18 (s, 1H), 9.02 (s, 1H), 7.94 (d, 
J = 2.0 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.40 – 7.30 (m, 3H), 7.22 – 7.12 
(m, 2H), 6.97 (d, J = 8.5 Hz, 1H), 6.00 (s, 1H), 3.83 – 3.75 (m, 5H), 3.20 (m, 1H), 2.99 (dd, J = 
14.0, 4.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 167.2, 159.5, 153.4, 136.2, 135.1, 134.3, 
131.6, 129.6, 125.9, 122.3, 121.2, 120.9, 120.1, 119.7, 118.3, 114.6, 112.0, 108.2, 105.9, 68.4, 
52.6, 50.6, 23.6 ppm; HRMS: Calcd for C24H17O4N2F [M+H]+: 417.12451, Found: 417.12441. 
 
Compound 87d:  
 
Compound 87d was synthesized according to the general procedure. Red amorphous solid; 
TLC (ethyl acetate): RF = 0.40; 1H NMR (400 MHz, CDCl3): δ 11.10 (s, 1H), 8.97 (s, 1H), 7.93 (d, 
J = 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.39 – 7.30 (m, 3H), 7.25 – 7.19 
(m, 1H), 7.17 – 7.10 (m, 1H), 6.00 (s, 1H), 6.91 (d, J = 8.6 Hz, 1H), 3.80 – 3.73 (m, 2H), 3.16 
(dd, J = 15.6, 12.0 Hz, 1H), 2.98 (dd, J = 15.6, 7.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 
159.7, 153.6, 136.3, 135.8, 134.4, 131.7, 129.6, 126.0, 123.3, 123.2, 120.7, 121.0, 120.0, 
118.2, 115.3, 114.1, 112.0, 108.1, 105.7, 68.2, 54.1, 23.4 ppm; HRMS: Calcd for C23H14O2N3F 
[M+H]+: 384.11428, Found: 384.11429. 
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Compound 87e:  
 
Compound 87e was synthesized according to the general procedure. Red amorphous solid; 
TLC (ethyl acetate): RF = 0.40; 1H NMR (400 MHz, CDCl3): δ 11.03 (s, 1H), 9.37 (s, 1H), 9.09 (s, 
1H), 7.74 (s, 1H), 7.56 (dd, J = 12.3, 8.0 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.18 – 7.12 (m, 2H), 
7.02 – 6.92 (m, 2H), 5.11 (t, J = 9.3Hz, 2H), 4.15 (m, 3H), 3.88 (m, 3H), 3.46 (t, J = 9.4 Hz, 2H); 
13C NMR (101 MHz, CDCl3) δ 196.4, 165.0, 164.7, 153.4, 150.8, 138.2, 135.8, 135.0, 132.4, 131.5, 
131.7, 127.6, 123.5, 121.6, 120.4, 119.6, 117.3, 116.7, 113.2, 111.7, 104.5, 70.3, 60.3, 50.2, 22.4 
ppm; HRMS: Calcd for C25H21O5N2 [M+H]+: 429.14450, Found: 429.14466. 
 
Compound 87f:  
 
Compound 87f was synthesized according to the general procedure. Red amorphous solid; 
TLC (ethyl acetate): RF = 0.40; 1H NMR (400 MHz, CDCl3): δ 10.96 (s, 1H), 9.45 (s, 1H), 9.07 (s, 
1H), 7.75 (s, 1H), 7.48 – 7.32 (m, 4H), 7.26 – 7.20 (m, 3H), 5.18 (t, J = 9.6 Hz, 2H), 3.91 (t, J = 
9.5 Hz, 2H), 3.41 (t, J = 9.5 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 196.8, 165.5, 153.6, 150.9, 
138.3, 135.4, 132.2, 131.5, 131.4, 127.7, 124.0, 123.6, 122.0, 121.5, 120.4, 119.4, 117.3, 116.8, 
115.2, 113.1, 111.4, 104.8, 65.2, 22.5 ppm; HRMS: Calcd for C24H18O3N3 [M+H]+: 396.13427, 
Found: 396.13401. 
 
III.4.2. Synthesis of the Methyl-protected Indoloquinolizines 90 
Synthesis of methyl-protected imines 88 and 89 
To a suspension of sodium hydride (28.2 mmol) in anhydrous DMF (20 mL) was added 
dropwise with stirring at -10 °C under argon a solution of compound 69a (16.7 mmol) in DMF 
(10 mL). The mixture was stirred for 1 h at -10 °C and then cooled to -60 °C before dropwise 
addition of a solution of methyl tosylate (18.4 mmol) in DMF (10 mL). Stirring was maintained 
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for 2 h at -60 °C and methanol (5 mL), water (5 mL) and saturated aqueous sodium chloride 
(250 mL) were added successively. The solution was extracted with dichloromethane (3×75 
mL), the organic extracts were combined, washed with water (30 mL) and dried over sodium 
sulfate. The solvents were removed under reduced pressure, the residue was taken up in 
dichloromethane and the solution was filtered through a pad of silica gel. Evaporation of the 
filtrate afforded compound 11 which was crystallized in ethyl acetate–95% ethanol. 
 
Compound 88:  
 
Compound 88 was synthesized according to the general procedure for Me-protected imines. 
Dark red amorphous solid: 1H NMR (400 MHz, DMSO-d6)  8.34 (s, 1H), 7.52 (d, J = 7.8Hz, 
1H), 7.39 (d, J = 8.9 Hz, 1H), 7.19 (t, J = 7.2 Hz, 1H), 7.07 (t, J = 7.3 Hz, 1H), 3.81 (t, J = 8.8 Hz, 
2H), 3.19 (s, 3H), 2.82 (t, J = 8.9 Hz, 2H); 13C NMR (100 MHz, DMSO-d6):  151.4, 136.8, 128.2, 
124.7, 123.6, 120.0, 119.3, 113.7, 112.5, 48.0, 34.7, 18.8 ppm; HRMS: Calcd for C12H13N2 
[M+H]+: 185.10732, Found: 185.10710.  
 
Compound 89:  
 
Compound 89 was synthesized according to the general procedure for Me-protected imines. 
Dark red amorphous solid: 1H NMR (400 MHz, DMSO-d6)  7.31 (d, J = 8.4 Hz, 1H), 7.04 (s, 
1H), 6.93 (d, J = 8.4 Hz, 1H), 3.79 – 3.71 (m, 5H), 3.24 (s, 3H), 2.84 (t, J = 8.0 Hz, 2H), 2.31 (s, 
3H); 13C NMR (100 MHz, DMSO-d6):  158.0, 154.4, 136.7, 129.1, 124.5, 122.5, 119.3, 113.6, 
112.0, 56.1, 48.1, 35.0, 22.1, 19.4 ppm; HRMS: Calcd for C14H17N2O [M+H]+: 229.13354, 
Found: 229.13307. 
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Synthesis of methyl-protected indoloquinolizines 90 
Indoloquinolizines 90 were synthesized following the general procedure for the synthesis of 
indoloquinolizines 72. 
 
Compound 90a:  
 
Compound 90a was synthesized according to the general procedures. Red amorphous solid; 
TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.33 (s, 1H), 
7.87 (s, 1H), 7.67 (s, 1H), 7.48 – 7.30 (m, 4H), 7.14 – 7.08 (m, 4H), 6.32 (s, 1H), 3.85 (s, 3H), 
3.81 – 3.78 (m, 1H), 3.65 – 3.58 (m, 4H), 3.20 – 3.16 (m, 1H), 2.96 – 2.91 (m, 1H); 13C NMR 
(101 MHz, CDCl3) δ 191.3, 167.0, 164.6, 149.7, 136.7, 136.1, 133.5, 131.6, 130.9, 127.5, 
121.8, 121.5, 120.7, 120.2, 117.4, 116.6, 116.0, 113.2, 112.1, 108.2, 67.4, 54.2, 50.1, 27.1, 
23.4 ppm; HRMS: Calcd for C25H23O4N2 [M+H]+: 415.16523, Found: 415.16520. 
 
Compound 90b:  
 
Compound 90b was synthesized according to the general procedures. Red amorphous solid; 
TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3)  11.28 (s, 1H), 
7.89 (s, 1H), 7.67 (s, 1H), 7.47 – 7.40 (m, 2H), 7.30 – 7.25 (m, 2H), 7.01 – 6.96 (m, 3H), 3.86 
(s, 3H), 3.83 (s, 3H), 3.77 – 3.70 (m, 5H), 3.51 (s, 3H), 3.16 – 3.10 (m, 1H) 2.93 – 2.87 (m, 1H); 
13C NMR (100 MHz, CDCl3):  192.0, 169.7, 168.2, 161.0, 153.3, 135.9, 134.2, 131.6, 130.1, 
129.1, 126.3, 124.4, 119.7, 118.5, 118.2, 117.6, 113.3, 111.3, 107.4, 105.9, 68.0, 53.7, 52.4, 
52.0, 33.7, 23.7, 21.9 ppm; HRMS: Calcd for C27H27O5N2 [M+H]+: 459.19145, Found: 
459.19137; [α]D20 -8.6 ° (c 0.002 in ethanol). 
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III.4.3. Synthesis of the Benzoquinolizines 96 and Benzopyridiniums 97 
Synthesis of 3,4-dihydroisoquinolines 94 
The 3,4-dihydroisoquinolines 94 were synthesized following the same general procedure as 
for the tryptamine derived imines 69. 
 
Compound 94a:  
 
Compound 94a was synthesized according to the general procedure for  substituted imines. 
Yellow amorphous solid: 1H NMR (400 MHz, CDCl3)  7.48 (d, J = 7.2 Hz, 1H), 7.35 – 7.26 (m, 
2H), 7.18 (d, J = 7.2 Hz, 1H), 3.66 (t, J = 7.2 Hz, 2H), 2.75 (q, J = 7.2 Hz, 2H), 2.67 (t, J = 7.2 Hz, 
2H), 1.21 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3):  168.0, 137.8, 130.2, 129.0, 127.5, 
126.8, 124.8, 46.8, 28.7, 26.1, 11.2 ppm; HRMS: Calcd for C11H14N [M+H]+: 160.11208, Found: 
160.11199. 
 
Compound 94b:  
 
Compound 94b was synthesized according to the general procedure for  substituted 
imines. Yellow amorphous solid: 1H NMR (400 MHz, CDCl3)  7.51 (d, J = 7.2 Hz, 1H), 7.34–
7.27 (m, 2H), 7.18 (d, J = 7.2 Hz, 1H), 3.66 (t, J = 7.4 Hz, 2H), 3.31 – 3.21 (m, 1H), 2.64 (t, J = 
7.4 Hz, 2H), 1.20 (d, J = 6.8 Hz, 6H); 13C NMR (100 MHz, CDCl3):  171.2, 138.2, 130.0, 128.8, 
127.5, 126.7, 124.6, 46.8, 31.6, 26.3, 20.7 ppm; HRMS: Calcd for C12H16N [M+H]+: 174.12773, 
Found: 174.12781. 
 
Compound 94c:  
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Compound 94c was synthesized according to the general procedure for  substituted imines. 
Yellow amorphous solid: 1H NMR (400 MHz, DMSO-d6)  8.48 (d, J = 5.7 Hz, 1H), 8.23 (d, J = 
8.3 Hz, 1H), 7.82 (d, J = 8.1 Hz, 1H), 9.66 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 7.59 (ddd, J = 8.3, 6.9, 
1.4 Hz, 1H), 7.49 (d, J = 5.7 Hz; 1H), 3.57 (tt, J = 11.6, 3.2 Hz, 1H), 2.04 – 1.91 (m, 4H), 1.88 – 
1.75 (m, 3H), 1.54 (qt, J = 12.5, 3.1 Hz, 2H), 1.40 (qt, J = 12.7, 3.4 Hz, 1H); 13C NMR (100 MHz, 
DMSO-d6):  165.9, 142.1, 136.6, 129.7, 127.7, 127.0, 126.5, 124.9, 119.1, 41.7, 32.8, 27.1, 
26.4 ppm; HRMS: Calcd for C15H20N [M+H]+: 214.15903, Found: 214.15894. 
 
Compound 94d:  
 
Compound 94d was synthesized according to the general procedure for  substituted 
imines. Yellow amorphous solid: 1H NMR (400 MHz, CDCl3)  6.97 (s, 1H), 6.67 (s, 1H), 3.90 
(s, 3H), 3.89 (s, 3H), 3.61 (t, J = 7.6 Hz, 2H), 2.62 (t, J = 7.6 Hz, 2H), 2.75 (q, J = 7.2 Hz, 2H), 
1.21 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3):  163.6, 150.8, 147.4, 131.1, 122.4, 110.2, 
109.0, 56.2, 55.9, 46.9, 25.7, 23.4 ppm; HRMS: Calcd for C13H18O2N [M+H]+: 220.13321, 
Found: 220.13335. 
 
Compound 94e:  
 
Compound 94e was synthesized according to the general procedure for  substituted imines. 
Yellow amorphous solid: 1H NMR (400 MHz, DMSO-d6)  7.04 (s, 1H), 6.70 (s, 1H), 3.92 (s, 
6H), 3.66 – 3.61 (m, 2H), 3.20 – 3.17 (m, 1H), 2.61 – 2.56 (q,  J = 6.7 Hz, 2H), 1.21 (d, J = 6.7 
Hz, 6H); 13C NMR (100 MHz, DMSO-d6):  170.9, 150.6, 147.5, 132.2, 121.8, 110.5, 108.7, 
56.4, 56.1, 47.1, 32.0, 26.2, 21.0 ppm; HRMS: Calcd for C14H20O2N [M+H]+: 234.14886, Found: 
234.14895. 
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Synthesis of Benzoquinolizines 96 
 General procedure for the racemic synthesis of ring-fused quinolizines:  
The cyclic imine (0.10 mmol; 1.0 eq.) was dissolved under argon in 5mL dry DMSO, and dry 
ZnCl2 (0.10 mmol; 1.0 eq) was added and stirred for 5min. Chromone diene 70 (0.10 mmol; 
1.0 eq.) was added and the reaction mixture was allowed to react for 12-24h at 80°C in a 
sealed tube under Ar. Disappearance of the chromone on TLC indicates complete reaction 
(cyclohexane/ethyl acetate 1:1). The reaction mixture is then diluted in 10 mL brine and 
extracted with 3x10mL DCM. The organic phase was dried over Na2SO4 evaporated to give a 
residue that is purified by flash chromatography to yield the ring-fused quinolizines as 
colorful solids. 
 
 General procedure for the asymmetric imino-Diels-Alder synthesis of ring-fused 
quinolizines:  
ZnEt2 (0.01 mmol; 20 mol%) and (R)-Binol (R)-80a or (R)-dianthracenylbinol (R)-80e (0.02 
mmol; 40 mol%) were dissolved under argon in 5mL dry toluene and stirred for 15 minutes, 
then the cyclic imine (0.05 mmol; 1.0 eq) was added to the reaction mixture which is 
subsequently cooled to -78°C. Chromone diene 70 (0.10 mmol; 1.0 eq.) was added and the 
reaction mixture was allowed to react for 12-24h at -78°C in a sealed tube under Ar. 
Disappearance of the chromone on TLC indicates complete reaction (cyclohexane/ethyl 
acetate 1:1). The reaction mixture is then evaporated to give a residue that is purified by 
flash chromatography to yield the ring-fused quinolizines as colorful solids. 
 
Compound 96a:  
 
Compound 96a was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.24 
(s, 1H), 7.94 (s, 1H), 7.64 (s, 1H), 7.53 – 7.51 (m, 1H), 7.40 – 7.16 (m, 6H), 6.97 – 6.90 (m, 1H), 
5.49 (s, 1H), 3.86 – 3.77 (m, 5H), 3.19 (dd, J = 13.9, 4.0 Hz, 1H), 2.97 (dd, J = 14.0, 4.0 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 190.6, 168.8, 159.9, 143.4, 136.2, 136.0, 135.9, 131.8, 130.0, 
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126.1, 123.9, 120.5, 120.0, 118.8, 118.4, 113.8, 112.0, 108.2, 68.1, 54.0, 45.2, 23.3 ppm; 
HRMS: Calcd for C22H20O4N [M+H]+: 362.13868, Found: 362.13867.  
 
Compound 96c:  
 
Compound 96c was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.22 (s, 1H), 7.99 (s, 1H), 7.65 (s, 1H), 7.54 – 7.50 (m, 1H), 7.39 – 7.20 (m, 6H), 6.97 
– 6.93 (m, 1H), 5.79 (s, 1H), 3.86 – 3.80 (m, 2H), 3.20 (dd, J = 14.0, 3.9 Hz, 1H), 2.98 (dd, J = 
14.0, 3.9 Hz, 1H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 190.9, 163.8, 160.0, 143.7, 136.3, 
136.0, 135.7, 131.9, 130.2, 126.3, 123.7, 120.5, 120.2, 118.8, 118.3, 113.8, 112.4, 108.2, 81.0, 
68.1, 45.2, 28.8, 28.7, 23.2 ppm; HRMS: Calcd for C25H26O4N [M+H]+: 404.18563, Found: 
404.18541. 
 
Compound 96d:  
 
Compound 96d was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H), 9.04 (s, 1H), 7.84 (s, 1H), 7.63 (s, 1H), 7.48 – 7.41 (m, 3H), 7.25 – 7.19 (m, 
1H), 7.33 – 7.30 (m, 1H), 7.08 – 7.00 (m, 3H), 6.09 (s, 1H), 3.85 – 3.79 (m, 2H), 3.20 – 3.13 (m, 
1H), 2.96 – 2.91 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 191.9, 153.4, 138.4, 136.1, 134.8, 132.5, 
130.3, 127.4, 127.0, 126.1, 122.7, 120.2, 118.4, 118.1, 116.1, 105.9, 83.8, 82.3, 69.1, 52.0, 23.4 
ppm; HRMS: Calcd for C21H17O2N2 [M+H]+: 329.12845, Found: 329.12811. 
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Compound 96e:  
 
Compound 96e was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 12.18 (s, 1H), 11.12 (s, 1H), 9.79 (s, 1H), 7.73 (s, 1H), 7.67 (s, 1H), 7.34 – 7.27 (m, 
2H), 7.19 – 7.12 (m, 2H), 7.05 – 7.01 (m, 1H), 6.94 – 6.88 (m, 2H), 6.11 (s, 1H), 4.06 – 4.02 (m, 
1H), 3.50 – 3.45 (m, 1H), 3.03 – 2.95 (m, 1H), 2.91 – 2.87 (m, 1H); 13C NMR (101 MHz, DMSO-
d6) δ 192.4, 173.1, 155.3, 153.8, 136.4, 132.4, 132.2, 132.0, 131.7, 129.3, 127.8, 125.7, 125.5, 
124.2, 116.4, 112.7, 111.8, 106.1, 67.9, 49.8, 22.5 ppm; HRMS: Calcd for C21H18O4N [M+H]+: 
348.12303, Found: 348.12274. 
 
Compound 96f:  
 
Compound 96f was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.24 
(s, 1H), 7.89 (s, 1H), 7.72 (s, 1H), 7.46 – 7.42 (m, 2H), 7.20 – 7.13 (m, 2H), 6.99 (s, 1H), 6.88 
(s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.58 (s, 3H), 3.52 – 3.46 (m, 1H), 3.43 – 3.36 (m, 4H); 2.96 – 
2.88 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 190.2, 170.0, 166.0, 158.9, 145.2, 135.1, 132.8, 
131.6, 131.1, 128.7, 127.5, 127.3, 123.1, 121.4, 119.5, 116.7, 116.0, 111.2, 105.1, 69.9, 56.3, 
56.2, 52.4, 49.8, 24.2 ppm; HRMS: Calcd for C25H26O6N [M+H]+: 436.17546, Found: 
436.17519. 
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Compound 96g:  
 
Compound 96g was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.23 (s, 1H), 7.88 (s, 1H), 7.71 (s, 1H), 7.47 – 7.42 (m, 2H), 7.20 – 7.12 (m, 2H), 7.00 
(s, 1H), 6.89 (s, 1H), 4.06 (q, J = 7.8 Hz, 2H), 3.81 (s, 3H), 3.80 (s, 3H), 3.46 – 3.38 (m, 5H), 2.95 
– 2.89 (m, 2H), 1.30 (t, J = 7.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 190.3, 169.9, 166.2, 158.8, 
145.3, 135.0, 132.7, 131.6, 131.2, 128.7, 127.6, 127.3, 123.7, 121.5, 119.5, 116.8, 116.1, 
111.4, 105.0, 69.9, 61.8, 56.3, 56.2, 49.7, 24.2, 15.0 ppm; HRMS: Calcd for C26H28O6N [M+H]+: 
450.19111, Found: 450.19098. 
 
Compound 96h:  
 
Compound 96h was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.17 (s, 1H), 7.88 (s, 1H), 7.74 (s, 1H), 7.47 – 7.42 (m, 2H), 7.22 – 7.14 (m, 2H), 6.98 
(s, 1H), 6.88 (s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.53 – 3.46 (m, 1H), 3.43 – 3.37 (m, 4H), 2.97 – 
2.90 (m, 2H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 190.3, 170.5, 166.4, 158.8, 145.2, 
135.2, 132.7, 131.5, 131.1, 128.6, 127.5, 127.0, 123.1, 121.6, 119.6, 116.7, 116.1, 111.2, 
105.9, 81.6, 70.1, 56.4, 56.3, 49.7, 28.9, 24.3 ppm; HRMS: Calcd for C28H32O6N [M+H]+: 
478.22241, Found: 478.22237. 
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Compound 96i:  
 
Compound 96i was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.18 
(s, 1H), 7.89 (s, 1H), 7.75 (s, 1H), 7.48 – 7.41 (m, 2H), 7.22 – 7.16 (m, 2H), 7.00 (s, 1H), 6.91 
(s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.52 – 3.45 (m, 1H), 3.41 – 3.37 (m, 4H), 2.93 – 2.87 (m, 2H); 
13C NMR (101 MHz, CDCl3) δ 190.7, 166.7, 158.8, 145.2, 135.1, 132.8, 131.7, 131.0, 128.7, 
127.4, 127.2, 123.2, 121.7, 119.8, 117.7, 116.8, 113.2, 111.7, 104.2, 69.8, 56.3, 56.3, 49.7, 
24.3 ppm; HRMS: Calcd for C24H23O4N2 [M+H]+: 403.16523, Found: 403.16497. 
 
Compound 96j:  
 
Compound 96j was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 12.04 
(s, 1H), 11.27 (s, 1H), 7.90 (s, 1H), 7.74 (s, 1H), 7.47 – 7.41 (m, 2H), 7.22 – 7.17 (m, 2H), 7.02 
(s, 1H), 6.93 (s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.50 – 3.44 (m, 1H), 3.40 – 3.35 (m, 4H), 2.94 – 
2.88 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 190.7, 172.4, 166.7, 158.0, 145.1, 135.1, 132.7, 
131.7, 131.1, 128.7, 127.8, 127.3, 123.2, 121.4, 119.8, 116.7, 114.7, 111.3, 104.2, 69.9, 56.3, 
56.2, 49.6, 24.7 ppm; HRMS: Calcd for C24H24O6N [M+H]+: 422.15981, Found: 422.15958. 
 
Compound 96k:  
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Compound 96k was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.25 
(s, 1H), 7.90 (s, 1H), 7.73 (s, 1H), 7.47 – 7.42 (m, 2H), 7.20 – 7.14 (m, 2H), 7.00 (s, 1H), 6.89 
(s, 1H), 4.02 – 3.94 (m, 4H), 3.58 (s, 3H), 3.52 – 3.47 (m, 1H), 3.41 – 3.35 (m, 4H), 2.97 – 2.90 
(m, 2H), 1.55 – 1.48 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 190.4, 170.1, 164.5, 158.8, 135.3, 
135.0, 132.1, 131.7, 131.0, 128.6, 127.5, 127.3, 123.4, 121.4, 119.5, 116.1, 111.2, 104.6, 70.4, 
67.9, 61.3, 61.2, 52.2, 49.7, 24.0, 15.3, 15.2 ppm; HRMS: Calcd for C27H30O6N [M+H]+: 
464.20676, Found: 464.20671; [α]D20 -14.8 ° (c 0.002 in ethanol). 
 
Compound 96l:  
 
Compound 96l was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.19 
(s, 1H), 7.90 (s, 1H), 7.73 (s, 1H), 7.47 – 7.41 (m, 2H), 7.22 – 7.18 (m, 2H), 7.01 (s, 1H), 6.89 
(s, 1H), 4.04 – 3.94 (m, 6H), 3.53 – 3.47 (m, 1H), 3.41 – 3.37 (m, 4H), 2.95 – 2.91 (m, 2H), 1.55 
– 1.43 (m, 9H); 13C NMR (101 MHz, CDCl3) δ 190.7, 170.2, 164.1, 158.9, 135.5, 134.8, 132.0, 
131.7, 131.2, 128.5, 127.5, 127.2, 123.4, 121.5, 119.5, 116.7, 111.2, 104.9, 70.5, 67.8, 61.6, 
61.3, 61.2, 49.8, 24.4, 15.9, 15.3, 15.2 ppm; HRMS: Calcd for C28H32O6N [M+H]+: 478.22241, 
Found: 478.22223. 
 
Compound 96m:  
 
Compound 96m was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H), 7.89 (s, 1H), 7.74 (s, 1H), 7.49 – 7.44 (m, 2H), 7.19 – 7.14 (m, 2H), 7.03 
(s, 1H), 6.91 (s, 1H), 4.02 – 3.94 (m, 4H), 3.53 – 3.47 (m, 1H), 3.41 – 3.36 (m, 4H), 2.96 – 2.90 
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(m, 2H), 1.55 – 1.42 (m, 15H); 13C NMR (101 MHz, CDCl3) δ 189.9, 170.4, 164.6, 158.8, 135.7, 
135.4, 132.1, 131.9, 131.2, 128.6, 127.4, 127.3, 123.7, 121.4, 119.6, 116.2, 111.2, 104.5, 70.0, 
81.1, 67.8, 61.3, 61.2, 49.6, 24.2, 15.3, 15.2, 14.7 ppm; HRMS: Calcd for C30H36O6N [M+H]+: 
506.25371, Found: 506.25344. 
 
Compound 96n:  
 
Compound 96n was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.09 
(s, 1H), 7.94 (s, 1H), 7.73 (s, 1H), 7.49 – 7.43 (m, 2H), 7.20 – 7.15 (m, 2H), 6.98 (s, 1H), 6.90 
(s, 1H), 4.03 – 3.94 (m, 4H), 3.58 – 3.45 (m, 1H), 3.40 – 3.34 (m, 4H); 2.95 – 2.89 (m, 2H), 1.54 
– 1.47 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 189.5, 164.7, 159.0, 135.3, 135.1, 132.2, 131.8, 
131.0, 128.6, 127.6, 127.3, 123.4, 121.5, 119.5, 118.6, 116.2, 111.5, 104.6, 69.9, 67.7, 56.3, 
56.1, 49.6, 24.2, 15.1, 14.9 ppm; HRMS: Calcd for C26H27O4N2 [M+H]+: 431.19653, Found: 
431.19647; [α]D20 -14.2 ° (c 0.002 in ethanol). 
 
Compound 96o:  
 
Compound 96o was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 12.04 (s, 1H), 11.13 (s, 1H), 7.93 (s, 1H), 7.74 (s, 1H), 7.48 – 7.41 (m, 2H), 7.23 – 7.16 
(m, 2H), 7.00 (s, 1H), 6.88 (s, 1H), 4.03 – 3.94 (m, 4H), 3.55 – 3.49 (m, 1H), 3.44 – 3.39 (m, 
4H), 2.96 – 2.90 (m, 2H), 1.54 – 1.48 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 190.6, 174.3, 162.5, 
158.9, 135.2, 135.1, 131.9, 131.4, 131.2, 128.4, 128.0, 127.9, 123.5, 121.4, 119.6, 116.1, 
111.0, 104.6, 69.9, 67.8, 61.3, 61.2, 49.6, 24.7, 15.2, 15.2 ppm; HRMS: Calcd for C26H28O6N 
[M+H]+: 450.19111, Found: 450.19087. 
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Compound 96p:  
 
Compound 96p was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.97 (s, 1H), 9.57 (br s, 2H), 7.88 (s, 1H), 7.74 (s, 1H), 7.47 – 7.41 (m, 2H), 7.20 – 
7.13 (m, 2H), 6.98 (s, 1H), 6.88 (s, 1H), 6.03 (s, 1H), 3.83 (s, 3H), 3.52 – 3.46 (m, 1H), 3.42 – 
3.36 (m, 1H), 2.97 – 2.90 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 190.2, 169.7, 164.4, 159.2, 
145.2, 145.0, 136.3, 134.7, 131.5, 128.6, 127.6, 127.3, 123.3, 121.3, 119.5, 116.7, 111.6, 
104.8, 70.5, 57.8, 52.3, 24.0 ppm; HRMS: Calcd for C22H20O6N [M+H]+: 394.12851, Found: 
394.12833. 
 
Compound 96q:  
 
Compound 96q was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.83 (s, 1H), 7.95 (s, 1H), 7.72 (s, 1H), 7.48 – 7.41 (m, 2H), 7.20 – 7.13 (m, 2H), 6.99 
(s, 1H), 6.89 (s, 1H), 3.60 – 3.54 (m, 1H), 3.41 – 3.35 (m, 1H); 2.93 – 2.88 (m, 2H); 13C NMR 
(101 MHz, CDCl3) δ 189.9, 164.8, 159.4, 145.3, 145.1, 136.7, 131.2, 131.1, 128.7, 127.6, 
127.3, 123.9, 121.4, 119.4, 118.9, 116.1, 110.6, 104.8, 70.3, 52.9, 24.4 ppm; HRMS: Calcd for 
C21H16O4N2 [M+H]+: 361.11828, Found: 361.11801. 
 
Compound 96r:  
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Compound 96r was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.98 
(s, 1H), 9.53 (br s, 2H), 7.88 (s, 1H), 7.73 (s, 1H), 7.46 – 7.42 (m, 2H), 7.20 – 7.13 (m, 2H), 6.98 
(s, 1H), 6.87 (s, 1H), 3.57 (s, 3H), 3.52 – 3.46 (m, 1H), 3.43 – 3.35 (m, 4H); 2.96 – 2.89 (m, 2H); 
13C NMR (101 MHz, CDCl3) δ 190.9, 170.7, 166.5, 158.7, 145.2, 145.1, 137.2, 134.6, 131.2, 
128.8, 127.5, 123.1, 121.5, 119.4, 116.6, 116.2, 111.7, 105.2, 69.9, 53.4, 52.3, 49.7, 24.4 ppm; 
HRMS: Calcd for C23H22O6N [M+H]+: 408.14416, Found: 408.14442. 
 
Compound 96s:  
 
Compound 96s was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.99 (s, 1H), 9.57 (br s, 2H), 7.90 (s, 1H), 7.73 (s, 1H), 7.48 – 7.41 (m, 2H), 7.23 – 
7.16 (m, 2H), 7.01 (s, 1H), 6.92 (s, 1H), 3.52 – 3.46 (m, 1H), 3.40 – 3.36 (m, 4H), 2.92 – 2.87 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 190.8, 166.8, 158.9, 145.4, 145.3, 132.7, 131.5, 128.6, 
127.3, 127.0, 124.5, 121.9, 119.7, 117.0, 116.9, 113.5, 111.8, 104.5, 70.0, 49.9, 47.1, 24.7 
ppm; HRMS: Calcd for C22H19O4N2 [M+H]+: 375.13393, Found: 375.13402. 
 
Compound 96t:  
 
Compound 96t was synthesized according to the racemic general procedure. Red amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.99 
(s, 1H), 9.54 (br s, 2H), 7.86 (s, 1H), 7.72 (s, 1H), 7.63 (s, 1H), 7.28 (s, 1H), 6.99 (s, 1H), 6.88 (s, 
1H), 5.99, (s, 1H), 3.59 (s, 3H), 3.55 – 3.50 (m, 1H), 3.42 – 3.37 (m, 1H), 2.94 – 2.87 (m, 2H) 
ppm; 13C NMR (101 MHz, CDCl3) δ 189.2, 170.5, 164.7, 156.3, 144.2, 144.0, 137.3, 134.6, 
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131.9, 128.5, 127.5, 127.2, 123.2, 121.5, 119.7, 116.3, 111.4, 104.7, 70.2, 67.8, 51.2, 24.0 
ppm; HRMS: Calcd for C22H18O6NCl2 [M+H]+: 462.05057, Found: 462.05024. 
 
Compound 96u:  
 
Compound 96u was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.87 (s, 1H), 9.54 (br s, 2H), 7.83 (s, 1H), 7.73 (s, 1H), 7.58 (s, 1H), 7.29 (s, 1H), 6.98 
(s, 1H), 6.88 (s, 1H), 6.01 (s, 1H), 3.51 – 3.47 (m, 1H), 3.41 – 3.35 (m, 1H); 2.90 – 2.81 (m, 2H); 
13C NMR (101 MHz, CDCl3) δ 190.2, 164.2, 158.7, 145.4, 145.3, 137.2, 131.1, 130.4, 128.5, 
127.7, 127.3, 123.5, 121.5, 119.7, 117.3, 116.0, 111.5, 104.2, 70.7, 49.8, 24.7 ppm; HRMS: 
Calcd for C21H15O4N2Cl2 [M+H]+: 429.04304, Found: 429.04281. 
 
Compound 96v:  
 
Compound 96v was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.96 (s, 1H), 9.57 (br s, 2H), 7.83 (s, 1H), 7.74 (s, 1H), 7.63 (s, 1H), 7.28 (s, 1H), 7.02 
(s, 1H), 6.88 (s, 1H), 3.57 (s, 3H), 3.53 – 3.48 (m, 1H), 3.40 – 3.34 (m, 4H), 2.93 – 2.87 (m, 2H) 
ppm; 13C NMR (101 MHz, CDCl3) δ 192.0, 168.7, 164.9, 158.6, 146.0, 145.9, 137.3, 131.6, 
131.2, 128.4, 127.5, 127.2, 123.1, 121.7, 119.6, 116.2, 111.2, 104.8, 71.0, 53.8, 52.1, 49.6, 
24.7 ppm; HRMS: Calcd for C23H20O6NCl2 [M+H]+: 476.06622, Found: 476.06593. 
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Compound 96w:  
 
Compound 96w was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 12.05 (s, 1H), 9.56 (br s, 2H), 7.81 (s, 1H), 7.72 (s, 1H), 7.63 (s, 1H), 7.26 (s, 1H), 6.98 
(s, 1H), 6.89 (s, 1H), 3.51 – 3.46 (m, 1H), 3.40 – 3.36 (m, 4H); 2.93 – 2.85 (m, 2H); 13C NMR 
(101 MHz, CDCl3) δ 189.7, 164.7, 158.5, 145.0, 144.8, 138.8, 133.9, 132.0, 128.7, 127.6, 
127.3, 123.0, 121.7, 119.6, 117.2, 116.1, 111.4, 104.7, 68.7, 51.7, 49.9, 24.5 ppm; HRMS: 
Calcd for C22H17O4N2Cl2 [M+H]+: 443.05599, Found: 443.05563. 
 
Compound 96x:  
 
Compound 96x was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.11 
(s, 1H), 7.90 (s, 1H), 7.60 (s, 1H), 7.53 (m, 1H), 7.48- – 7.45 (m, 2H), 7.36 – 7.34 (m, 1H), 7.22 
– 7.18 (m, 2H), 7.12 – 7.08 (m, 1H), 6.89 – 6.87 (m, 1H), 3.88 (s, 3H), 3.82 – 3.73 (m, 2H), 3.49 
(s, 3H), 3.20 – 3.15 (m, 1H), 2.97 – 2.93 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 168.7, 
160.3, 153.7, 136.2, 135.8, 132.4, 131.7, 126.0, 123.2, 121.4, 120.0, 118.4, 114.0, 112.0, 
110.3, 108.2, 105.8, 68.2, 54.1, 52.8, 26.2, 23.4 ppm; HRMS: Calcd for C23H22O4N [M+H]+: 
376.15433, Found: 376.15427; [α]D20 -14.1° (c 0.002 in ethanol). 
 
Compound 96y:  
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Compound 96y was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.40 
(s, 1H), 8.02 (s, 1H), 7.54 (s, 1H), 7.44 – 7.38 (m, 2H), 7.25 (d, J = 6.5 Hz, 1H), 7.17 – 7.11 (m, 
3H), 7.01 – 6.95 (m, 2H), 3.85 – 3.79 (m, 1H), 3.74 – 3.68 (m, 1H), 3.67 (s, 3H), 3.30 (q, J = 7.5 
Hz, 2H), 3.18 (dd, J = 14.1, 4.0 Hz, 1H), 2.97 (dd, J = 14.0, 4.0 Hz, 1H), 1.90 (t, J = 7.5 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ 192.2, 167.5, 164.1, 149.6, 136.8, 136.0, 135.9, 134.2, 133.5, 
130.9, 121.9, 120.7, 120.5, 117.6, 116.7, 116.2, 111.2, 108.5, 68.7, 54.7, 49.5, 26.6, 25.0, 14.6 
ppm; HRMS: Calcd for C24H24O4N [M+H]+: 390.16998, Found: 390.16994; [α]D20 -15.6 ° (c 
0.002 in ethanol). 
 
Compound 96z:  
 
Compound 96z was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.39 
(s, 1H), 7.99 (s, 1H), 7.54 (s, 1H), 7.42 – 7.31 (m, 2H), 7.20 – 7.09 (m, 4H), 6.98 – 6.93 (m, 2H), 
3.84 – 3.78 (m, 1H), 3.73 – 3.68 (m, 4H), 3.18 – 3.13 (m, 1H), 2.93 – 2.87 (m, 2H); 1.59 (d, J = 
6.8 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 192.0, 168.0, 164.0, 149.6, 136.9, 136.4, 136.1, 
134.5, 133.2, 130.8, 124.3, 121.7, 120.9, 120.2, 117.5, 116.5, 116.2, 111.1, 108.7, 68.5, 55.1, 
49.5, 38.3, 25.1, 16.3 ppm; HRMS: Calcd for C25H26O4N [M+H]+: 404.18563, Found: 
404.18562; [α]D20 -18.3 ° (c 0.002 in ethanol). 
 
Compound 96aa:  
 
Compound 96aa was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.50; 1H NMR (400 MHz, CDCl3) δ 11.32 
(s, 1H), 7.91 (s, 1H), 7.59 (s, 1H), 7.42 – 7.35 (m, 2H), 7.20 – 7.11 (m, 4H), 6.99 – 6.93 (m, 2H), 
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3.78 – 3.72 (m, 2H), 3.61 (s, 3H), 3.16 – 3.11 (m, 1H), 2.94 – 2.87 (m, 1H); 2.10 – 1.69 (m, 
11H); 13C NMR (101 MHz, CDCl3) δ 192.1, 167.9, 164.1, 149.6, 136.7, 136.1, 135.9, 134.0, 
133.4, 130.9, 124.3, 120.9, 120.4, 117.6, 116.7, 116.3, 111.4, 108.8, 68.9, 54.5, 49.7, 42.1, 
26.8, 26.7, 26.6, 26.2, 26.0, 25.0 ppm; HRMS: Calcd for C28H30O4N [M+H]+: 444.21693, Found: 
444.21688; [α]D20 -19.2 ° (c 0.002 in ethanol). 
 
Compound 96ab:  
 
Compound 96ab was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.20 (s, 1H), 7.87 (s, 1H), 7.71 (s, 1H), 7.46 - 7.41 (m, 2H), 7.21 - 7.13 (m, 2H), 6.98 
(s, 1H), 6.88 (s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.59 (s, 3H), 3.52 – 3.47 (m, 1H), 3.43 – 3.37 (m, 
1H), 3.33 (q, J = 7.8 Hz, 2H), 3.16 (dd, J = 13.9, 4.0 Hz, 1H), 2.97 (dd, J = 13.9, 4.0 Hz, 1H), 1.96 
(t, J = 7.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 191.3, 171.2, 166.1, 158.4, 145.1, 135.1, 132.7, 
131.7, 131.0, 128.7, 127.4, 127.3, 123.0, 121.5, 119.5, 116.8, 116.1, 111.3, 105.0, 69.9, 56.4, 
56.2, 52.5, 24.4, 24.1, 14.1 ppm; HRMS: Calcd for C26H28O6N [M+H]+: 450.19111, Found: 
450.19096. 
 
Compound 96ac:  
 
Compound 96ac was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.19 (s, 1H), 7.88 (s, 1H), 7.70 (s, 1H), 7.45 – 7.40 (m, 2H), 7.20 – 7.12 (m, 2H), 6.98 
(s, 1H), 6.87 (s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.60 (s, 3H), 3.52 – 3.47 (m, 1H), 3.43 – 3.37 (m, 
1H), 3.16 (dd, J = 13.9, 4.0 Hz, 1H), 2.94 – 2.86 (m, 2H); 1.65 (d, J = 7.0 Hz, 6H); 13C NMR (101 
MHz, CDCl3) δ 191.3, 171.2, 166.1, 158.4, 145.1, 135.1, 132.7, 131.7, 131.0, 128.7, 127.4, 
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127.3, 123.0, 121.5, 119.5, 116.8, 116.1, 111.3, 105.0, 69.9, 56.4, 56.2, 52.5, 24.4, 24.1, 14.1 
ppm; HRMS: Calcd for C27H30O6N [M+H]+: 464.20676, Found: 464.20689. 
 
Compound 96ad:  
 
Compound 96ad was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.10 (s, 1H),  7.90 (s, 1H), 7.62 (s, 1H), 7.41 – 7.34 (m, 2H), 7.23 (d, J = 7.6 Hz, 1H), 
6.97 (t, J = 7.6 Hz, 1H), 6.90 (s, 1H), 6.87 (s, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.69 – 3.58 (m, 5H), 
3.15 – 3.09 (m, 1H), 2.90 – 2.84 (m, 1H), 2.11 - 1.78 (m, 11H); 13C NMR (101 MHz, CDCl3) δ 
193.2, 171.2, 166.1, 149.8, 146.3, 146.1, 135.8, 134.0, 133.0, 130.9, 124.2, 120.9, 120.6, 
118.0, 116.9, 116.3, 111.0, 108.2, 68.7, 56.1, 55.7, 52.0, 49.6, 42.1, 26.8, 26.6, 26.5, 26.1, 
26.0, 24.3 ppm; HRMS: Calcd for C30H34O6N [M+H]+: 504.23806, Found: 504.23789. 
 
Compound 96ae:  
 
Compound 96ae was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.31 
(s, 1H), 7.91 (s, 1H), 7.57 (s, 1H), 7.41 – 7.35 (m, 2H), 7.19 – 7.06 (m, 4H), 6.98 – 6.94 (m, 2H), 
3.80 – 3.74 (m, 1H), 3.72 (td, J = 14.1, 5.6 Hz, 1H), 3.64 (s, 3H), 3.24 (dd, J = 14.2, 4.1 Hz, 1H), 
3.00 (dd, J = 14.2, 4.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 192.8, 164.7, 149.5, 136.7, 136.3, 
136.0, 134.0, 133.5, 130.8, 124.3, 121.8, 120.9, 120.5, 117.5, 116.8, 116.1, 111.4, 108.8, 66.6, 
55.0, 49.5, 25.3 ppm; HRMS: Calcd for C22H19O2N2 [M+H]+: 343.14420, Found: 343.14417; 
[α]D20 -13.2 ° (c 0.002 in ethanol). 
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Compound 96af:  
 
Compound 96af was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H), 7.94 (s, 1H), 7.56 (s, 1H), 7.45 – 7.38 (m, 2H), 7.23 (d, J = 7.0 Hz, 1H), 
7.16 – 7.10 (m, 3H), 7.00 – 6.95 (m, 2H), 3.84 – 3.78 (m, 1H), 3.73 – 3.68 (m, 1H), 3.32 (q, J = 
7.7 Hz, 2H), 3.17 (dd, J = 14.0, 4.0 Hz, 1H), 2.98 (dd, J = 14.0, 4.0 Hz, 1H), 1.93 (t, J = 7.7 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 192.2, 167.5, 164.1, 149.6, 136.8, 136.0, 135.9, 134.2, 
133.5, 130.9, 121.9, 120.7, 120.5, 117.6, 116.7, 116.2, 111.2, 108.5, 68.7, 49.5, 26.6, 25.0, 
14.6 ppm; HRMS: Calcd for C23H21O2N2 [M+H]+: 357.15975, Found: 357.15953. 
 
Compound 96ag:  
 
Compound 96ag was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.29 (s, 1H), 8.03 (s, 1H), 7.57 (s, 1H), 7.41 – 7.31 (m, 2H), 7.19 – 7.07 (m, 4H), 6.98 
– 6.91 (m, 2H), 3.84 – 3.78 (m, 1H), 3.73 – 3.67 (m, 1H), 3.17 – 3.13 (m, 1H), 2.94 – 2.87 (m, 
2H), 1.61 (d, J = 6.9 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 192.7, 164.3, 149.4, 136.7, 136.8, 
136.2, 134.3, 133.4, 130.7, 124.4, 121.6, 120.8, 120.0, 117.4, 116.7, 116.1, 114.0, 111.0, 
108.6, 68.7, 49.4, 38.8, 25.2, 16.3 ppm; HRMS: Calcd for C24H23O2N2 [M+H]+: 371.17540, 
Found: 371.17513. 
 
Compound 96ah:  
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Compound 96ah was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.20 (s, 1H), 7.92 (s, 1H), 7.58 (s, 1H), 7.42 – 7.34 (m, 2H), 7.19 – 7.09 (m, 4H), 6.99 
– 6.92 (m, 2H), 3.78 – 3.73 (m, 2H), 3.15 – 3.11 (m, 1H), 2.95 – 2.89 (m, 1H); 2.10 – 1.71 (m, 
11H); 13C NMR (101 MHz, CDCl3) δ 190.1, 166.2, 149.7, 136.7, 136.0, 135.9, 134.4, 133.0, 
130.8, 124.3, 120.9, 120.3, 117.6, 116.7, 116.2, 115.5, 111.4, 108.7, 68.9, 49.9, 42.3, 26.7, 
26.6, 26.5, 26.2, 26.0, 24.9 ppm; HRMS: Calcd for C27H27O2N2 [M+H]+: 411.20670, Found: 
411.20641. 
 
Compound 96ai:  
 
Compound 96ai was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.20 (s, 1H), 7.86 (s, 1H), 7.70 (s, 1H), 7.47 – 7.41 (m, 2H), 7.21 – 7.13 (m, 2H), 6.98 
(s, 1H), 6.88 (s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.53 – 3.47 (m, 1H), 3.42 – 3.37 (m, 1H), 3.34 
(q, J = 7.8 Hz, 2H), 3.12 (dd, J = 13.9, 4.0 Hz, 1H), 2.98 (dd, J = 13.9, 4.0 Hz, 1H), 1.99 (t, J = 7.8 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 191.4, 166.1, 158.9, 145.2, 135.2, 132.0, 131.7, 131.1, 
128.6, 127.4, 127.2, 123.0, 121.6, 119.5, 116.7, 116.2, 116.1, 111.4, 104.9, 69.8, 56.7, 56.6, 
24.3, 24.1, 14.0  ppm; HRMS: Calcd for C25H25O4N2 [M+H]+: 417.18088, Found: 417.18067. 
 
Compound 96aj:  
 
Compound 96aj was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.18 (s, 1H), 7.87 (s, 1H), 7.74 (s, 1H), 7.45 – 7.39 (m, 2H), 7.20 – 7.13 (m, 2H), 6.98 
(s, 1H), 6.88 (s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.51 – 3.47 (m, 1H), 3.43 – 3.37 (m, 1H), 3.18 
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(dd, J = 14.0, 4.0 Hz, 1H), 2.94 - 2.87 (m, 2H); 1.66 (d, J = 7.0 Hz, 6H); 13C NMR (101 MHz, 
CDCl3) δ 191.2, 166.1, 158.3, 145.1, 135.9, 132.7, 131.6, 131.0, 128.8, 127.4, 127.2, 123.0, 
121.7, 119.5, 116.7, 116.1, 111.2, 105.3, 70.0, 56.3, 56.2, 55.3, 24.2, 24.1, 14.4 ppm; HRMS: 
Calcd for C26H26O4N2 [M+H]+: 431.19653, Found: 431.19647. 
 
Compound 96ak:  
 
Compound 96ak was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.14 
(s, 1H),  7.91 (s, 1H), 7.61 (s, 1H), 7.40 – 7.32 (m, 2H), 7.22 (d, J = 7.4 Hz, 1H), 6.98 (t, J = 7.4 
Hz, 1H), 6.91 (s, 1H), 6.89 (s, 1H), 3.80 (d, 6H), 3.69 – 3.58 (m, 2H), 3.16 – 3.03 (m, 1H), 2.89 
– 2.83 (m, 1H), 2.12-1.71 (m, 11H); 13C NMR (101 MHz, CDCl3) δ 192.0, 164.0, 149.7, 146.5, 
146.1, 135.7, 134.0, 133.2, 130.9, 124.1, 120.9, 120.5, 118.1, 117.6, 116.5, 116.2, 111.1, 
108.7, 68.5, 56.0, 55.8, 49.6, 42.2, 26.8, 26.7, 26.5, 26.2, 26.1, 24.2 ppm; HRMS: Calcd for 
C29H31O4N2 [M+H]+: 471.22783, Found: 471.22780; [α]D20 -17.4 ° (c 0.002 in ethanol). 
 
Compound 96al:  
 
Compound 96al was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.09 (s, 1H), 7.95 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 2.0 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 
7.41 – 7.32 (m, 3H), 7.22 – 7.13 (m, 2H), 6.99 – 6.95 (d, J = 8.3 Hz, 1H), 5.99 (s, 1H), 3.82 – 
3.74 (m, 5H), 3.22 – 3.18 (m, 1H), 2.97 (dd, J = 13.9, 3.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 
190.7, 167.2, 159.6, 153.4, 138.4, 136.2, 135.6, 134.3, 131.7, 129.8, 127.4, 125.8, 122.4, 
120.8, 120.4, 114.7, 112.2, 105.9, 68.7, 52.7, 50.6, 23.4 ppm; HRMS: Calcd for C22H19O4NF 
[M+H]+: 380.12926, Found: 380.12898. 
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Compound 96am:  
 
Compound 96am was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.13 (s, 1H), 7.94 (d, J = 1.9 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 
7.39 – 7.31 (m, 3H), 7.21 – 7.14 (m, 2H), 6.98 - 6.95 (d, J = 8.2 Hz, 1H), 6.03 (s, 1H), 3.83 – 
3.77 (m, 5H), 3.23 – 3.19 (m, 1H), 2.95 (dd, J = 14.1, 3.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 
190.4, 167.8, 159.8, 153.6, 138.4, 136.3, 135.6, 134.1, 131.7, 129.7, 127.2, 125.9, 122.4, 
120.7, 120.3, 114.3, 112.1, 105.9, 68.6, 52.6, 50.8, 23.7 ppm; HRMS: Calcd for C22H19O4NCl 
[M+H]+: 396.09971, Found: 396.09949. 
 
Compound 96an:  
 
Compound 96an was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.16 (s, 1H), 7.94 (d, J = 1.9 Hz, 1H), 7.66 (d, J = 1.9 Hz, 1H), 7.47 – 7.42 (m, 4H), 
7.23 – 7.15 (m, 2H), 7.01 - 6.97 (d, J = 8.2 Hz, 1H), 6.00 (s, 1H), 3.83 – 3.76 (m, 5H), 3.23 – 
3.18 (m, 1H), 2.96 (dd, J = 14.0, 4.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 191.0, 167.4, 159.4, 
153.2, 138.3, 136.7, 135.6, 134.1, 131.8, 129.8, 127.5, 125.8, 122.7, 120.9, 120.7, 114.6, 
112.2, 105.6, 68.8, 52.5, 50.6, 23.1 ppm; HRMS: Calcd for C22H19O4NBr [M+H]+: 440.04920, 
Found: 440.04904. 
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Compound 96ao:  
 
Compound 96ao was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.14 (s, 1H), 7.92 (d, J = 2.0 Hz, 1H), 7.61 (d, J = 2.0 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 
7.38 – 7.31 (m, 3H), 7.20 – 7.14 (m, 2H), 6.99 – 6.95 (d, J = 8.1 Hz, 1H), 6.00 (s, 1H), 3.82 – 
3.75 (m, 5H), 3.22 – 3.17 (m, 1H), 3.00 (dd, J = 13.9, 3.9 Hz, 1H), 2.42 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 190.3, 167.7, 159.9, 153.5, 138.4, 136.3, 135.6, 134.2, 131.8, 129.6, 127.2, 
125.5, 122.4, 121.0, 120.3, 114.2, 112.1, 105.8, 68.7, 52.6, 50.5, 24.6, 23.7 ppm; HRMS: Calcd 
for C23H22O4N [M+H]+: 376.15433, Found: 376.15412. 
 
Compound 96ap:  
 
Compound 96ap was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 7.90 (d, J = 2.4 Hz, 1H), 7.62 (d, J = 2.4 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 
7.37 – 7.30 (m, 3H), 7.21 – 7.14 (m, 2H), 6.98 – 6.94 (d, J = 8.0 Hz, 1H), 6.04 (s, 1H), 3.81 – 
3.74 (m, 5H), 3.23 – 3.17 (m, 1H), 2.94 (dd, J = 14.0, 4.0 Hz, 1H), 2.71 (q, J = 8.1 Hz, 2H), 1.34 
(t, J = 8.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 191.0, 167.9, 159.4, 153.7, 138.5, 136.6, 135.3, 
134.1, 131.9, 129.5, 127.3, 125.6, 122.9, 121.2, 120.2, 114.9, 112.0, 107.4, 68.9, 52.4, 50.1, 
28.3, 23.7, 15.1 ppm; HRMS: Calcd for C24H24O4N [M+H]+: 390.16998, Found: 390.16967. 
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Compound 96aq:  
 
Compound 96aq was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.11 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 
7.37 – 7.30 (m, 3H), 7.20 – 7.14 (m, 2H), 6.98 – 6.93 (d, J = 8.0 Hz, 1H), 6.02 (s, 1H), 3.80 – 
3.74 (m, 5H), 3.23 – 3.16 (m, 1H), 2.96 (dd, J = 13.8, 4.1 Hz, 1H), 2.80 (t, J = 7.0 Hz, 1H), 1.30 
(d, J = 6.9 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 190.7, 167.8, 159.3, 153.8, 138.4, 136.7, 
135.3, 134.2, 131.8, 129.5, 127.4, 125.6, 123.2, 120.9, 120.2, 114.7, 112.5, 107.3, 69.2, 52.3, 
50.2, 33.1, 23.6, 23.2 ppm; HRMS: Calcd for C25H26O4N [M+H]+: 404.18563, Found: 
404.18537. 
 
Compound 96ar:  
 
Compound 96ar was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H), 7.88 (s, 1H), 7.51 (s, 1H), 7.43 (s, 1H), 7.30 (d, J = 5.0 Hz, 1H), 7.10 (d, 
J = 5.2 Hz, 1H), 6.92 (s, 1H), 6.89 (s, 1H), 3.83 (s, 3H), 3.82 (s, 3H), 3.69 – 3.63 (m, 4H), 3.51 – 
3.46 (m, 4H), 3.13 – 3.07 (m, 1H), 2.87 – 2.83 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 189.7, 
171.2, 165.4, 149.5, 146.0, 145.8, 135.6, 134.2, 133.2, 130.8, 128.2, 124.1, 120.4, 118.0, 
116.3, 116.2, 111.1, 108.4, 68.6, 55.6, 51.2, 49.2, 25.3, 24.1 ppm; HRMS: Calcd for 
C25H25O6NF [M+H]+: 454.16604, Found: 455.16571. 
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Compound 96as:  
 
Compound 96as was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.30 
(s, 1H), 7.90 (s, 1H), 7.59 (s, 1H), 7.46 (s, 1H), 7.30 (d, J = 5.9 Hz, 1H), 7.03 (d, J = 5.9 Hz, 1H), 
6.90 (s, 1H), 6.85 (s, 1H), 3.82 (d, 6H), 3.68 – 3.61 (m, 4H), 3.52 – 3.46 (m, 5H), 3.14 – 3.09 
(m, 1H), 2.89 – 2.85 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 189.7, 170.4, 165.4, 149.5, 146.0, 
145.9, 135.7, 134.1, 133.3, 130.6, 128.2, 124.1, 120.8, 117.5, 116.6, 116.1, 111.1, 108.6, 68.7, 
55.7, 51.3, 49.3, 25.0, 24.1 ppm; HRMS: Calcd for C24H26O6NCl [M+H]+: 470.13649, Found: 
470.13643; [α]D20 -9.8 ° (c 0.002 in ethanol). 
 
Compound 96at:  
 
Compound 96at was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.24 (s, 1H), 7.89 (s, 1H), 7.62 (s, 1H), 7.45 (s, 1H), 7.31 (d, J = 6.0 Hz, 1H), 7.04 (d, 
J = 6.0 Hz, 1H), 6.92 (s, 1H), 6.89 (s, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.70 – 3.63 (m, 4H), 3.51 – 
3.45 (m, 4H), 3.13 – 3.09 (m, 1H), 2.88 – 2.84 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 190.2, 
170.7, 165.5, 149.6, 146.0, 145.7, 135.5, 134.1, 133.2, 130.7, 128.2, 124.2, 120.7, 117.6, 
116.4, 116.1, 111.1, 108.5, 68.6, 55.7, 51.3, 51.2, 49.3, 25.3, 24.2 ppm; HRMS: Calcd for 
C25H25O6NBr [M+H]+: 514.085098, Found: 514.08574. 
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Compound 96au:  
 
Compound 96au was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.26 
(s, 1H),  7.89 (s, 1H), 7.60 (s, 1H), 7.45 (s, 1H), 7.26 (d, J = 7.6 Hz, 1H), 6.96 (t, J = 7.6 Hz, 1H), 
6.91 (s, 1H), 6.86 (s, 1H), 3.80 (d, 6H), 3.68 – 3.61 (m, 4H), 3.50 – 3.44 (m, 4H), 3.15 – 3.09 
(m, 1H), 2.89 – 2.82 (m, 1H), 2.41 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 193.1, 169.5, 164.4, 
149.4, 146.1, 146.0, 135.7, 134.0, 133.2, 130.7, 124.1, 120.7, 120.4, 117.5, 116.5, 116.1, 
111.7, 108.6, 68.6, 56.1, 55.8, 51.2, 49.4, 25.0, 24.5, 21.3 ppm; HRMS: Calcd for C26H28O6N 
[M+H]+: 450.19111, Found: 450.19103; [α]D20 -12.9 ° (c 0.002 in ethanol). 
 
Compound 96av:  
 
Compound 96av was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.21 (s, 1H),  7.91 (s, 1H), 7.61 (s, 1H), 7.47 (s, 1H), 7.28 (d, J = 7.5 Hz, 1H), 6.98 - 
6.95 (m, 2H), 6.88 (s, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.66 – 3.62 (m, 4H), 3.51 – 3.45 (m, 4H), 
3.15 – 3.10 (m, 1H), 2.87 – 2.83 (m, 1H), 2.72 (q, J = 8.0 Hz, 2H), 1.31 (t, J = 8.0 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 192.0, 170.3, 164.8, 149.2, 146.1, 145.9, 135.7, 134.2, 133.1, 130.6, 
124.4, 120.8, 120.4, 117.4, 116.6, 116.2, 111.7, 108.8, 68.6, 56.2, 55.7, 51.2, 49.5, 29.2, 25.3, 
21.4, 15.0 ppm; HRMS: Calcd for C27H30O6N [M+H]+: 464.20676, Found: 464.20651. 
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Compound 96aw:  
 
Compound 96aw was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.18 (s, 1H),  7.90 (s, 1H), 7.62 (s, 1H), 7.48 (s, 1H), 7.23 (d, J = 7.5 Hz, 1H), 6.99 – 
6.94 (m, 2H), 6.89 (s, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.65 – 3.61 (m, 4H), 3.50 – 3.45 (m, 4H), 
3.16 – 3.11 (m, 1H), 2.87 – 2.81 (m, 2H), 1.22 (d, J = 6.4 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 
190.4, 170.1, 164.9, 149.3, 146.2, 145.8, 135.7, 134.3, 133.1, 130.7, 124.5, 120.6, 120.5, 
117.3, 116.8, 116.2, 111.6, 108.4, 68.6, 56.1, 55.8, 51.2, 49.6, 34.0, 30.7, 25.2, 21.2 ppm; 
HRMS: Calcd for C28H32O6N [M+H]+: 478.22241, Found: 478.22217. 
 
Compound 96ax:  
 
Compound 96ax was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.11 (s, 1H), 7.89 (d, J = 2.7 Hz, 1H), 7.64 (d, J = 2.7 Hz, 1H), 7.46 (d, J = 7.9 Hz, 1H), 
7.39 – 7.33 (m, 3H), 7.20 – 7.15 (m, 2H), 7.00 (d, J = 8.0 Hz, 1H), 6.04 (s, 1H), 3.81 – 3.74 (m, 
2H), 3.19 – 3.13 (m, 1H), 2.94 (dd, J = 14.1, 3.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 190.2, 
159.7, 153.5, 138.5, 136.3, 135.7, 134.2, 131.9, 129.6, 127.3, 125.5, 122.7, 121.0, 120.2, 
114.3, 113.6, 112.1, 106.0, 69.2, 52.1, 24.2 ppm; HRMS: Calcd for C21H16O2N2F [M+H]+: 
347.11903, Found: 347.11869. 
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Compound 96ay:  
 
Compound 96ay was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.08 (s, 1H), 7.93 (d, J = 2.3 Hz, 1H), 7.71 (d, J = 2.4 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 
7.36 – 7.29 (m, 3H), 7.22 – 7.17 (m, 2H), 6.95 (d, J = 8.0 Hz, 1H), 5.98 (s, 1H), 3.80 – 3.75 (m, 
2H), 3.18 – 3.13 (m, 1H), 3.00 (dd, J = 13.7, 3.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 191.3, 
160.2, 153.7, 138.4, 136.2, 135.7, 134.5, 131.9, 129.9, 127.3, 125.3, 122.7, 121.0, 120.8, 
114.3, 113.7, 112.1, 105.4, 69.1, 52.3, 24.3 ppm; HRMS: Calcd for C21H16O2N2Cl [M+H]+: 
363.08948, Found: 363.08911. 
 
Compound 96az:  
 
Compound 96az was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.05 (s, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.70 (d, J = 2.0 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 
7.35 – 7.29 (m, 3H), 7.23 – 7.17 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.03 (s, 1H), 3.82 – 3.76 (m, 
2H), 3.19 – 3.14 (m, 1H), 2.99 (dd, J = 13.8, 3.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 191.4, 
159.8, 153.9, 138.6, 136.2, 135.5, 134.4, 131.9, 129.8, 127.8, 125.6, 122.4, 121.2, 120.7, 
114.2, 113.7, 112.3, 105.7, 69.8, 52.4, 24.4 ppm; HRMS: Calcd for C21H16O2N2Br [M+H]+: 
407.03897, Found: 407.03861. 
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Compound 96ba:  
 
Compound 96ba was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.30; 1H NMR (400 MHz, CDCl3) δ 11.20 
(s, 1H), 7.88 (s, 1H), 7.60 (s, 1H), 7.44 (s, 1H), 7.25 (d, J = 8.0 Hz, 1H), 6.97 (t, J = 8.0 Hz, 1H), 
6.92 (s, 1H), 6.87 (s, 1H), 3.82 (d, 6H), 3.67 – 3.59 (m, 1H), 3.49 – 3.43 (m, 4H), 3.16 – 3.10 
(m, 1H), 2.89 – 2.83 (m, 1H), 2.42 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 190.5, 164.5, 150.1, 
146.5, 146.2, 135.5, 134.9, 133.1, 130.6, 124.2, 120.6, 120.5, 118.1, 117.6, 116.4, 116.1, 
111.1, 108.5, 68.4, 56.2, 55.7, 49.6, 25.1, 24.6, 22.0 ppm; HRMS: Calcd for C25H25O4N2 
[M+H]+: 417.18088, Found: 417.18086; [α]D20 -13.4 ° (c 0.002 in ethanol). 
 
Compound 96bb:  
 
Compound 96bb was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.09 (s, 1H), 7.89 (d, J = 2.0 Hz, 1H), 7.62 (d, J = 2.0 Hz, 1H), 7.46 (d, J = 8.1 Hz, 1H), 
7.37 – 7.31 (m, 3H), 7.22 – 7.16 (m, 2H), 6.97 (d, J = 8.0 Hz, 1H), 5.99 (s, 1H), 3.80 – 3.75 (m, 
2H), 3.23 – 3.19 (m, 1H), 2.99 (dd, J = 14.1, 4.0 Hz, 1H), 2.74 (q, J = 8.0 Hz, 2H), 1.33 (t, J = 8.0 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 189.4, 160.2, 153.6, 138.7, 136.2, 135.8, 134.1, 131.9, 
129.6, 127.3, 125.4, 122.4, 122.1, 120.9, 114.3, 113.4, 112.1, 105.9, 68.8, 51.0, 28.5, 24.6, 
15.1 ppm; HRMS: Calcd for C23H21O2N2 [M+H]+: 357.15975, Found: 357.15949. 
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Compound 96bc:  
 
Compound 96bc was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.46 (d, J = 8.1 Hz, 1H), 
7.37 – 7.31 (m, 3H), 7.19 – 7.14 (m, 2H), 6.96 (d, J = 8.1 Hz, 1H), 6.03 (s, 1H), 3.81 – 3.74 (m, 
2H), 3.23 – 3.15 (m, 1H), 2.98 (dd, J = 14.0, 4.1 Hz, 1H), 2.82 (t, J = 7.0 Hz, 1H), 1.33 (d, J = 6.9 
Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 191.2, 159.3, 153.5, 138.3, 136.6, 135.4, 134.1, 131.9, 
129.6, 127.3, 125.6, 123.1, 122.0, 120.4, 114.7, 113.6, 112.4, 107.4, 69.0, 50.3, 33.4, 23.5, 
23.1 ppm; HRMS: Calcd for C24H23O2N2 [M+H]+: 371.17540, Found: 371.17517. 
 
Compound 96bd:  
 
Compound 96bd was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.17 (s, 1H), 7.85 (s, 1H), 7.56 (s, 1H), 7.43 (s, 1H), 7.22 (d, J = 7.5 Hz, 1H), 7.03 (d, 
J = 7.4 Hz, 1H), 6.97 (s, 1H), 6.90 (s, 1H), 3.80 (s, 3H), 3.79 (s, 3H), 3.64 – 3.59 (m, 1H), 3.50 – 
3.46 (m, 4H), 3.17 – 3.12 (m, 1H), 2.89 – 2.84 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 190.7, 
164.5, 150.3, 146.5, 146.3, 135.6, 134.9, 133.1, 130.6, 127.1, 124.3, 120.4, 120.2, 118.1, 
116.4, 116.2, 111.4, 108.6, 68.4, 56.7, 55.8, 49.4, 24.7, 24.3 ppm; HRMS: Calcd for 
C24H22O4N2F [M+H]+: 421.15581, Found: 421.15559. 
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Compound 96be:  
 
Compound 96be was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.30; 1H NMR (400 MHz, CDCl3) δ 11.24 
(s, 1H), 7.87 (s, 1H), 7.58 (s, 1H), 7.42 (s, 1H), 7.21 (d, J = 7.4 Hz, 1H), 7.04 (d, J = 7.4 Hz, 1H), 
6.93 (s, 1H), 6.88 (s, 1H), 3.78 (d, 6H), 3.66 – 3.59 (m, 1H), 3.49 – 3.44 (m, 4H), 3.16 – 3.11 
(m, 1H), 2.90 – 2.85 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 190.4, 164.4, 150.2, 146.4, 146.3, 
135.6, 134.8, 133.0, 130.7, 127.1, 124.1, 120.5, 120.3, 118.2, 116.5, 116.1, 111.4, 108.5, 68.4, 
56.3, 55.9, 49.3, 24.9, 24.2 ppm; HRMS: Calcd for C24H22O4N2Cl [M+H]+: 437.12626, Found: 
437.12623; [α]D20 -8.6 ° (c 0.002 in ethanol). 
 
Compound 96bf:  
 
Compound 96bf was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.20 (s, 1H),  7.88 (s, 1H), 7.57 (s, 1H), 7.41 (s, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.03 (d, 
J = 7.6 Hz, 1H), 6.90 (s, 1H), 6.87 (s, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 3.66 – 3.60 (m, 1H), 3.5 – 
3.46 (m, 4H), 3.14 – 3.10 (m, 1H), 2.90 – 2.86 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 192.1, 
165.2, 150.3, 146.6, 146.0, 135.5, 134.8, 133.0, 130.8, 127.1, 124.2, 120.5, 120.2, 118.1, 
116.4, 116.0, 111.4, 108.6, 68.4, 56.7, 55.7, 49.2, 24.9, 24.3 ppm; HRMS: Calcd for 
C24H22O4N2Br [M+H]+: 481.07575, Found: 481.07548. 
 
 
 
 
 
III. Experimental Part  219 
 
 
Compound 96bg:  
 
Compound 96bg was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.30; 1H NMR (400 MHz, CDCl3) δ 11.20 
(s, 1H), 7.88 (s, 1H), 7.60 (s, 1H), 7.44 (s, 1H), 7.25 (d, J = 8.0 Hz, 1H), 6.97 (t, J = 8.0 Hz, 1H), 
6.92 (s, 1H), 6.87 (s, 1H), 3.82 (d, 6H), 3.67 – 3.59 (m, 1H), 3.49 – 3.43 (m, 4H), 3.16 – 3.10 
(m, 1H), 2.89 – 2.83 (m, 1H), 2.42 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 190.5, 164.5, 150.1, 
146.5, 146.2, 135.5, 134.9, 133.1, 130.6, 124.2, 120.6, 120.5, 118.1, 117.6, 116.4, 116.1, 
111.1, 108.5, 68.4, 56.2, 55.7, 49.6, 25.1, 24.6, 22.0 ppm; HRMS: Calcd for C25H25O4N2 
[M+H]+: 417.18088, Found: 417.18086; [α]D20 -13.4 ° (c 0.002 in ethanol). 
 
Compound 96bh:  
 
Compound 96bh was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.22 (s, 1H), 7.90 (s, 1H), 7.63 (s, 1H), 7.45 (s, 1H), 7.23 (d, J = 8.0 Hz, 1H), 6.98 (t, J 
= 8.0 Hz, 1H), 6.93 (s, 1H), 6.85 (s, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.66 – 3.62 (m, 1H), 3.49 – 
3.44 (m, 4H), 3.15 – 3.10 (m, 1H), 2.90 – 2.85 (m, 1H), 2.72 (q, J = 8.0 Hz, 2H), 1.31 (t, J = 8.0 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 190.4, 164.6, 150.0, 146.7, 146.1, 135.4, 134.8, 133.0, 
130.7, 124.1, 120.5, 120.4, 118.0, 117.5, 116.3, 116.0, 111.1, 108.7, 68.4, 56.0, 55.6, 49.5, 
28.0, 25.2, 24.6, 14.9 ppm; HRMS: Calcd for C26H27O4N2 [M+H]+: 431.19653, Found: 
431.19619. 
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Compound 96bi:  
 
Compound 96bi was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.22 (s, 1H), 7.90 (s, 1H), 7.63 (s, 1H), 7.45 (s, 1H), 7.26 (d, J = 8.0 Hz, 1H), 6.98 (t, J 
= 8.0 Hz, 1H), 6.91 (s, 1H), 6.88 (s, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.65 – 3.60 (m, 1H), 3.50 – 
3.44 (m, 4H), 3.16 – 3.11 (m, 1H), 2.87 – 2.81 (m, 2H), 1.22 (d, J = 6.4 Hz, 6H); 13C NMR (101 
MHz, CDCl3) δ 190.0, 166.2, 150.0, 146.7, 146.2, 135.6, 134.9, 133.2, 130.5, 124.3, 120.7, 
120.4, 118.1, 117.7, 116.4, 116.2, 111.1, 108.6, 68.5, 56.3, 49.7, 33.2, 25.1, 24.8, 23.2, 22.1 
ppm; HRMS: Calcd for C27H29O4N2 [M+H]+: 445.21218, Found: 445.21197. 
 
Compound 96bj:  
 
Compound 96bj was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.95 (s, 1H), 7.87 (s, 1H), 7.74 (s, 1H), 7.63 (s, 1H), 7.28 – 7.22 (m, 3H), 7.01 (s, 1H), 
6.88 (s, 1H), 6.12 (s, 1H), 3.58 (s, 3H), 3.53 – 3.49 (m, 1H), 3.42 – 3.35 (m, 1H), 2.94 – 2.89 (m, 
2H) ppm; 13C NMR (101 MHz, CDCl3) δ 192.0, 170.5, 164.7, 158.8, 135.4, 135.1, 132.1, 131.8, 
131.5, 128.5, 127.4, 127.3, 123.4, 119.4, 116.0, 111.2, 104.7, 70.3, 67.8, 54.1, 52.2, 24.0 ppm; 
HRMS: Calcd for C22H18O4NCl2 [M+H]+: 430.06074, Found: 430.06036. 
 
Compound 96bk:  
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Compound 96bk was synthesized according to the racemic general procedure. Red 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, 
CDCl3) δ 11.81 (s, 1H), 7.88 (s, 1H), 7.75 (s, 1H), 7.63 (s, 1H), 7.29 (s, 1H), 7.00 (s, 1H), 6.88 (s, 
1H), 6.14 (s, 1H), 3.54 – 3.50 (m, 1H), 3.42 – 3.37 (m, 1H), 2.95 – 2.89 (m, 2H) ppm; 13C NMR 
(101 MHz, CDCl3) δ 192.0, 164.7, 158.8, 135.4, 135.1, 132.1, 131.8, 131.5, 128.5, 127.4, 
127.3, 123.4, 121.2, 119.4, 116.0, 114.2, 111.2, 104.7, 70.3, 67.8, 52.2, 25.1 ppm; HRMS: 
Calcd for C21H15O2N2Cl2 [M+H]+: 397.05051, Found: 397.05023. 
 
Compound 96bl:  
 
Compound 96bl was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.99 
(s, 1H), 7.85 (s, 1H), 7.73 (s, 1H), 7.62 (s, 1H), 7.29 (s, 1H), 7.00 (s, 1H), 6.89 (s, 1H), 3.74 (s 
,3H), 3.73 (s, 3H), 3.58 (s, 3H), 3.52 – 3.48 (m, 1H), 3.42 – 3.34 (m, 4H), 2.94 – 2.83 (m, 2H) 
ppm; 13C NMR (101 MHz, CDCl3) δ 190.4, 170.1, 164.5, 158.8, 135.3, 135.0, 132.1, 131.7, 
131.0, 128.6, 127.5, 127.3, 123.4, 121.4, 119.5, 116.1, 111.2, 104.6, 70.4, 67.9, 56.3, 56.2, 
52.2, 49.7, 24.0 ppm; HRMS: Calcd for C25H243O6N [M+H]+: 504.09752, Found: 504.09747; 
[α]D20 -13.8 ° (c 0.002 in ethanol). 
 
Compound 96bm:  
 
Compound 96bm was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 12.04 
(s, 1H), 7.82 (s, 1H), 7.74 (s, 1H), 7.60 (s, 1H), 7.27 (s, 1H), 6.97 (s, 1H), 6.88 (s, 1H), 3.75 (s 
,3H), 3.74 (s, 3H),  3.51 – 3.47 (m, 1H), 3.41 – 3.36 (m, 4H); 2.93 – 2.81 (m, 2H); 13C NMR (101 
MHz, CDCl3) δ 191.4, 164.1, 158.6, 135.4, 135.0, 132.4, 131.6, 131.1, 128.5, 127.5, 127.3, 
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123.4, 121.5, 119.5, 117.4, 116.0, 111.2, 104.2, 70.3, 67.8, 56.4, 56.3, 49.7, 24.5 ppm; HRMS: 
Calcd for C24H21O4N2 [M+H]+: 471.08729, Found: 471.08726; [α]D20 -13.4 ° (c 0.002 in 
ethanol). 
 
Synthesis of Benzopyridinium 97 
The benzopyridinium 97 were synthesized following the standard procedure for the 
synthesis of indolopyridiniums 87. 
 
Compound 97a: 
 
Compound 97a was synthesized according to the general procedure. Red amorphous solid; 
TLC (ethyl acetate): RF = 0.40; 1H NMR (400 MHz, CDCl3): δ 10.97 (s, 1H), 9.42 (s, 1H), 9.08 (s, 
1H), 7.74 (s, 1H), 7.40 – 7.16 (m, 5H), 6.94 – 6.90 (m, 1H), 5.22 (t, J = 9.0 Hz, 2H), 3.94 (s, 3H), 
3.46 (t, J = 9.5 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 196.8, 165.4, 164.6, 153.8, 150.9, 138.1, 
135.4, 132.3, 131.3, 127.6, 122.2, 121.6, 120.4, 119.4, 118.4, 117.3, 113.1, 111.4, 104.9, 70.7, 
60.2, 22.6 ppm; HRMS: Calcd for C22H18O4N [M+H]+: 360.12303, Found: 360.12298. 
 
Compound 97b: 
 
Compound 97b was synthesized according to the general procedure. Red amorphous solid; 
TLC (ethyl acetate): RF = 0.40; 1H NMR (400 MHz, CDCl3): δ 10.96 (s, 1H), 9.42 (s, 1H), 9.07 (s, 
1H), 7.75 (s, 1H), 7.39 – 7.18 (m, 6H), 5.18 (t, J = 9.1 Hz, 2H), 3.41 (t, J = 9.5 Hz, 2H); 13C NMR 
(101 MHz, CDCl3) δ 196.6, 165.3, 153.6, 150.9, 136.4, 135.4, 132.2, 131.7, 127.7, 123.5, 122.0, 
121.5, 120.3, 119.4, 118.2, 117.4, 113.1, 111.4, 104.7, 65.2, 22.4 ppm; HRMS: Calcd for 
C21H15O2N2 [M+H]+: 327.11280, Found: 327.11247. 
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III.4.4. Synthesis of Ring-Fused Quinolizines 98-101 
Compound 98a:  
 
Compound 98a was synthesized according to the racemic general procedure. Orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.40; 1H NMR (400 MHz, 
CDCl3) 11.72 (s, 1H), 8.10 (s, 1H), 7.74 – 7.66 (m, 2H), 7.53 – 7.48 (m, 2H), 7.32 (s, 1H), 7.05 – 
6.99 (m, 2H), 6.10 (s, 1H), 3.72 (s, 3H), 3.14 – 3.10 (m, 2H), 3.02 – 2.97 (m, 2H); 13C NMR (101 
MHz, CDCl3) δ 189.8, 169.9, 168.5, 153.9, 136.2, 135.4, 134.0, 131.5, 128.0, 126.0, 124.0, 
123.3, 123.2, 121.5, 120.1, 118.4, 68.3, 54.2, 52.9, 23.4 ppm; HRMS: Calcd for C20H18O4NS 
[M+H]+: 368.09511, Found: 368.09509. 
 
Compound 98b:  
 
Compound 98b was synthesized according to the racemic general procedure. Orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.40; 1H NMR (400 MHz, 
CDCl3) 11.74 (s, 1H), 8.08 (s, 1H), 7.75 – 7.66 (m, 2H), 7.52 – 7.46 (m, 2H), 7.33 (s, 1H), 7.06 – 
6.99 (m, 2H), 6.15 (s, 1H), 3.18 – 3.11 (m, 2H), 3.04 – 2.96 (m, 2H); 13C NMR (101 MHz, CDCl3) 
δ 191.3, 163.6, 152.6, 134.9, 134.8, 132.7, 131.6, 131.3, 126.7, 124.9, 124.2, 122.2, 121.4, 
120.0, 118.7, 115.4, 70.0, 52.3, 25.0 ppm; HRMS: Calcd for C19H15O2N2S [M+H]+: 335.08487, 
Found: 335.08481.  
 
Compound 99a:  
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Compound 12a was synthesized according to the racemic general procedure. Yellow 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.50; 1H NMR (400 MHz, 
CDCl3) δ 11.59 (s, 1H), 7.91 (s, 1H), 7.52 – 7.42 (m, 3H), 7.27 (s, 1H), 6.96 (m, 1H), 5.11 (m, 
1H), 3.61 (s, 3H), 2.94 – 2.86 (m, 2H), 1.63 – 1.31 (m, 12H); 13C NMR (101 MHz, CDCl3) δ 191.7, 
169.2, 163.9, 151.5, 137.2, 130.8, 126.5, 122.2, 121.0, 118.2, 117.4, 115.6, 110.2, 62.1, 49.0, 
37.6, 37.0, 32.4, 28.6, 26.4, 26.0, 25.5 ppm; HRMS: Calcd for C22H26O4N [M+H]+: 368.18563, 
Found: 368.18561. 
 
Compound 99b:  
 
Compound 99b was synthesized according to the racemic general procedure. Yellow 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.45; 1H NMR (400 MHz, 
CDCl3) δ 11.51 (s, 1H), 7.93 (s, 1H), 7.53 – 7.44 (m, 3H), 7.28 (s, 1H), 6.95 (m, 1H), 5.04 (m, 
1H), 2.96 – 2.89 (m, 2H), 1.64 – 1.34 (m, 12H); 13C NMR (101 MHz, CDCl3) δ 191.7, 163.8, 
151.2, 135.9, 130.1, 126.5, 122.7, 121.9, 120.0, 118.8, 117.4, 115.4, 110.1, 60.6, 37.7, 37.5, 
32.4, 28.3, 27.0, 26.4, 25.2 ppm;  HRMS: Calcd for C21H23O2N2 [M+H]+: 335.17540, Found: 
335.17536. 
 
Compound 99c:  
 
Compound 99c was synthesized according to the racemic general procedure. Yellow 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.45; 1H NMR (400 MHz, 
CDCl3) δ 11.43 (s, 1H), 8.07 (s, 1H), 7.49 – 7.43 (m, 2H), 7.24 (s, 1H), 6.99 (d, J = 6.8 Hz, 1H), 
5.14 (m, 1H), 3.55 (s, 3H), 2.91 – 2.86 (m, 2H), 1.58 – 1.32 (m, 12H); 13C NMR (101 MHz, CDCl3) 
δ 192.6, 169.6, 163.4, 151.4, 138.0, 137.0, 129.5, 126.4, 121.8, 118.0, 117.0, 115.4, 110.5, 
III. Experimental Part  225 
 
 
59.8, 49.1, 37.3. 37.0, 32.2, 28.6, 27.2, 26.8, 25.1 ppm; HRMS: Calcd for C22H25O4NCl [M+H]+: 
402.14666, Found: 402.14662. 
 
Compound 99d:  
 
Compound 99d was synthesized according to the general procedures. Yellow amorphous 
solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.39 
(s, 1H), 8.05 (s, 1H), 7.48 – 7.42 (m, 2H), 7.26 (s, 1H), 7.01 (d, J = 7.0 Hz, 1H), 5.01 (m, 1H), 
2.92 – 2.87 (m, 2H), 1.60 – 1.34 (m, 12H); 13C NMR (101 MHz, CDCl3) δ 190.4, 162.1, 153.7, 
136.4, 130.1, 126.8, 122.2, 121.5, 120.1, 118.9, 117.8, 115.6, 110.3, 60.4, 38.0, 37.0, 32.9, 
28.2, 27.3, 26.7, 25.5 ppm; HRMS: Calcd for C21H22O2N2Cl [M+H]+: 369.13643, Found: 
369.13637. 
 
Compound 100a:  
 
Compound 100a was synthesized according to the general procedures. Red amorphous solid; 
TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.53 (s, 1H), 
7.94 (s, 1H), 7.61 (s, 1H), 7.49 – 7.41 (m, 3H), 7.25 (s, 1H), 3.42 (s, 3H), 2.65 – 2.59 (m, 2H), 
1.96 (s, 3H), 1.64 – 1.56 (m, 2H), 1.50 – 1.44 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 189.6, 
170.1, 163.9, 153.6, 140.0, 137.1, 128.9, 126.4, 122.3, 121.0, 118.4, 115.9, 69.1, 53.1, 50.6, 
44.9, 26.4, 22.1 ppm; HRMS: Calcd for C18H20O4N [M+H]+: 314.13868, Found: 314.13687; 
[α]D20 -18.8 ° (c 0.002 in ethanol). 
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Compound 100b:  
 
Compound 13b was synthesized according to the general procedures. Red amorphous solid; 
TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.35; 1H NMR (400 MHz, CDCl3) δ 11.49 (s, 1H), 
7.92 (s, 1H), 7.47 – 7.40 (m, 3H), 7.24 (s, 1H), 7.02 – 6.99 (m, 1H), 2.63 – 2.60 (m, 2H), 2.00 
(m, 3H), 1.66 – 1.59 (m, 2H), 1.51 – 1.46 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 189.0, 163.4, 
153.2, 140.3, 137.6, 128.4, 126.6, 122.3, 121.0, 118.6, 117.3, 116.0, 69.2, 50.5, 44.8, 26.3, 
22.5 ppm; HRMS: Calcd for C17H17O2N2 [M+H]+: 281.12845, Found: 281.12842; [α]D20 -19.4 ° 
(c 0.002 in ethanol). 
 
Compound 101a:  
 
Compound 101a was synthesized according to the racemic general procedure. Yellow 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.45; 1H NMR (400 MHz, 
CDCl3) δ 11.12 (s, 1H), 7.98 (s, 1H), 7.50 – 7.41 (m, 3H), 7.31 (s, 1H), 7.02 (d, J = 6.9 Hz, 1H), 
4.99 (m, 1H), 3.41 (s, 3H), 2.76 – 2.71 (m, 2H), 1.63 – 1.55 (m, 3H), 1.50 – 1.43 (m, 3H); 13C 
NMR (101 MHz, CDCl3) δ 192.1, 168.2, 163.5, 149.9, 137.6, 130.7, 127.3, 122.6, 121.9, 119.2, 
115.6, 110.3, 61.3, 53.6, 50.1, 29.4, 26.3, 22.2 ppm; HRMS: Calcd for C18H20O4N [M+H]+: 
314.13868, Found: 314.13865.  
 
Compound 101b:  
 
Compound 101b was synthesized according to the racemic general procedure. Yellow 
amorphous solid; TLC (cyclohexane/ethyl acetate, 1:1 v/v): RF = 0.40; 1H NMR (400 MHz, 
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CDCl3) δ 11.15 (s, 1H), 7.98 (s, 1H), 7.49 – 7.42 (m, 3H), 7.29 (s, 1H), 7.01 (d, J = 7.1 Hz, 1H), 
4.97 (m, 1H), 2.77 – 2.72 (m, 2H), 1.63 – 1.56 (m, 3H), 1.51 – 1.43 (m, 3H); 13C NMR (101 MHz, 
CDCl3) δ 191.6, 163.9, 150.1, 137.5, 130.4, 127.6, 122.5, 121.8, 119.4, 117.8, 115.4, 109.8, 
61.7, 50.0, 29.6, 26.7, 22.6 ppm; HRMS: Calcd for C17H17O2N2 [M+H]+: 281.12845, Found: 
281.12840. 
 
III.4.5. Synthesis of Indoloindolizines 111 and Dihydropyridoisoindoles 112 
Compound 111a: 
 
Compound 111a was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.20 
(s, 1H), 8.89 (s, 1H), 7.79 (s, 1H), 7.71 (s, 1H), 7.50 – 7.36 (m, 4H), 7.24 – 7.18 (m, 3H), 4.24 
(s, 1H), 4.15 (s, 1H), 3.84 (s, 3H), 3.65 (s, 3H), 3.55 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 189.7, 
167.2, 150.9, 135.8, 135.1, 132.5, 131.9, 131.3, 127.5, 127.0, 123.4, 121.8, 120.4, 119.5, 118.4, 
117.5, 117.0, 115.2, 110.7, 99.2, 70.2, 68.4, 56.3, 55.1, 26.8 ppm; HRMS: Calcd for C25H23O5N2 
[M+H]+: 431.16015, Found: 431.16999. 
 
Compound 111b: 
 
Compound 111b was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.20 
(s, 1H), 9.02 (s, 1H), 7.87 (s, 1H), 7.61 – 7.57 (m, 2H), 7.37 – 7.30 (m, 2H), 7.20 – 7.14 (m, 2H), 
6.97 (d, J = 8.6 Hz, 1H), 4.30 (s, 1H), 4,22 (s, 1H), 3.85 (s, 3H), 3.79 (s, 3H), 3.54 (s, 3H); 13C 
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NMR (101 MHz, CDCl3) 190.5, 170.1, 159.8, 153.5, 136.1, 135.8, 134.2, 131.7, 129.4, 126.0, 
123.4, 123.1, 120.8, 120.0, 119.1, 118.4, 114.0, 112.1, 108.2, 105.8, 68.1, 58.7, 54.3, 52.8, 
24.5 ppm; HRMS: Calcd for C25H22O5N2F [M+H]+: 449.15073, Found: 449.15044. 
 
Compound 111c: 
 
Compound 111c was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.14 
(s, 1H), 9.01 (s, 1H), 7.94 (s, 1H), 7.62 (s, 1H), 7.47 – 7.41 (m, 2H), 7.30 – 7.23 (m, 3H), 6.99 – 
6.92 (m, 2H), 4.30 (s, 1H), 4.23 (s, 1H), 3.87 (s, 3H), 3.65 (s, 3H); 13C NMR (101 MHz, CDCl3) 
13C NMR (100 MHz, CDCl3):  191.1, 161.3, 153.0, 136.5, 134.7, 134.4, 130.0, 127.5, 125.8, 
120.8, 119.6, 119.1, 118.5, 118.4, 118.2, 116.8, 113.5, 112.7, 107.6, 106.2, 67.0, 59.1, 53.2, 
22.8 ppm; HRMS: Calcd for C24H20O3N3 [M+H]+: 398.14992, Found: 398.14971. 
 
Compound 111d: 
 
Compound 111d was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.07 
(s, 1H), 9.03 (s, 1H), 7.94 (s, 1H), 7.68 (s, 1 H), 7.57 (s, 1H), 7.37 – 7.30 (m, 2H), 7.24 – 7.17 
(m, 2H), 7.00 (d, J = 8.4 Hz, 1H), 4.31 (s, 1H), 4.23 (s, 1H), 3.78 (m, 3H), 3.74 (s, 3H); 13C NMR 
(101 MHz, CDCl3) 190.0, 157.9, 153.4, 138.0, 135.7, 134.2, 129.5, 126.3, 125.0, 123.4, 
123.1, 122.8, 120.2, 119.2, 118.7, 114.0, 113.7, 112.0, 108.3, 105.9, 68.3, 58.1, 54.5, 22.8 
ppm; HRMS: Calcd for C24H19O3N3F [M+H]+: 416.14050, Found: 416.14011. 
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Compound 111e: 
 
Compound 111e was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.09 
(s, 1H), 9.06 (s, 1H), 7.75 (s, 1H), 7.70 (s, 1H), 7.32 – 7.28 (m, 2H), 7.18 – 7.11 (m, 3H), 7.04 – 
6.99 (m, 1H), 6.90 – 6.85 (m, 2H), 6.13 (s, 1H), 4.30 (s, 1H), 4.22 (s, 1H), 3.75 (s, 3H); 13C NMR 
(101 MHz, DMSO-d6) δ 188.7, 170.2, 155.3, 153.9, 136.2, 134.3, 133.0, 132.1, 131.4, 129.7, 
125.8, 124.0, 121.1, 119.9, 119.0, 117.9, 116.2, 111.6, 106.8, 106.0, 67.4, 59.0, 52.3 ppm; 
HRMS: Calcd for C23H19O4N2 [M+H]+: 387.13393, Found: 387.13367. 
 
Compound 111f: 
 
Compound 111f was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.20 
(s, 1H), 9.07 (s, 1H), 7.92 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 
7.39 – 7.30 (m, 3H), 7.23 – 7.12 (m, 2H), 6.97 (d, J = 8.4 Hz, 1H), 6.07 (s, 1H), 4.30 (s, 1H), 4.22 
(s, 1H), 3.77 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 190.3, 167.2, 159.6, 153.4, 136.1, 135.1, 
134.3, 131.6, 130.2, 129.6, 125.7, 122.3, 121.2, 120.7, 119.6, 118.3, 114.6, 112.0, 108.1, 
105.9, 68.3, 52.7, 50.6 ppm; HRMS: Calcd for C23H18O4N2F [M+H]+: 405.12451, Found: 
405.12437. 
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Compound 111g: 
 
Compound 111g was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.11 
(s, 1H), 9.04 (s, 1H), 7.94 (d, J = 1.5 Hz, 1H), 7.62 (d, J = 1.5 Hz, 1H), 7.45 – 7.37 (m, 2H), 7.32 
(d, J = 8.2 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.09 – 7.01 (m, 2H), 6.94 (m, 
1H), 6.02 (s, 1H), 4.34 (s, 1H), 4.26 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 190.0, 153.3, 136.0, 
134.9, 132.4, 130.3, 126.2, 122.7, 121.4, 119.6, 118.4, 117.9, 117.4, 117.0, 116.1, 114.0, 113.7, 
108.8, 106.9, 105.0, 82.2, 59.1 ppm; HRMS: Calcd for C22H16O2N3 [M+H]+: 354.12370, Found: 
354.12349. 
 
Compound 111h: 
 
Compound 111h was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.17 
(s, 1H), 9.04 (s, 1H), 7.95 (d, J = 1.7 Hz, 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.46 (d, J = 8.9 Hz, 1H), 
7.39 – 7.31 (m, 4H), 7.25 – 7.17 (m, 2H), 5.99 (s, 1H), 4.31 (s, 1H), 4.21 (s, 1H); 13C NMR (101 
MHz, CDCl3) δ 190.4, 153.6, 136.4, 135.8, 134.4, 131.8, 129.6, 128.0, 126.4, 125.0, 123.2, 
120.7, 121.0, 120.7, 119.7, 118.3, 114.1, 112.2, 108.1, 105.8, 68.2, 54.0 ppm; HRMS: Calcd 
for C22H15O3N3F [M+H]+: 372.11428, Found: 372.11402. 
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Compound 112a: 
 
Compound 112a was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.18 
(s, 1H), 7.91 (s, 1H), 7.70 (s, 1H), 7.46 – 7.39 (m, 2H), 7.22 – 7.14 (m, 2H), 6.98 (s, 1H), 6.88 
(s, 1H), 4.32 (s, 1H), 4.21 (s, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.58 (s, 3H), 3.44 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 190.2, 170.0, 166.0, 158.9, 145.2, 135.1, 132.8, 131.6, 131.1, 128.7, 
127.5, 123.1, 121.4, 119.5, 116.7, 116.0, 111.2, 105.1, 69.9, 56.3, 56.2, 52.4, 49.8, 24.2; 
HRMS: Calcd for C24H24O6N [M+H]+: 422.15981, Found: 422.15971. 
 
Compound 112b: 
 
Compound 112b was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.19 
(s, 1H),  7.91 (s, 1H), 7.58 (s, 1H), 7.45 (s, 1H), 7.32 (d, J = 6.0 Hz, 1H), 7.13 (d, J = 6.0 Hz, 1H), 
6.90 (s, 1H), 6.85 (s, 1H), 4.29 (s, 1H), 4.20 (s, 1H), 3.82 (d, 6H), 3.78 (s, 3H), 3.52 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 189.6, 169.7, 165.4, 149.7, 146.0, 145.7, 138.0, 135.7, 134.2, 130.6, 
128.2, 123.2, 122.1, 120.8, 117.5, 116.6, 111.1, 108.6, 68.7, 60.1, 58.7, 54.3, 54.2, 24.1 ppm; 
HRMS: Calcd for C24H23O6NF [M+H]+: 440.15039, Found: 440.15012. 
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Compound 112c: 
 
Compound 112c was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.45; 1H NMR (400 MHz, CDCl3) δ 11.19 
(s, 1H), 7.87 (s, 1H), 7.64 (s, 1H), 7.44 (s, 1H), 7.21 – 7.03 (m, 3H), 6.93 (s, 1H), 6.87 (s, 1H), 
4.31 (s, 1H), 4.22 (s, 1H), 3.82 (d, 6H), 3.49 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 190.4, 164.5, 
150.2, 146.5, 146.2, 138.7, 134.9, 133.1, 130.4, 124.2, 120.5, 118.2, 118.0, 117.6, 116.5, 
113.2, 111.1, 108.5, 68.6, 56.2, 56.0, 55.7, 24.6 ppm; HRMS: Calcd for C23H21O4N2 [M+H]+: 
389.14958, Found: 389.14921. 
 
Compound 112d: 
 
Compound 112d was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.08 
(s, 1H), 7.90 (s, 1H), 7.57 (s, 1H), 7.43 (s, 1H), 7.20 (d, J = 7.8 Hz, 1H), 7.07 (d, J = 7.8 Hz, 1H), 
6.91 (s, 1H), 6.87 (s, 1H), 4.29 (s, 1H), 4.21 (s, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 3.47 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 190.7, 164.4, 150.8, 146.3, 146.0, 135.6, 134.9, 133.1, 131.2, 130.6, 
127.1, 124.4, 122.6, 120.5, 118.4, 116.5, 111.4, 108.6, 68.4, 60.4, 55.7, 55.6, 24.1 ppm; 
HRMS: Calcd for C23H20O4N2F [M+H]+: 407.14016, Found: 407.14003. 
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Compound 112e: 
 
Compound 112e was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.19 
(s, 1H), 7.92 (s, 1H), 7.63 (s, 1H), 7.54 – 7.51 (m, 1H), 7.39 – 7.18 (m, 6H), 6.94 – 6.90 (m, 1H), 
5.47 (s, 1H), 4.30 (s, 1H), 4.23 (s, 1H), 3.83 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 189.4, 168.7, 
159.8, 143.4, 136.3, 136.0, 133.5, 131.7, 130.0, 128.4, 126.2, 123.9, 120.1, 118.7, 113.8, 
112.7, 108.3, 107.2, 68.2, 59.8, 52.5 ppm; HRMS: Calcd for C21H18O4N [M+H]+: 348.12303, 
Found: 348.12289. 
 
Compound 112f: 
 
Compound 112f was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.12 
(s, 1H), 7.98 (d, J = 2.0 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.43 – 7.32 (m, 4H), 7.23 – 7.13 (m, 
2H), 6.99 – 6.94 (d, J = 7.9 Hz, 1H), 6.04 (s, 1H), 4.32 (s, 1H), 4.22 (s, 1H), 3.84 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 190.0, 167.5, 159.5, 153.7, 138.3, 136.7, 135.7, 134.0, 133.0, 129.7, 
127.6, 126.0, 122.3, 121.0, 120.3, 114.8, 112.3, 105.8, 69.9, 60.1, 52.5 ppm; HRMS: Calcd for 
C21H17O4NF [M+H]+: 366.11361, Found: 366.11347. 
 
Compound 112g: 
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Compound 112g was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.15 
(s, 1H), 7.91 (s, 1H), 7.64 (s, 1H), 7.54 – 7.50 (m, 1H), 7.37 – 7.19 (m, 6H), 6.95 – 6.91 (m, 1H), 
5.62 (s, 1H), 4.32 (s, 1H), 4.24 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 190.2, 159.6, 144.0, 136.7, 
135.7, 135.6, 133.4, 131.2, 130.0, 128.3, 126.5, 124.0, 120.2, 118.6, 113.9, 112.8, 108.2, 
107.1, 68.7, 59.7 ppm; HRMS: Calcd for C20H14O2N2 [M+H]+: 315.11280, Found: 315.11296. 
 
Compound 112h: 
 
Compound 112h was synthesized according to the asymmetric Diels-Alder procedure. Red 
solid; TLC (cyclohexane/ethyl acetate, 3:2 v/v): RF = 0.40; 1H NMR (400 MHz, CDCl3) δ 11.08 
(s, 1H), 7.95 (d, J = 2.1 Hz, 1H), 7.68 (d, J = 2.1 Hz, 1H), 7.42 – 7.31 (m, 4H), 7.23 – 7.13 (m, 
2H), 7.00 – 6.95 (d, J = 8.0 Hz, 1H), 6.02 (s, 1H), 4.31 (s, 1H), 4.22 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 191.2, 159.3, 153.8, 138.3, 136.4, 135.4, 134.7, 133.1, 129.2, 126.4, 126.2, 122.4, 
121.7, 120.0, 118.7, 114.5, 112.5, 105.7, 69.7, 59.9 ppm; HRMS: Calcd for C20H14O2N2F 
[M+H]+: 333.10338, Found: 333.10310. 
 
III.4.6. Synthesis of Ring Closed Quinolizines 114 and 117 
Ring-closed quinolizines 114 and 117 were synthesized following the standard procedure of 
asymmetric Diels-Alder reaction. 
 
Compound 114a:  
 
Compound 114a was synthesized according to the asymmetric general procedure. orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.50 (decomposition); 1H 
NMR (400 MHz, CDCl3):  9.19 (s, 1H), 7.94 – 7.90 (m, 1H), 7.49 – 7.41 (m, 3H), 7.29 – 7.20 
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(m, 3H), 7.04 – 6.96 (m, 2H), 6.03 – 5.97 (m, 1H), 5.53 – 5.49 (m, 1H), 3.80 – 3.74 (m, 2H), 
3.15 – 3.08 (m, 1H), 2.91 – 2.86 (m, 1H); HRMS: Calcd for C24H17O2N4 [M+H]+: 393.13460, 
Found: 393.13443.  
 
Compound 114b:  
 
Compound 114b was synthesized according to the asymmetric general procedure. orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.50 (decomposition); 1H 
NMR (400 MHz, CDCl3):  9.13 (s, 1H), 7.95 – 7.91 (m, 1H), 7.48 – 7.40 (m, 3H), 7.28 – 7.20 
(m, 3H), 7.06 – 6.95 (m, 2H), 6.04 – 5.96 (m, 1H), 5.55 – 5.49 (m, 1H), 3.80 – 3.73 (m, 8H), 
3.15 – 3.09 (m, 1H), 2.91 - 2.86 (m, 1H); HRMS: Calcd for C26H23O6N2 [M+H]+: 459.15506, 
Found: 459.15471.  
 
Compound 114c:  
 
Compound 114c was synthesized according to the asymmetric general procedure. orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.50 (decomposition); 1H 
NMR (400 MHz, CDCl3):  9.19 (s, 1H), 7.94 – 7.91 (m, 1H), 7.60 – 7.55 (m, 1H), 7.47 – 7.41 
(m, 2H), 7.29 – 7.20 (m, 2H), 7.02 – 6.98 (m, 1H), 6.89 – 6.84 (m, 1H), 5.55 – 5.50 (m, 1H), 
3.86 (s, 3H), 3.80 – 3.74 (m, 5H), 3.16 – 3.09 (m, 1H), 2.91 – 2.88 (m, 1H); HRMS: Calcd for 
C26H21O3N4 [M+H]+: 437.16082, Found: 437.16058.  
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Compound 114d:  
 
Compound 114d was synthesized according to the asymmetric general procedure. orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.50 (decomposition); 1H 
NMR (400 MHz, CDCl3):  9.07 (s, 1H), 7.93 – 7.89 (m, 1H), 7.61 – 7.58 (m, 1H), 7.47 – 7.42 
(m, 2H), 7.30 – 7.22 (m, 3H), 7.02 – 6.97 (m, 1H), 6.89 – 6.84 (m, 1H), 3.86 (s, 3H), 3.80 – 3.74 
(m, 8H), 3.17 – 3.10 (m, 4H), 2.91 – 2.86 (m, 1H); HRMS: Calcd for C28H27O7N2 [M+H]+: 
503.18128, Found: 503.18102.  
 
Compound 117a:  
 
Compound 117a was synthesized according to the asymmetric general procedure. orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.50 (decomposition); 1H 
NMR (400 MHz, CDCl3):  7.93 – 7.88 (m, 1H), 7.58 – 7.54 (m, 1H), 7.39 – 7.20 (m, 5H), 7.02 
– 6.98 (m, 1H), 6.89 – 6.83 (m 1H), 6.04 – 5.95 (m, 1H), 3.85 – 3.79 (m, 2H), 3.15 – 3.09 (m, 
1H), 2.90 – 2.86 (m, 1H); HRMS: Calcd for C22H16O2N3 [M+H]+: 354.12370, Found: 354.12339.  
 
Compound 117b:  
 
Compound 117b was synthesized according to the asymmetric general procedure. orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.50 (decomposition); 1H 
NMR (400 MHz, CDCl3):   7.89 (m, 1H), 7.59 (m, 1H), 7.37 – 7.18 (m, 6H), 7.03 – 6.98 (m, 1H), 
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6.88 – 6.83 (m, 1H), 6.05 – 5.98 (m, 1H), 3.87 – 3.79 (m, 8H), 3.15 – 3.08 (m, 1H), 2.91 – 2.86 
(m, 1H); HRMS: Calcd for C24H22O6N [M+H]+: 420.14416, Found: 420.14402.  
 
Compound 117c:  
 
Compound 117c was synthesized according to the asymmetric general procedure. orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.50 (decomposition); 1H 
NMR (400 MHz, CDCl3): 7.94 (m, 1H), 7.69 – 7.64 (m, 1H), 7.58 – 7.53 (m, 1H), 7.47 – 7.42 
(m, 2H), 7.29 – 7.21 (m, 1H), 7.02 – 6.97 (m, 1H), 6.81 – 6.74 (m 1H), 3.89 (s, 6H), 3.80 – 3.72 
(m, 5H), 3.16 – 3.08 (m, 1H), 2.91 – 2.86 (m, 1H); HRMS: Calcd for C25H21O4N3 [M+H]+: 
428.16048, Found: 428.16014.  
 
Compound 117d:  
 
Compound 117d was synthesized according to the asymmetric general procedure. orange 
amorphous solid; TLC (cyclohexane/ethyl acetate, 2:1 v/v): RF = 0.50 (decomposition); 1H 
NMR (400 MHz, CDCl3):  7.99 (m, 1H), 7.70 – 7.63 (m, 1H), 7.59 – 7.53 (m, 1H), 7.47 – 7.43 
(m, 2H), 7.27 – 7.21 (m, 1H), 7.01 – 6.95 (m, 1H), 6.81 – 6.75 (m 1H), 3.93 – 3.87 (m, 12H), 
3.81 – 3.74 (m, 5H), 3.16 – 3.09 (m, 1H), 2.93 – 2.87 (m, 1H); HRMS: Calcd for C27H28O6N 
[M+H]+: 494.18094, Found: 494.18072.  
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